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Abstract 
The omnipresence of DNA-damaging agents and the chemical instability of certain 
chemical bonds in DNA have made it essential for living organisms to develop 
systems of DNA repair. Repair of damaged DNA is necessary to prevent lesions from 
causing disruption of essential cellular functions or from converting into permanent 
mutations that lead to malignancy or cell death. Nucleotide excision repair (NER) is 
just one of the repair systems that has evolved to protect cells from the consequences 
of DNA damage. The NER system protects DNA from the widest variety of lesions 
induced by agents such as UV irradiation, cross-linking agents and free radicals. 
Defects in NER are associated with the human inherited disorder xeroderma 
pigmentosum, which predisposes to skin cancer. We have previously reported the 
generation of DNA repair deficient mice by the targeted inactivation of the NER gene 
ERCC1. The mice were born severely runted and died, prior to weaning, with liver 
failure. Investigations into the consequences of ERCCJ deficiency in other tissues 
have been severely constrained by the limited lifespan of the knockout mice. One of 
the initial reasons for generating the ERCCJ -deficient mice was to study UV-induced 
tumourogenesis. Although ERCC1 has not been associated with any known human 
disorder these mice serve as a model for NER deficiency. 
The aims of this work were to study the pattern of ERCC] expression in mouse 
tissues to determine if a tissue specific expression was evident. Secondly, we aimed 
to bring about the phenotypic rescue of the lethal liver phenotype of the ER CC] nulls 
in order to study the consequences of ERCCJ deficiency in other tissues. 
In all mammals the skin is the first line of defence against the harmful effects of UV 
irradiation. A novel ERCC] mRNA has been identified in mouse skin. Subsequent 
characterisation of the transcript demonstrated that the difference between the normal 
and skin-specific ERCC] mRNA was at the 5' end and is due to differential initiation 
of transcription. As with the normal ERCCJ transcript the novel skin-specific 
transcript did not appear to be induced by UV irradiation. 
A functional ERCC] minigene was constructed to facilitate subsequent analysis of 
the upstream promoter region and identification of the sequences involved in the 
regulation of the observed skin-specific pattern of expression. The minigene 
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corrected the UV sensitivity of ERCC]-deficient cultured cells but did not exhibit the 
characteristic skin-specific expression pattern at the level of mRNA analysis. 
A pilot study for a potential gene therapy approach to increasing the lifespan of the 
ERCCJ knockout mice was completed. Recombinant ecotropic retroviruses 
containing ERCCJ coding sequences were produced using a murine leukaemia virus 
derived viral vector and viral packaging cell line. The resultant ERCC] retrovirus 
was shown to partially correct the UV sensitivity associated with pools of ERCCJ-
deficient mouse embryonic fibroblasts. Clones, subsequently isolated from the 
transduced pools, were shown to be phenotypically corrected to wild type levels. The 
observed phenotypic correction correlated with expression of a retroviral ERCC1 
mRNA. 
A transthyretin regulated ERCC1 transgene was used to bring about the targeted 
expression of ERCC1 in the liver. Pronuclear injection of the transgene was used to 
produce a transgenic mouse line containing -5 copies of the transgene integrated at a 
single site. Expression of this transgene on an ERCCJ -deficient background resulted 
in the correction of the lethal liver phenotype. Transgene positive nulls were not as 
severely runted and survived for between 9 and 12 weeks compared to the three-week 
survival of the transgene negative ERCC1-deficient mice. The consequences of 
ERCCJ deficiency in other tissues were studied. Abnormalities were identified in the 
skin and kidneys of adult transgene positive nulls. 
An investigation into the consequences of DNA repair deficiency on UV-B induced 
immunosuppression revealed that antigen presenting epidermal Langerhans cells, in 
the transgene positive nulls, did not show the normal pattern of accumulation in the 
lymph nodes following UV irradiation. 
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Perhaps more than any other property, genomic stability is essential in all organisms. 
As the carrier of the genetic code it is essential, for normal cell function and 
ultimately for survival, that the integrity of the DNA molecule is maintained. The 
reliable maintenance of any form of data is generally dependent on the stability of the 
medium on which it is stored and in this respect cellular DNA is no different. The 
data that is, in this case, DNA is continually under threat of molecular changes and 
rearrangements, each of which can potentially result in changes to the informational 
accuracy of the genetic code. Alterations to the DNA molecule can arise, either 
spontaneously as a consequence of normal cellular activities, or as a result of 
environmental agents. Irrespective of the origin of the DNA lesion, in order to 
prevent the manifestation of possible deleterious consequences, all living organisms 
have evolved a number of mechanisms for repairing damaged DNA. 
As was the case for most areas of molecular biology, initial awareness and 
subsequent understanding of the mechanisms involved in the repair or tolerance of 
damaged DNA came from studies of prokaryotic systems in particular the bacterium 
Escherichia coli. The old adage of, 'what is true for E. coli is true for the elephant' is 
certainly relevant in most biological processes and to a certain extent DNA repair is 
no exception. Although many of the DNA repair mechanisms have been conserved 
throughout evolution, the eukaryotic organism is clearly more complex. In simple 
terms, the eukaryotic genome is very much larger (3.OxlO 9 compared to 4.2x10 6 bp) 
and composed of multiple chromosomes. Additionally, the multicellular nature of 
higher eukaryotes demands strict regulation of cell division and differentiation. DNA 
damage is known to impair both of these processes. Accordingly, some of the 
mechanisms of DNA repair present in eukaryotes are much more complex than those 
characterised in E. co/i. Today, the focus of many DNA repair studies is towards 
developing a greater understanding of how these DNA repair mechanisms function in 
mammalian systems. 
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1.2 DNA damage 
The simplest classification of DNA damage is either as spontaneous or 
environmental in origin. Whilst spontaneous damage refers to lesions that arise as a 
consequence of normal cellular processes such as DNA replication, environmental 
damage refers to lesions induced by exogenous factors such as UV irradiation. 
However, even this simplest of classification systems is not unambiguous as the 
chemical consequences of some spontaneous damage can result in identical changes 
to those brought about by environmental agents. For example, DNA strand breaks 
introduced by clastogenic agents such as ionising radiation can also result from 
endogenous factors activated by normal cellular metabolism. The variety of 
spontaneous alterations that can occur and the range of environmental agents that 
lead to DNA damage are reviewed in Friedberg, Walker and Siede (1995). 
Base mismatches arising from replicative infidelity are believed to occur once in 
every 109 nucleotides inserted during DNA synthesis. However, inappropriate base 
pairing can also result from the spontaneous deamination of cytosine, adenine and 
guanine leading to the presence of uracil, hypoxanthine and xanthine in the DNA 
molecule, respectively. In addition to the incorporation of uracil as a consequence of 
deamination of cytosine, it can also occur if the synthesis of TMP from dUMP is 
inhibited. This results in an increase in the abundance of dUTP relative to TTP and 
thus promotes the incorporation of uracil relative to thymine into DNA. It is possible 
for each of the bases to experience a transient change in its bonding capacity, a 
tautomeric shift. These tautomers include the rare enol forms of thymine and guanine 
as well as the rare imino forms of adenine and cytosine. As such, if any of the bases 
in the template strand is present in the form of its tautomer, during DNA synthesis, 
misincorporation of bases in the daughter strand can occur. The loss of bases, 
depurination and depyrimidination can result from spontaneous hydrolysis of the 
glycosyl bonds. Finally, spontaneous damage of DNA can result from attack by 
reactive oxygen species or free radicals. These reactive species, such as H202, can be 
the products of normal metabolic processes and are capable of inducing helical 
distorting base damage. Lesions arising from the attack of free radicals on DNA 
include 8-hydroxyguanine and thymine glycol. The guanine lesion is capable of 
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mispairing during replication, whilst the thymine glycol appears to act as a replicative 
block. 
The vast range of environmental DNA damaging agents and the lesions they induce 
makes it impracticable to present a comprehensive list within the context of this 
thesis. Instead, an overview of the principle classes of agents and their lesions is 
presented. lonising radiation itself induces a variety of DNA lesions including single 
and double strand breaks, base and sugar damage and the indirect damage caused by 
free radicals formed as a consequence of the radiation. 
Alkylating agents are chemicals which damage DNA by introducing bulky adducts. 
Alkylation being the introduction of methyl or ethyl groups to reactive sites of the 
bases and phosphodiester backbone. Guanine is particularly susceptible to alkylation, 
becoming methylated at the 06  position, forming 06-methylguanine, which is capable 
of mispairing with thymine. 
Cross-linking agents, including mitomycin C and certain psoralens, can damage 
DNA by the introduction of inter- and intrastrand cross-links. Interstrand cross-links 
are effective in the prevention of strand separation and as such are capable of 
preventing normal transcriptional and replicative processes. 
A number of chemicals present as environmental pollutants, including 
benzo[a]pyrene present in cigarette smoke, can be metabolised by cells to form 
electrophilic reactants. The resultant DNA lesion varies according to the actual agent. 
Generally, they result in the addition of helix distorting bulky chemical adducts. 
Finally, UV radiation is probably the most extensively studied environmental DNA 
damaging agent. The UV spectrum is divided into three wavelength bands of UVA 
(400-320 nm), UVB (320-290 nm) and UVC (290-100 nm). Solar radiation consists 
principally of UVA and UVB, with UVC being absorbed by the Ozone layer. Despite 
this, laboratory studies of UV induced damage often use UVC (260nm) emitting 
sources which introduce DNA lesions identical to those caused by the longer, and 
more biologically significant, UVB wavelengths. UV irradiation can result in a whole 
host of lesions including cross-links and strand breaks. When DNA is exposed to UV 
radiation with a wavelength of 260nm adjacent pyrimidines become fused as covalent 
links are formed between the respective carbon 6 and 5 atoms. The resultant 
El 
cyclobutane pyrimidine dimer leads to distortion of the DNA helix. Another UV 
irradiation product is the pyrimidine-pyrimidine [6-4] photoproduct, which is a 
noncyclic bond between adjacent pyrimidines. The bond forming between the carbon 
6 of the 5' pyrimidine and the carbon 4 of the 3' pyrimidine. Again this photoproduct 
formation brings about distortion of the DNA helix. 
It is evident that there are a vast number of different DNA lesions caused by a equally 
varied number of agents or events. However, rather than maintaining several 
pathways specific for each of the DNA lesions, eukaryotes have evolved a limited 
number of repair pathways capable of dealing with several types of lesion. 
1.3 Mechanisms of DNA repair 
The survival of any given cell is dependent on the appropriate expression and 
functioning of the considerable number of proteins encoded by the cellular DNA. 
Cell viability is thus heavily dependent on the efficient removal of lesions from its 
DNA. A comprehensive discussion of each of the cellular responses to DNA damage 
would be outwith the scope of this thesis, instead a concise description of the 
principle repair pathways will be presented. Included in the many repair pathways 
evident in eukaryotic cells are direct reversal of damage, base excision repair, 
mismatch repair, double strand-break repair and finally, the focus of this thesis, 
nucleotide excision repair 
1.4 Direct reversal of DNA damage 
In the direct repair pathways damaged DNA is returned to its normal state by means 
of an enzyme-catalysed activity (reviewed by Sancar, 1996). The classic example of 
direct reversal of damage is photoreactivation. In E. coli the enzyme DNA photolyase 
repairs UV induced cyclobutane pyrimidine dimers by using a light stimulated 
electron transfer reaction to monomerise the dimer. A similar correcting activity has 
not been confirmed in higher eukaryotes. The simple rejoining of single strand breaks 
by DNA ligase has been observed in E. coli, but the significance of this process in 
mammalian cells remains ambiguous. For ligation to occur the free ends of the DNA 
require 3'OH and 5'P termini. In most cases the strand breaks commonly introduced 
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by radiation result in damage to the DNA strand ends, and as such require processing 
by additional enzymes prior to ligation. 
An example of a direct repair pathway that is evident in all species is the repair of 
alkylation damage by the enzyme 0 6-methylguanine transferase (0 6-MGT). The 
DNA lesion 06-methylguanine is introduced by alkylating agents such as 
methylnitro-nitrosoguanidine (MNNG) and methylnitrosourea (MNU). The repair of 
the lesion involves the transfer of the methyl group from the DNA to a cysteine 
residue on the enzyme resulting in the permanent inactivation of the enzyme and the 
formation of S-methyl cysteine. 
1.5 Double-strand break repair by end joining 
Double-strand breaks (DSBs) are introduced into DNA by environmental agents such 
as ionising radiation or during failed recombination reactions. In higher eukaryotes 
DSBs are repaired by non-homologous or illegitimate end joining (reviewed by 
Wood, 1996). The DNA-dependent protein kinase (DNA-PK) is pivotal in V(D)J 
recombination and non-homologous end joining. The actual nature of the mechanism 
by which DNA-PK effects DNA repair has yet to be characterised, although possible 
models have been proposed (summarised by Jackson and Jeggo, 1995). The DNA-
PK consists of a catalytic subunit and an associated DNA binding element (Ku). The 
binding of Ku to the DNA ends activates the DNA-PK, which is subsequently 
thought to recruit accessory repair proteins to the lesion where it might be responsible 
for their activation by phosphorylation. The actual in vivo targets for this 
phosphorylating activity remain to be determined. It is possible that the DNA-PK 
molecule serves to align the two ends of the double strand break, acting as a bridging 
factor, to facilitate ligation. 
The double-strand break repair mechanism has characteristics in common with the 
V(D)J rearrangement process, the lymphoid site-specific recombination mechanism 
that is responsible for generating a diverse repertoire of immunoglobin and T-cell 
receptor genes by recombining various gene segments. Both processes involve 
double strand breaks and the joining of non-homologous ends. Severe combined 
immune deficient (scid) mutant mice are deficient in B- and T-cells due to a defect in 
r.:4 
V(D)J recombination. Cells from these mice are sensitive to ionising radiation 
suggesting that the scid protein plays a role in double-strand break repair. A number 
of X-ray sensitive rodent cell lines have been identified and the cloning of the 
complementing (XRCC) genes will enable further elucidation of the double strand 
break repair mechanism. 
1.6 Double strand break repair by homologous recombination 
In addition to the non-homologous end joining mechanism, double-strand breaks can 
be repaired by the more biologically complex mechanism of homologous 
recombination (reviewed by Kanaar et al., 1998). In this mechanism the second intact 
copy of the chromosome acts as the repair template, to ensure faithful restoration of 
any sequence loss at the break point. The RAD52 epistasis group genes, from S. 
cerevisiae, have been identified as those required for DSB repair by homologous 
recombination. A number of mammalian homologues to these yeast genes have also 
been isolated, pointing to evolutionary conservation of this pathway. The ends of the 
double strand break are processed, by a nuclease activity, to produce single stranded 
3' overhangs. The single-stranded DNA ends from the damaged chromosome invade 
the homologous intact duplex DNA, initiating strand exchange. Following the 
formation of a joint molecule between the damaged and undamaged duplex DNAs, 
DNA is synthesised from the damaged ends using the intact strands as templates 
(branch migration). Finally the crossed DNA strands (Holliday junctions) are 
resolved, by a resolvase which cleaves to the two separate duplexes. It is often 
suggested that this more accurate repair pathway is favoured in the unicellular lower 
eukaryotes and mammalian germ and stem cells where the non-homologous end-
joining is more likely to result in errors if nucleotides are added or lost at the break 
and the less accurate end-joining mechanism is tolerated in differentiated somatic 
cells where much of the genome is no longer functional. 
1.7 Base excision repair 
Base excision repair (BER) refers to the pathway in which DNA bases, damaged by 
spontaneous hydrolysis or attack by free radicals, are generally removed and DNA is 
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repaired (reviewed in Friedberg, Walker and Siede, 1995; Wood, 1996 and Lindahi, 
Karran and Wood, 1997). In BER the damaged or inappropriate base is recognised by 
one of several DNA glycosylases, which hydrolyses the gylcosylic bond linking the 
damaged base to the deoxyribose sugar and thus releases the base, generating an 
abasic site (Figure 1.1). Each of the glycosylases, including uracil-DNA glycosylase 
and 3-methyladenine-DNA glycosylase, is specific for a small subset of lesions. The 
repair of the resultant apurinic or apyrimidinic (AP) site is initiated by the action of 
an AP endonuclease, which produce incisions in the phosphodiester backbone by 
hydrolysing the bond to the 5' of the AP site. The completion of BER involves the 
removal of the 5' phosphate residue, generated by the action of the AP endonuclease, 
repair synthesis and ligation. The majority of AP sites are repaired by DNA 
polymerase 13  (pol f3) which adds a single nucleotide to the 3' end and removes the 5' 
terminal phosphate residue. Subsequent ligation is performed by DNA ligase ffi. 
Alternatively, longer repair tracts can result when the polymerase (either poif3, polE 
or pol) adds a number of nucleotides, in a nick translation reaction displacing the 
parental strand in the process. This generates an overhanging 5' terminal single 
stranded tract, which is removed by the action of structure specific nuclease DNase 
IV. This pathway shows a requirement for PCNA. Ligation of the termini is carried 
out by DNA ligase I. Recently, it was shown that the base excision repair of oxidised 
pyrimidine lesions, such as thymine glycol, is activated by the nucleotide excision 
repair enzyme XPG. The function of XPG in the base excision repair of oxidative 
damage is distinct from its NER endonuclease activity indicating overlapping 
functions for the components of the various repair pathways (Kiungland et al., 1999). 
1.8 Mismatch repair 
The DNA mismatch repair (MMR) pathway serves to correct errors resulting from 
inappropriate incorporation of nucleotide bases during replication. The discovery that 
mutations in mismatch repair genes segregate with hereditary non polyposis colon 
cancer has lead to a greater interest in this postreplicative repair process, in recent 
years (reviewed by Lindahi, Karran and Wood, 1997 and Jiricny, 1998). In mammals, 
mismatch repair is carried out using protein homologues of the E. co/i MMR proteins 
Figure 1.1 Schematic representation of BER pathways 
A model for the mechanism of base excision repair, adapted from Wood 1996. The 
sugar phosphate backbone is indicated by lines, whilst bases are depicted by circles. 
Open circles represent bases present in the DNA molecule before repair and closed 
circles are the bases introduced by the repair mechanism. See text for details. 
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MutS and MutL, indicating that this repair pathway has been conserved during 
evolution. At this point in time, whilst there is some understanding of how 
mismatches are recognised, little is known about the mechanisms which identify the 
incorrect strand or the processes involved in the excision and repair of the 
mismatched sequences. 
Mismatch recognition is performed by heterodimeric protein complexes hMutSa 
(hMSH2 and hMSH6, human homologues of MutS) or hMutS (hMSH2 and 
hMSH3, human homologues of MutS). The hMutSa complex binds preferentially to 
single base mismatches, single base and two base loops, whilst hMUTSP recognises 
mismatches resulting in loops of more than two bases. The hMutL complex (hMLH1 
and hPMS2, the human homologues of MutL) is recruited to the DNA-protein 
complexes whereby it acts as a secondary recognition factor which is required to bind 
before excision and repair can take place. Following mismatch recognition the 
incorrect base and surrounding sequences up to 1kb away are excised, before repair 
synthesis using the normal template strand takes place. The precise nature of this 
excision, polymerisation and ligation process remains to be determined for higher 
eukaryotes. Recently, the DNA replication protein, proliferating cell nuclear antigen 
(PCNA), has been implicated in MMR. It is possible that the interaction between 
MMR proteins and PCNA may be responsible for the strand discrimination. The 
subsequent excision and repair processes may employ proteins responsible for 
analogous functions in the nucleotide excision repair pathway (NER). Evidence 
supporting the interaction between MMR and NER was gained from yeast two-
hybrid analysis which showed that the MMR MSH2 interacted with six different 
NER proteins (RAD1, RAD2, RAD3, RADiO, RAD14 and RAD25) (Bertrand et al., 
1998). The precise nature and biological significance of these interactions remains to 
be determined. A model for MMR is presented in Figure 1.2. 
1.9 Nucleotide excision repair 
Nucleotide excision repair (NER), the principle focus of the work to be presented in 
this thesis, is perhaps the most extensively studied of the repair pathways. This 
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Figure 1.2 Schematic representation of the mechanism of human mismatch 
repair 
A model for the mechanism of mismatch repair, adapted from Lindahi 1997. The 
sugar-phosphate backbone is indicated by lines, whilst bases are depicted by circles. 
Open circles represent bases present in the DNA molecule before repair and closed 
circles are the bases introduced by the repair mechanism. Repair proteins are 
represented by shaded ellipses. See text for details. 
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pathway is capable of removing the broadest range of DNA lesions including the 
UV-induced photoproducts (cyclobutane pyrimidine dimers and 6-4 photoproducts), 
bulky chemical adducts and intrastrand cross-links. In the simplest of terms NER 
consists of five steps: damage recognition, dual incision, excision, repair synthesis, 
and ligation (reviewed by Sancar, 1996; Wood, 1996; and Lindahl, Karran and 
Wood, 1997). 
As with the other repair pathways described already, the study of NER in higher 
eukaryotes was greatly aided by the characterisation of the less complicated NER 
pathway in E. coli. In E. coli DNA lesions are first recognised by the UvrA2B 
helicase complex, the UvrA subunits then dissociate leaving the UvrB bound at the 
site of damage where it recruits the UvrC subunit which in turn mediates the 
incisions to either side of the lesion. The lesion is then excised, by the combined 
action of UvrD and DNA polymerase I, as a 12-13 base oligonucleotide with the 
bound Uvr subunits. The resultant gap is filled in by DNA polymerase I and sealed 
by DNA ligase. 
In mammals, NER consists of two subpathways, the first pathway global genome 
repair (GGR) deals with DNA lesions throughout the genome, whilst the second 
pathway, transcription-coupled repair (TCR), is involved in the repair of lesions in 
actively transcribed genes. The gene products involved in mammalian NER were 
largely identified by means of studies involving NER mutant cell lines from the 
seven xeroderma pigmentosum complementation groups (A through G), and UV-
sensitive rodent cell lines defective in their excision repair cross complementing 
(ER CC) genes. It has been shown that some of the ERCC genes are identical to the 
XP genes, where this is true, the XP nomenclature has been adopted. The current 
model for mammalian NER indicates the involvement of 25 polypeptides. 
The initial step in mammalian NER is the identification of the DNA lesion. This is 
believed to be performed by the proteins XPA and RPA which both bind 
preferentially to damaged DNA and have been shown to interact with each other 
(Robins et al., 1991 and He et al., 1995). In addition to the XPA-RPA complex, both 
XPC and XPE have been shown to bind preferentially to damaged DNA, although 
the precise role of XPE in NER is as yet undetermined. In vitro reconstitution studies 
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have shown that XPE is not essential for repair up to the point of incision in vitro. 
XPC is not required for transcription-coupled repair (Venema et al., 1991). Recently 
published in vitro studies have shown that XPC, as a complex with HHR23B, may be 
responsible for damage detection in the global repair pathway prior to damage 
verification by XPA (Sugasawa et al., 1998). The XPA-RPA complex recruits the 
basal transcription factor TFIIH, which has as two of its subunits the DNA helicases 
XPB and XPD (van Vuuren et al., 1994), to the damaged site. The action of the 
helicases serves to unwind the DNA in the damaged region. This localised unwinding 
facilitates the access of the endonucleases to the region of damage. Whilst the DNA 
is unwound by the action of the helicases, RPA binds to the undamaged DNA strand 
where it is believed to prevent inappropriate incision of the undamaged strand by 
endonucleases. 
The first incision at the damaged site is performed by the XPG nuclease, which binds 
to RPA on the 3' side of the lesion (O'Donovan et at., 1994). The lesion-carrying 
strand is then cut at about 6 to 9 bases 3' to the lesion (Huang et at., 1992 and Moggs 
et at., 1996). The 5' incision is made by a second structure specific endonuclease, the 
ERCC1-XPF complex (Sijbers et al., 1996), 16 to 25 bases 5' to the lesion. Both in 
vivo and in vitro studies have indicated that the ERCC1-XPF endonuclease is 
positioned at the damaged site by virtue of an interaction between ERCC 1 and the 
XPA component of the bound XPAIRPA complex (Li et al., 1994 and Saijo et al., 
1996). The damaged 22-30 base oligonucleotide is then removed with some of the 
repair proteins still bound (Mu et al., 1996). The size of the excised fragment and the 
positions of the incisions relative to the lesion vary according to the nature of the 
lesion. The remaining single stranded gap is filled in by the concerted action of the 
still bound RPA, DNA polymerase S or E, PCNA, replication factor C (RFC) and 
finally DNA ligase seals the repair patch (Figure 1.3). 
Bohr et at. (1985) first reported that UV-induced pyrimidine dimers were more 
efficiently repaired in active genes than in the genome overall. This analysis was later 
extended to show that the dimers were more efficiently removed from the transcribed 
strand and that the rate repair of the non-transcribed strand did not differ from overall 
genome repair. The precise nature of the mechanism behind this transcription- 
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Figure 1.3 Schematic representation of the mechanism of nucleotide excision 
repair in mammals 
A model for the mechanism of mammalian nucleotide excision repair, adapted from 
Wood, 1996. The sugar-phosphate backbone is indicated by lines, whilst bases are 
depicted by circles. Open circles represent bases present in the DNA molecule before 
repair and closed circles are the bases introduced by the repair mechanism. Repair 
proteins are as identified and are represented by shaded ellipses. See text for details. 
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coupled repair remains to be determined. It is believed that the repair mechanism is 
initiated when the RNA polymerase II complex becomes stalled at a DNA lesion in 
the transcribed strand of the duplex. Additional polypeptides, including CSA and 
CSB, are believed to be involved in altering the conformation of the stalled RNA 
polymerase to facilitate the initial binding of the repair factors XPA, RPA (TFII1H is 
already bound in its capacity as a transcription factor), after which the repair process 
proceeds as described for GGR. 
1.10 Human inherited disorders of nucleotide excision repair (NER) 
Genomic instability is associated with a number of human inherited disorders 
including Fanconi anaemia (FA), ataxia telangiectasia (AT) and Blooms syndrome 
(BS). Each of these diseases is characterised by hypersensitivity to particular 
mutagenic agents and a predisposition to cancer. At a cellular level, these disorders 
are characterised by defective cellular responses to DNA damage as opposed to 
defects in excision repair or its auxiliary processes. Although cells from FA patients 
show defective repair of cross-links, additional evidence points to a primary defect of 
cell cycle, control, failure to prevent the replication of cross-linked DNA resulting in 
chromosome damage. Cells from AT patients show hypersensitivity to ionising 
radiation thought to be as a consequence of the failure to arrest the cell cycle in order 
to permit the repair of strand breaks. The hypermutability associated with Bloom's 
syndrome is thought to be as a consequence of a reduced ability to resolve certain 
DNA structures generated during replication, leading to error prone recombination. 
Defective NER has been associated with three diverse human inherited disorders 
xeroderma pigmentosum (XP), Cockayne's syndrome (CS) and the photosensitive 
form of trichothiodysrophy (PIBIDS). The clinical features of the classical forms of 
these disorders will be described in this section (reviewed in Friedberg, Walker and 
Siede, 1995 and Cleaver, 1995). 
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease, occurring in the 
population at between 1 in 250,000 and 1 in 40,000 according to geographic location. 
Patients are clinically characterised by severe photosensitivity of exposed regions of 
the skin, pigmentation abnormalities, a predisposition to skin cancers (2000-fold 
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higher than normal), elevated incidence of tumours on other sun exposed tissues 
including tongue and eyes, increased rate of internal cancers (20-fold higher than 
normal), and neurological abnormalities including deafness and progressive 
neurodegeneration, are evident in 20% of XP patients. The average age for the onset 
of skin neoplasias is 8 years, 50 years younger than in the general population. 
Cockayne's syndrome (CS) is an extremely rare disorder in which the patients are 
clinically characterised by virtue of early presentation of UV sensitivity, with 
significant erythema following minimal sun exposure, dwarfed appearance following 
arrest of growth and development, impaired sexual development, progressive 
neurological abnormalities resulting from neurodemyelination and mental 
retardation. Additional features of CS include deafness, dental caries and retinal 
pigmentary degeneration. CS patients do not show pigmentation abnormalities or 
present a predisposition to cancers. 
Trichothiodystrophy (T'FD) is another autosomal recessive disorder. The clinical 
features of TTD include brittle hair and nails resulting from deficiency of cysteine-
rich matrix proteins, ichthyosis (fish-like scaled skin), short stature, mental 
retardation, and distinctive facial features (protruding ears and receding chin). A form 
of TTD, with additional symptoms is represented by the acronym PIBIDS, indicating 
the presence of photosensitivity, intellectual impairment, brittle hair, ichthyosis, 
decreased fertility and short stature. Photosensitive TTD patients do not present a 
predisposition for skin cancers. 
The principle clinical features of these disorders are summarised in the table overleaf 
(Table 1.1) 
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Table 1.1 Summary of the clinical features of XP, CS and photosensitive TTD 
Clinical feature XP CS TTD 
UV-sensitivity + + + + 
Abnormal skin pigmentation ++ - - 
Skin cancer ++ - - 
Brittle hair and nails - - + 
Short stature - + + 
Mental retardation - + + 
Neurodemyelination - + ? 
Neurological degeneration + - 
1.11 Genetic basis and complexity of the human inherited disorders XP, CS and 
TTD 
Clinically, XP, CS and TTD present as quite distinct diseases yet there is evidence 
that these disorders do, infact, overlap with each other. In some cases patients have 
presented combined features of XP/CS and XP/TTD. 
The cause of the XP phenotype was first identified as defective NER when cells from 
XP patients were seen to display increased sensitivity to DNA damaging agents and a 
reduced level of unscheduled DNA synthesis (UDS). It was noted that the levels of 
sensitivity and UDS showed marked variation between patients. The highest degree 
of sensitivity was found in cells from XPA patients whilst cells from XPE patients 
showed a near normal sensitivity to UV irradiation. Subsequent cell fusion studies 
revealed that this variation was a function of heterogeneity at the molecular level. XP 
patients fall into seven complementation groups (XPA through XPG) and an 
additional variant group XPV (clinical symptoms of XPV match the classical form 
without neurological abnormalities, cells do not exhibit NER deficiency). The genes 
for the A, B, C, D, F and G complementation groups have now been cloned. In many 
cases the XP genes have been found to be identical to genes isolated from earlier 
studies involving 11 UV-sensitive rodent complementation groups, mainly Chinese 
hamster ovary cell derived. The genes complementing these rodent cells 
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Table 1.2 Summary of NER disease complementation groups and genes. 
Complementation Cloned Clinical Gene function 
Group (gene) ERCC Gene presentation  
XPA XP Damage recognition 
(Tanaka, 1989)  
XPB 3 XP/ XP-CS DNA helicase, subunit of TFIIH 
(Weeda et al., / TTD 
1990)  
XPC - XP Global genome repair 
(Legerski and 
Peterson, 1992)  
XPD 2 XP/ XP-CS DNA helicase, subunit of TFIIH 
(Weber, 1988)  / TTD  
XPE - XP Damage recognition? 
(Gene not cloned) 
XPF 4 XP Endonuclease, 5' of lesion 
(Thompson, 1994)  
XPG 5 XP / XP-CS Endonuclease, 3' of lesion 
(Mudgett and 
Maclnnes, 1990)  
XPV - XP Unknown 
(Gene not cloned) 
CSA - CS Transcription-coupled repair 
(Gene not cloned) 
CSB 6 CS Transcription-coupled repair 
(Troelstra et al., 
1990)  
TTDA - TTD TFffli subunit 
(Gene not cloned) 
- 1 - Endonuclease, 5'of lesion 
(Westerveld 
1984)  
were denoted excision repair cross-complementing (ERCC). The relationship 
between the previously cloned ERCC genes and the XP complementation groups is 
summarised in Table 1.2. 
Cell fusion experiments revealed that there were two complementation groups in the 
classical form of CS; CSA and CSB. However it has been shown that in addition to 
these groups patients with XPB, XPD or XPG can present a combined XP/CS 
phenotype. Similarly, it was found that the XPB or XPD genes complemented the 
underlying molecular defects in several TTD patients. These XP genes did not 
complement one additional TTD complementation group, TTDA. Together these 
findings suggest that in addition to the eight XP complementation groups, there are 
five 5 CS complementation groups (including the three XP/CS groups) and three 
TTD complementation groups (including the two XP/TTD groups). 
The identification of the genetic complexity underlying these disorders raised a 
number of questions concerning the mechanisms by which mutations in certain genes 
could give rise to disorders with phenotypic consequences as divergent as a 2000-
fold higher incidence to skin cancer (XP) and no predisposition to cancers (CS and 
TTD). This enigma will be considered further in the following section. 
1.12 Correlation between NER deficiency and predisposition to cancer 
If XP is first considered in isolation, it has been shown that most of the XP genes 
have a clear role in NER. Despite retaining the transcription-coupled repair pathway, 
XPC patients still exhibit a predisposition to skin cancers, suggesting that the cancer 
proneness is a function of defective GGR. The excepted model being that failure to 
repair DNA damage leads to mutations which then result in carcinogenesis when 
mutations occur in genes involved with the control of cell growth and division. The 
cancer predisposition of the NER proficient XPV group is apparently caused by a 
defective post-replication repair process. 
At the molecular level the cells from XP, TTD and CS patients are all defective in 
NER, CS cells being deficient in only the transcription-coupled element of NER, yet 
at the clinical level the symptoms are so divergent. Despite the shared cellular defect 
in NER, it has been suggested that the clinical symptoms presented by CS and TTD 
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patients represent defects in basal transcription, reflecting the roles played by the 
relevant gene products in both transcription and DNA repair. Whilst it would be 
predicted that the complete loss of transcription would be lethal, it is not difficult to 
imagine how impaired transcription could lead to symptoms such as growth 
retardation. Consequently, both CS and TTD have been described as 'transcription 
syndromes'. This hypothesis will be considered by focusing on the XPD gene 
(reviewed by Chu, 1996). It has been shown that mutations in XPD are associated 
with XP, XP/CS and TTD. XPD is a subunit of the TFIIH basal transcription factor, 
which in addition to its role in NER is involved in loading RNA polymerase H onto 
promoters to initiate transcription. An XPD mutation affecting the repair capacity of 
TFIIH would result in XP. Whilst a mutation that impaired the transcriptional 
capacity of TFIIH could compromise the synthesis of certain proteins, for example 
the sulphur-containing proteins absent from the hair of TTD patients. This model is 
referred to as the 'transcription syndrome' hypothesis. Intrinsic, to this hypothesis is 
the suggestion that the phenotypic consequences of mutations in the XPD gene would 
correlate with particular regions (functional domains) of the XPD gene product. It 
appears that the mutations, characterised thus far, are clustered in the carboxy-
terminal region of the gene and the mutations do not reveal either XP or TTD. 
domains. It is clear that no single mutation is shared by an XP and TTD patient and, 
as such, the mutations appear to be XP or lTD specific. This hypothesis provides a 
plausible explanation for the 'non-repair' symptoms associated with TTD and CS. It 
appears that the overlapping phenotypic complexity of these disorders stems from the 
additional functions played by NER proteins in other cellular processes. 
1.13 Cloning and characterisation of ERCC1 
Of the many genes involved in the complex mechanism of NER, the work presented 
in this thesis focuses on ERCC1. A review of the ERCC1 studies performed to date 
will be presented. Genetic complementation of UV sensitive rodent cell lines (1-11) 
led to the molecular cloning of the excision repair cross complementing genes 1 to 6 
(ERCCJ-6). As described previously, subsequent studies revealed that the majority of 
these genes were complementing genes for several of the XP groups (ERCC2, 3, 4, 5) 
in addition to the CS group B (ERCC6). The remaining ERCC gene ERCC1 failed to 
complement any of the known NER disease complementation groups (van Duin et 
al., 1989), and has yet to be associated with any other known human disorder. All of 
the other cloned NER genes have been associated with inherited disorders and, as 
such, have been shown not to be essential for viability. It remains possible that a 
human ERCC1 inherited disorder remains to be identified or that ERCC1 deficiency 
is not compatible with viability in humans. The survival of xeroderma pigmentosum 
patients, completely lacking in NER, suggests that if ERCCJ deficiency in humans is 
not compatible with survival it may have a further, as yet, unconfirmed function, the 
inactivation of which is lethal. 
The human ERCC1 gene, the first mammalian DNA repair gene to be cloned, was 
cloned by virtue of its ability to complement the UV sensitive CHO cell line 43-313 
(Westerveld et al., 1984). The ERCC1 mutation in this cell line was only recently 
characterised as a missense mutation at the 98th amino acid residue (Hayashi et al., 
1998). The gene consists of ten exons spanning 15kb of chromosome 19 and gives 
rise to a major mRNA transcript of 1.1kb, with alternative splicing and differential 
polyadenylation resulting in additional transcripts of 1kb, 3.4kb and 3.8kb 
respectively (van Duin et al., 1987). The role of the alternatively spliced 1kb 
transcript, lacking exon 8, is unclear as it has been demonstrated that it does not 
encode a repair proficient product (van Duin etal., 1986). The cloned human ERCCJ 
cDNA was used to isolate the mouse ERCC1 homologue, which also consists of ten 
exons spanning about 16kb of mouse chromosome 7 (van Duin et al., 1988). At the 
nucleotide level the sequence similarity between the two coding regions is 82%. The 
3' end of the ERCCJ gene, in mouse and man, overlaps with the 3' end of another 
gene ASEJ (antisense ERCC1), the function of which remains to be elucidated (van 
Duin et al., 1989). 
In both cases, the expression of ERCCJ is driven by a promoter devoid of all 
classical promoter elements such as GC-rich regions, TATA and CAAT boxes. 
ERCCJ transcription is not induced by UV irradiation and occurs at low levels in all 
tissues and developmental stages examined to date. This finding is in agreement with 
the promoters of other NER genes including XPA (van Oostrom etal., 1994). 
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1.14 The ERCC1 protein 
The ERCC 1 protein is known to complex with the XPF protein to form a structure 
specific endonuclease responsible for making the 5' incision in mammalian NER 
(Sijbers et al., 1996). Additional functions for ERCC1 remain to be determined, 
although the hypersensitivity of ERCCJ mutants to cross-linking agents and 
homology with yeast recombination proteins may indicate a role in a recombination 
pathway. 
The ERCC1 cDNA has an open reading frame that encodes a polypeptide of 297 
amino acids in humans, and 298 amino acids in mouse, with an estimated molecular 
weight of 33 kDa. The overall identity between the encoded proteins is 85% with 
most of the amino acid variation being at the N-terminal region of the proteins. There 
is 70% identity in the first 100 amino acids, 97% identity in the next 100 amino acids 
and 89% identity in amino acids 200 to 298. The encoded proteins harbour a putative 
DNA binding domain and a nuclear location signal (NLS). The NLS is located at the 
N-terminal region of the protein between residues 17-23, whilst the DNA binding 
domain spans residues 134-156 (Hoeijmakers etal., 1986). 
The translated mouse and human ERCCJ sequences show extensive homology with 
the Saccharomyces cerevisiae RADIO and Saccharomyces pombe swiiO genes. The 
homology between the mouse and human ERCC 1 proteins and the yeast RAD 10 and 
swi10 is most significant in the middle region of the proteins (corresponding to the 
C-terminal regions of the yeast proteins). There is no significant homology between 
the N-termini of the proteins. In yeast, RADIO complexes with RAD1 to form an 
endonuclease which makes the 5' NER incision, analogous to the role of the 
ERCCJ/XPF complex in mammals. The yeast proteins are known to play a role in 
mitotic recombination, such a function remains to be shown for the mammalian 
homologues (Tomkinson et al., 1993 and Bardwell et al., 1994). The mammalian 
proteins also have an additional 83 C-terminal residues that are absent from the yeast 
homologues. This C-terminal 'extension' of the mammalian proteins shares 
homology with regions of the E. coli NER excision protein UvrC (van Duin et al., 
1986 and Hoeijmakers et al., 1986). The observed 'homology points to the 
conservation of basic DNA repair mechanisms through evolution. 
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Mutational analysis has indicated that the repair capacity of the ERCC 1 protein was 
not compromised by deletion of the first 91 N-terminal residues, whereas deletion of 
only 5 residues at the C-terminal resulted in complete inactivation of the protein 
(Sijbers et al., 1996). The C-terminal deletions effect the region of shared homology 
with the UvrC of E. coli, the C-terminal region of which was recently shown to be 
involved in DNA binding and incision (Moolenaar et al., 1998). Similarly, it has 
been shown that the overexpression of an ERCC 1 protein with only two additional 
residues inserted in the C-terminal region resulted the induction of sensitivity to 
cross-linking agents in repair proficient cells, suggesting that the mutant protein 
competed against the endogenous wild type ERCC 1 to impair the repair process (Belt 
et al., 1991). The low level of ERCC 1 protein is a common feature of cells from XPF 
patients, suggesting that where ERCC 1 is unable to form a complex the free protein 
is not stable (Yagi et al., 1997). 
1.15 The interactions of ERCC1 with XPF and XPA 
The first evidence of an interaction between ERCC 1 and the XPF proteins came from 
the observation that cell free extracts from rodent ERCCI and ERCC4 mutant cells as 
well as human XPF cells did not complement each other in vitro. This indicated that 
the complementing activity that was absent from the ERCC1 mutant cells was in 
some way associated with the complementing activity of ERCC4 and XPF cells. It 
was already known that the ERCCI cDNA did not complement either ERCC4 or XPF 
cells, but at this point although the complementing ERCC4 and XPF genes had yet to 
be cloned they were believed to be equivalent. Furthermore it was shown that when 
ERCC1 was depleted from wild type cell extracts (using antibodies), the depleted 
extract was no longer able to complement the ERCC4 or XPF cells (van Vuuren et 
al., 1993). It was subsequently demonstrated that the correcting activities for the 
ERCCJ, ERCC4 and XPF co-purified as a high molecular weight species of 
approximately 100-120 kDa. This complex was used to correct the repair defects of 
each of the groups in vitro (Biggerstaff et al., 1993). Further purification and 
characterisation of the complex showed that it contained ERCC1 and a 112kDa 
species, presumably ERCC4 or XPF, which was capable of endonuclease activity 
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(Park et al., 1995). It was later confirmed that ERCC4 and XPF were equivalent 
(Sijbers et al., 1996). Thus it was known that ERCC1 formed a heterodimeric 
complex with XPF to constitute an endonuclease. 
Only recently has the precise nature of the interaction between ERCC 1 and XPF been 
determined. Using a series of C- and N-terminal truncated recombinant ERCC 1 and 
XPF proteins it has been demonstrated that the minimal domain for stable XPF 
binding spans residues 224 to 297 of the human ERCC1, whereas residues 814-905 
in XPF were deemed sufficient for the stable binding to ERCC1 (de Laat et al., 
1998). Somewhat surprisingly, the interaction domains in ERCC1 and XPF do not 
coincide with the binding domains previously identified for the S. cerivisiae 
homologues RADIO and RAD 1. Indeed, the binding domain in ERCC 1 maps to the 
C-terminal extension that shares homology with the E. coli NER protein UvrC. The 
relative positions of the protein interaction domains of ERCC 1, XPF and XPA are 
illustrated in the Figure below (Figure 1.4). 
Figure 1.4 Summary of ERCC1 interaction domains 
XPF: 	11 	 814 	905 
A schematic representation of the known interaction domains of ERCC 1, XPF and 
XPA. Amino acid residues (human) are numbered and the interaction domains are 
indicated by diagonally striped boxes. 
In addition to its endonuclease forming association with XPF, ERCC 1 has also been 
shown to interact with the XPA protein. The currently accepted model for NER 
suggests that DNA lesions are first recognised and bound by XPA, the primary 
recognition protein. It is believed that this interaction is responsible for the 
appropriate positioning of the endonuclease at the damaged site. XPA itself interacts 
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with numerous other factors including RPA and the basal transcription factor TFIIH. 
The ERCC1/XPF complementing complex was isolated from cell free extracts by 
binding to an XPA affinity colunm, demonstrating the formation of a ternary 
complex between XPA and the ERCC1/XPF heterodimer (Park and Sancar, 1994). 
Two hybrid analysis and in vitro studies with truncated recombinant proteins have 
shown that there is a direct interaction between residues 92-119 of ERCC1 and 
residues 75-1 14 of XPA (Lei et al., 1994) (Figure 1.4). Analysis of the UV sensitive 
rodent cell line CH043-3B has shown that the mutant form of ERCC 1 expressed in 
this cell line is capable of binding with XPF in vitro but fails to interact with XPA 
(Hayashi et al., 1998). 
1.16 Gene targeting 
The simplest and most direct method of determining the function of any gene is to 
assess the consequences of its loss of function. Whilst a number of animal models of 
human disorders have been identified following spontaneous and randomly 
introduced mutations, simple factors of animal husbandry mean that to rely on this 
approach to identify and study the consequences of specific gene inactivating 
mutations would be too time consuming and extremely costly. The development of 
gene-targeting technology has meant that we are no longer reliant on random 
mutagenesis events to provide animal models of human disorders. Gene targeting is 
defined as "homologous recombination between DNA sequences residing in the 
chromosome and newly introduced DNA sequences, enabling the transfer of any 
desired alteration of the cloned sequences into the genome of a living cell" 
(Cappechi, 1989). Whereas it was initially only possible to 'knockout' genes, today's 
advanced technology means a variety of other alterations are possible (reviewed by 
Melton, 1994). In many cases more subtle gene alterations are required to faithfully 
mimic actual human disorders, as with the point mutations in the prion protein (PrP) 
gene associated with familial Creutzfeldt-Jakob disease (a neurodegenerative 
disorder) (Moore et al, 1995). In cases where the inactivation of a gene results in 
embryonic lethality (Bentley et al, 1996) conditional deletion of the gene in specific 
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tissues of the adult can be used as a means of studying the consequences of loss of 
gene expression in later stages of development (Selbert et al., 1998). 
The success of a gene-targeting strategy relies on the ability of the introduced cloned 
sequences to recombine with homologous endogenous sequences and, most 
importantly, the ability to enrich for, and identify these events. When DNA is 
introduced to a cell it can either randomly integrate into the genome, or integrate by 
homologous recombination. To enrich for the latter event a positive-negative 
selection strategy is employed (Mansour et al., 1988). Positive selection simply 
identifies those cells that have integrated the exogenous targeting vector DNA. The 
most frequently used positive selection system involves selecting for the bacterial 
neomycin phosphotransferase gene (ned) by resistance to culturing in G418. 
Selection against random integration events is achieved by flanking the homologous 
sequences with negative selectable markers, such as the Herpes simplex virus 
thymidine kinase gene (TK) or, alternatively, a mouse hypoxanthine 
phosphoribosyltransferase (HPRT) minigene. In the event of a random integration 
event, the linearised targeting vector integrates by its ends and, consequently, the 
negative selectable markers will be integrated into the genome. Selection against 
these markers is achieved by the culturing of transfected cells in medium with the 
toxic thymidine analogue gancyclovir (GC) and 6-thioguanine (6-TG), respectively. 
After selective enrichment, homologous recombination events are then confirmed 
using a PCR assay specific for the targeted allele before further comprehensive 
analysis by Southern blot. The targeted inactivation of the mouse ERCC1 gene by 
Selfridge et al. provides an illustration of the successful application of such a 
positive-negative selection strategy. In this instance positive selection and insertional 
inactivation was achieved by inserting a neo' cassette into exon 5 of the ERCCJ gene. 
Negative selection was enabled by including both, a TK and an HPRT minigene at 
either end of the region of homology (Figure 1.5). 
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Figure 1.5 Strategy for the targeted inactivation of ERCC1 in mouse embryonic 
stem cells (HM-1) 
A representation of the positive negative selection procedure adopted for targeting 
strategies in HPRT-deficient embryonic stem cells. The 15kb mouse ERCC1 gene is 
shown schematically, exons are numbered and shown by vertical open boxes and 
introns are depicted by horizontal open boxes. The linear targeting vector is also 
shown schematically, homologous sequences of the targeting vector are represented 
by filled boxes and exons are numbered. HPRT minigene is represented by a heavily 
stippled box. Herpes simplex virus thymidine kinase gene (TK) is represented by a 
lightly stippled box. Neomycin transferase cassette (NEO) is represented by a 
diagonally striped box. 
The targeting vector consisted of a region of homology spanning exons four to six of 
the ERCC1 gene, with two flanking markers for negative selection as shown. In the 
event of random integration of the vector sequences the negative selectable markers 
are also integrated into the genome. Only after homologous recombination events are 
the cells are neomycin positive and G418 resistant, HPRT negative and 6TG 
resistant, TK negative and gancyclovir resistant. The arrows indicate the predicted 
homologous recombination event. The structure of the targeted ERCCJ allele is 
shown schematically and shows the integrated vector sequences as filled boxes and 
the endogenous gene sequences as open boxes. The arrowheads indicate the positions 






1.17 Production of knockout mice using an HPRT-deficient embryonic stem cell 
line (HM-1) 
The targeting of an allele in cultured embryonic stem cells is generally the first step 
towards generating mice heterozygous and homozygous for the targeted alteration 
(Mcwhir et al, 1993 and Redhead et al, 1996). Mouse embryonic stem cells are 
derived from the inner cell mass of blastocysts, in vivo these cells differentiate to 
form all cell types in the developing mouse. When cultured in vitro the cells maintain 
their pluripotency (Evans et al, 1981). Thus, following successful gene targeting, ES 
cells can be microinjected into a host blastocyst, which is then surgically re-
implanted into the uterus of a pseudopregnant recipient mouse. The pluripotent stem 
cells are capable of contributing to all tissues of the developing animal, including the 
germline. The chimaeric offspring can be identified by means of their heterogeneous 
coat colouring. For instance, if the stem cell line in question is derived from a 
chinchilla coloured 129/01a mouse, when these cells are injected into a Ba1bC (white 
coat) host blastocyst any chimaeras will have a mixed chinchilla and white coat. The 
extent of chimaerism will be reflected by how much chinchilla colouring is evident in 
the coat. If the pluripotent targeted stem cells have indeed contributed to the 
germline, any alteration to the genome can be transmitted to the offspring of the 
chimaeras following test matings. Germline transmission can also be monitored by 
means of observing the coat and eye colours of the offspring from the chimaeras, 
where ES cell derived progeny result in different colours from host embryo derived 
progeny, due to the presence of different markers in the two strains. In the event of 
germline transmission of a targeted autosomal locus 50% of the offspring will inherit 
the targeted allele. Thus by means of gene targeting in mouse embryonic stem cells 
and generation of chimaeras by blastocyst injection it is possible to generate mice 
carrying an engineered genomic alteration (Figurel.6). 
The HPRT-deficient stem cell line HM-1 was derived from blastocysts from an 
HPRT-deficient 129/01a mouse line. This mouse strain had been generated by 
blastocyst injection of E14TG2A a spontaneous HPRT-deficient derivative of the 
wild type E14 stem cell line (Hooper, 1987). The HM-1 cell line was shown to 
contribute to the germline more frequently than the original E14TG2A line (Magin et 
Figure 1.6 Generation of mice from gene targeted embryonic stem cells 
Schematic representation of the procedure involved in generating mice heterozygous 
for a targeted gene alteration (adapted from Melton, 1994). 
ES cells are isolated from the inner cell mass of blastocysts from strain 129/01a mice. 
Gene targeting is performed whilst in culture and targeted ES cells are injected into 
the blastocyst cavity of a host embryo from a different strain (e.g. BalbC). Injected 
embryos are implanted into pseudopregnant foster mothers for development to term. 
Chimaeric offspring are identified by means of altered coat colour. 
To assess whether the ES cells have contributed to the germline of these animals, the 
chimaeras are test mated (e.g. with BalbC). Germline transmission of the 129/01a 
derived gametes is determined by transmission of the 129/01a markers for coat and 
eye colour. The 129 derived HM-1 cells are homozygous for the white bellied agouti 
(Aw) allele, and homozygous for the chinchilla (cdl)  allele at the albino locus, which 
confers a tan (chinchilla) coat colour. The HM-1 cells also carry a homozygous 
recessive allele (p) at a third locus (P) which confers pink eyes. The BalbC recipient 
embryos and studs are homozygous for the wild type alleles at the agouti (A) and 
pink eyed (P) loci as well as being albino (c/c). The albino locus is epistatic to the 
pink eyed locus so BalbC have white coats and pink eyes. Following test matings 
between HM-1 chimaeras and BalbC studs germline transmission of the ES cell 
markers is recognisable at birth; germline pups are grey with black eyes and will have 
the genetic make-up c'"/c, pIP, AWIA.  The combination of a single chinchilla allele 
with the alleles of the agouti locus results in a grey coat colour, and eye pigmentation 
is also restored. 50% of the gem-dine offspring will carry the targeted allele. Non 
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al., 1992). The male HM-1 cells are HPRT-deficient by virtue of lacking the first two 
exons of the X-linked HPRT allele (Thompson, 1989). HPRT catalyses an early step 
in the purine salvage pathway in mammals. It is possible to select against HPRT 
activity in vitro by culturing cells in medium with the toxic purine analogue 6-TG. 
Thus HPRT minigenes can be used as negative selectable markers when targeting is 
performed in HM-1 cells (see Figure 1.5). When targeting is performed in an HPRT-
deficient ES cell line such as HM-1 it is also possible to select for HPRT activity. 
HPRT is selected for by culturing cells in medium with hypoxanthine, aminopterin 
and thymidine (HAT). Aminopterin inhibits de novo synthesis of purines and 
pyrimidines. The HPRT activity enables cells to bypass the aminopterin induced 
metabolic block by utilising hypoxanthine and thymidine via the purine and 
pyrimidine salvage pathways. Thus HPRT minigenes can also be used as positive 
selectable markers if necessary (see section 1.17). 
1.18 Introduction of subtle gene alterations by 'double replacement targeting' 
In many instances the complete inactivation or 'knockout' of a gene is not the desired 
result -of a gene targeting experiment. When attempting to model a human disorder it 
is often the case that the human mutation being modelled does not actually result in a 
completely inactive gene, thus it would not be possible to make direct comparisons 
between the phenotypic consequences of a partially active human allele and a null 
allele in a mouse model. To be able to mimic the more subtle mutations of a human 
disorder a method of 'double replacement' gene targeting has been developed (see 
Figure 1 .7)(Stacey et al., 1994). This targeting strategy requires the use of an HPRT-
deficient ES cell line such as HM-1 in order to exploit the ability to select for and 
against HPRT activity. A first round of gene targeting is performed to introduce an 
HPRT selectable marker into the target locus. The HPRT minigene is selected for by 
culturing cells in medium supplemented with HAT. In this round of targeting, 
negative selection is enabled by incorporating a TK gene into the targeting vector. 
The first round of targeting generates a knockout allele. 
The second targeting step is designed to replace the inactivating HPRT marker gene 
with sequences homologous to the target gene bearing an engineered subtle 
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Figure 1.7 Double-replacement gene targeting strategy 
A hypothetical two step 'double replacement' strategy for the introduction of a point 
mutation in exon five of the mouse ERCCJ gene is shown schematically. The 
endogenous gene is represented by vertical open boxes for exons and horizontal 
boxes for introns. The homologous sequences of the first round 'knockout' vector are 
shown in black, the HPRT minigene is shown as a striped box and the TK gene is 
shown as a stippled box. Homologous sequences of the second round targeting vector 
are shown in grey and the subtle alteration is indicated by an asterisk. 
The first targeting step is designed to knockout the gene by replacing one of the 
exons and its flanking sequence with an HPRT minigene. The knockout vector also 
contains a TIC gene to enable positive-negative selection. Selection at this stage is for 
HPRT (HAT) and against TIC (gancyclovir). Homologous recombination events are 
confirmed by PCRs specific for the targeted allele. 
In the second targeting step the HPRT marker itself is replaced by the gene segment 
carrying the subtle alteration. Selection at this stage is for the loss of HPRT activity 
using 6TG. Random integration of the vector will not result in loss of the minigene. 
The presence of the subtle alteration can be confirmed using PCR analysis, often 




3 4 	 6 	 KNOCKOUT 








alteration. Selecting for the loss of the HPRT marker gene activity enriches for 
homologous recombination events. Selection against HPRT activity is achieved by 
culturing cells in the toxic purine analogue 6-TG. At both targeting steps the 
homologous recombination events are identified using PCR. As the second step 
introduces a subtle change at the target locus it is often necessary to use restriction 
fragment length polymorphism and, or sequence analysis to confirm the presence of 
point mutations( Moore et al., 1995). 
1.19 Conditional gene targeting 
The deletion of a particular gene may result in an embryonic lethal (Bentley et al., 
1996) or early developmental lethal (McWhir et al., 1993) phenotype and as such 
further analysis of gene function in vivo is somewhat limited. A further advance in 
gene targeting methodology, utilising site specific recombinases and homologous 
recombination, has provided a means of bypassing such phenotypic constraints. This 
strategy enables genes to be deleted in specific tissues or at desired stages of 
development (reviewed by Kilby et al., 1993 and Cohen-Tannoudji, 1998). 
The most frequently used method exploits the loxPiCre recombinase system from the 
bacteriophage P1. Cre (causes recombination) has been identified as a site specific 
recombinase that is capable of catalysing recombination between 34bp recognition 
sequences called loxP (locus of cross over) sites. As part of its life cycle the 
bacteriophage P1 replicates as a plasmid in E. coli. The loxPiCre recombinase system 
serves to maintain the replicating genome as a monomer, dimers are resolved by Cre 
mediated recombination. When the loxP sites are arranged in the same (head to tail) 
orientation the recombination event results in the deletion of the intervening 
sequences as a circular molecule carrying one of the loxP sites, the second loxP site 
remains in its original position. To exploit this mechanism for the purposes of gene 
targeting, conventional targeting strategies are employed to flank the gene or gene 
segment of interest with two loxP sites (described as floxing) in a head to tail 
orientation. With expression of Gre the sequences lying between the loxP sites are 
excised and the gene is inactivated. Inversion of the sequences between two loxP 
sites occurs if the recognition sequences are arranged in a head to head orientation. 
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Furthermore, it is possible for intermolecular recombination events to occur between 
loxP sites on different chromosomes, resulting in reciprocal translocations. 
Following the floxing of a locus in ES cells, the key to the success of this system lies 
with the chosen method of Cre expression. It is possible to observe Cre-mediated 
recombination in vitro following the transient expression of Gre in the targeted ES 
clone (Xiao and Weaver, 1997). In the context of conditional or stage specific gene 
deletion, it is first necessary to produce germline mice with the foxed, allele. The 
recombinase is then introduced by mating the foxed mice with mice carrying a Cre 
transgene under the control of an appropriate tissue specific, stage specific or 
inducible promoter (Schwenk et al., 1998). The foxed locus will only be deleted in 
those cells where or when Gre is expressed. Thus conditional gene targeting can be 
used to monitor the consequences of gene inactivation that might otherwise have 
been lethal. It would be difficult to underestimate the potential in this area of gene 
manipulation. The limiting factor at this stage is the production and characterisation 
of the appropriate Gre expressing transgenics. Advances in this technology will be 
facilitated by a recent agreement to establish a 'library' of Cre mice and the setting 
up of a database of all the Gre mice characterised so far (meeting review by Rossant 
and McMahon, 1999). 
1.20 Animal models 
As the number of cloned human genes continues to grow so, it seems, does the 
number of knockout mice. The ability to modify the mouse genome by means of 
homologous recombination in embryonic stem cells facilitates the use of mouse 
models to study most biological systems and to model human diseases related to loss 
of gene function. One of the systems that has benefited from this form of analysis is 
the mechanism of DNA repair. A recent review of the field listed 52 independent 
mouse knockout models that are associated with various cellular responses to DNA 
damage (Friedberg et al., 1998). Several of these mutant models involve genes 
associated with human diseases arising from defective DNA repair, such as 
xeroderma pigmentosum (e.g. Sands et al., 1995). However, it is often the case that 
the phenotypic consequences of gene inactivation in the mouse do not accurately 
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model the consequences in humans. For example, HPRT deficiency in man results in 
the severe neurological disorder Lesch-Nyhan syndrome (Lesch and Nyhan, 1964) 
whilst HPRT-deficient mice are phenotypically normal, reflecting species differences 
in the affected purine metabolism pathway (Hooper et a!;, 1987). Whilst this in itself 
can provide useful insights into differences between analogous biological systems in 
man and mouse, it can restrict any development of therapies for the diseases in 
question. With this in mind, examples of mouse models of defective NER are 
considered below. 
1.21 XPA-deficient mice: a model for XP? 
Of the seven human XP complementation groups XPA patients generally present the 
most severe symptoms including neurological abnormalities in 20% of cases 
(Cleaver, 1995). There have been two independent reports describing the generation 
and characterisation of XPA-deficient mice (de Vries et al., 1995 and Nakane et al., 
1995). Whilst the structure of the targeted alleles differed, a neo cassette inserted into 
exon four of one mouse and exons three and four deleted in the other, both mice were 
confirmed as complete nulls by northern or western blot analysis. In both cases the 
mice were perfectly viable, apparently normal and fertile. NER deficiency was 
demonstrated in terms of the hypersensitivity of fibroblast cell lines, derived from 
these animals, to UV and genotoxic compounds. Residual repair of <5% was 
measured in the mouse fibroblasts, compared to <2% seen in human XPA cells. A 
marked predisposition to UVB induced skin cancer, relative to wild type littermates, 
was also reported for both 'knockout' strains. A subsequent publication reported that 
21% of XPA mice aged over 1 year developed spontaneous tumours of the liver (de 
Vries et al., 1997). In this context the animals accurately modelled the human 
patients and were suitable models for studying the high incidence of skin cancers in 
group A XP patients. 
At the ages of 13 and 18 months neither of the mouse models exhibited any of the 
neurological abnormalities, including progressive neurodegeneration, associated with 
patients from the XPA complementation group. 
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1.22 CSB-mutated mice: a model for Cockayne's syndrome? 
The CSB gene was disrupted by the insertion of a premature stop codon in the fifth 
exon, to closely mimic a mutation previously characterised in a human patient. 
Whilst the mutated allele gave rise to a mRNA fusion transcript, no wild type protein 
was detected. The mutant CSB mice were viable and showed a small but significant 
growth deficit compared to wild type animals. Behavioural analysis was interpreted 
to suggest evidence of mild neurological dysfunction. In this context the mice were 
said to display mild Cockayne's syndrome symptoms. Unlike human CSB patients 
the fertile mice did not exhibit impaired sexual development nor did they show any 
signs of dysmyelination. 
As with the human cells, the fibroblast cell lines derived from the CSB mice were 
defective in the transcription-coupled repair, whilst global genome repair was 
unaffected. Although human CSB patients are sensitive to UV they do not show any 
increased incidence of skin cancer. However, the CSB mice were not only sensitive 
to UV but revealed a clear predisposition to skin cancers. It was suggested that the 
difference in cancer predisposition observed between humans and mice was a result 
of global genome repair in the mouse being less efficient than in humans. Further it 
was felt that the short lifespan and repeated hospitalisation of CS patients may 
conceal any predisposition to UV induced skin cancers in humans. 
1.23 XPD mutated mice: a model for trichothiodystrophy? 
The complete inactivation of XPD in the mouse resulted in a pre-implantation 
embryonic lethal phenotype (de Boer et al., 1998). The severity Of the phenotype was 
attributed to the abolition of basal transcription following the inactivation of the 
TFIIH transcription factor. Subsequently, mice were generated carrying a point 
mutation in the XPD gene which mimicked a mutation characterised in a patient with 
the photosensitive form of TTD. The arginine 722 to tryptophan mutation in exon 22 
was engineered using a single-step 'gene-cDNA fusion targeting' strategy. Basically, 
the 3' end of the mouse gene was replaced with the equivalent 3' end sequences from 
the human cDNA, carrying the point mutation. It was argued that this approach of 
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'humanising' the C-terminal region of the mouse protein would result in a more 
accurate reflection of the human patient. 
Mice homozygous for this mutation reflected several of the symptoms of TTD 
patients. The observed UV sensitivity, brittle hair due to deficiency of the cysteine 
rich matrix proteins, retarded growth, skin abnormalities, reduced fertility, and 
reduced lifespan all faithfully mirror the human condition. The XPD mutated mice 
suffered occasional tremors which may have been indicative of neurological 
abnormalities, although no defects in myelination were seen. It has been suggested 
that the manifestation of neurological abnormalities in humans is as a consequence of 
greater accumulation of DNA lesions in cells of the nervous system. 
It was noteworthy that the mouse embryonic fibroblasts with this mutation exhibited 
the same increased UV sensitivity (1.5 fold higher than wild type) as the equivalent 
human cells. However, as with the CSB mice the TTD mice revealed a clear 
predisposition to UVB and chemical-induced skin cancers, representing a major 
divergence from the TTD patients. Once more it was suggested that the increased 
incidence of cancers in the mouse might reflect a less efficient global repair 
mechanism in these animals relative to humans. As the components of NER are 
conserved between the two species this would suggest that the differences in cancer 
predisposition, seen between animal models and the human patients, may lie in a 
repair regulating mechanism which differs between the two species. It is possible that 
cell cycle arrest in rodent cells might not be as efficient as in humans and as such 
rodent cells may be more inclined to proceed with cell division without completion 
of DNA repair, resulting in an accumulation of mutations. 
1.24 ERCC1- deficient mice: the original NER deficient mouse model 
ERCC1 deficiency has yet to be associated with any human disorder and it had been 
suggested, on this basis, that ERCCJ deficiency in the mouse would result in an 
embryonic lethal phenotype. The ERCCI-deficient mice produced by this laboratory 
constituted the first mouse model of defective NER (McWhir et at., 1993). Since the 
production of the first ERCC1 - deficient mice, we have produced a second 
independent ERCC1 knockout line (Melton, unpublished data) and two additional 
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ERCC1 targeted lines have been reported by a group in Holland (Weeda et al., 1997). 
In our original knockout, inactivation was brought about by the insertion of a neor 
cassette into exon five, whilst the first of the Dutch knockouts involved the insertion 
of a neor  cassette into exon seven. The second line reported by the Dutch involved 
the introduction of a subtle mutation; a seven amino acid carboxy-terminal truncation 
was engineered by introducing a premature stop codon at residue 292. Our second 
ERCC1 knockout line (KT#209), was produced as an intermediate step towards the 
production of mice carrying a foxed ERCCJ allele, lacks exons 3, 4 and 5 and has an 
HPRT minigene inserted in between exons 2 and 6 (Figure 1.8a). Although the 
structures of the targeted alleles vary between each of the mice, if all of the targeted 
alleles are complete knockouts less variation in the phenotypic consequences would 
be anticipated. - 
We first reported that ERCCJ -deficient mice were viable but died prematurely before 
weaning at the age of three weeks. The ERCC1 nulls were severely runted compared 
to wild type littermates, weighing only 20% of wild type (Figure 1.8b). Detailed 
analysis suggested that the cause of death in these animals was likely to be hepatic 
failure. At birth, some hepatocyte nuclei were already enlarged and polyploid; by the 
age of three weeks, the number of enlarged nuclei had increased and polyploid and 
aneuploid nuclei were detected. Polyploidy is normally only observed in adult livers. 
Further, elevated levels of p53 were detected in the liver, brain and kidneys of the 
ERCC1 nulls, indicating persistence of DNA damage in these tissues. Despite the 
detection of p53 there was no evidence of increased apoptosis in the corresponding 
tissues. The general cachexic appearance of the mutant mice was characteristic of 
significantly aged animals. Northern blot analysis carried out on tissues from the 
ERCCJ nulls showed that an ERCCJ/neo' fusion transcript, believed to result from 
polyadenylation within the neo' cassette, was detectable. 
The Dutch ER CC] knockout mice survived for up to 78 days whilst those carrying 
the subtle mutation lived for up to 6 months, but were infertile. The improved 
survival of the Dutch mice relative to our nulls may be a consequence of differing 
genetic backgrounds or could possibly reflect a residual ERCC1 activity in these 
lines. In addition to the phenotypic consequences previously reported by ourselves, 
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Figure 1.8 Comparison of ERCC1 targeted alleles and the consequences of 
ERCCJ inactivation in the mouse 
Schematic representation of the known ERCCI targeted allele structures. Exons 
are numbered and indicated by vertical boxes , introns are indicated by horizontal 
boxes. Selectable markers are represented by shaded boxes, and the point mutation is 
indicated by an asterisk. The regions of the targeted alleles that correspond to the 
integrated sequences of the receptive targeting vectors are shown in black. The 
original knockout allele involved inactivation by insertion of a neoT  cassette in exon 
5, the KT#209 allele is inactivated by replacement of exons 3 to 5 with an HPRT 
minigene. The Dutch knockout allele involved inactivation by insertion of a neo' 
cassette in exon 7, the subtle alteration involved the introduction of point mutation 
(stop codon) in exon 10 and a selectable marker into intron 9. 
Illustration of the severe runting caused by ERCCJ deficiency. Comparison of a 
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the Dutch mice also exhibited nuclear abnormalities of the kidney and additional 
histological evidence indicative of renal dysfunction. They also reported an absence 
of subcutaneous fat and early onset deposition of ferritin in the spleen, which can 
result from an increased turnover of erythrocytes. The development of thee 
additional features is likely to be as a consequence of the extended lifespan of these 
animals relative to our nulls. All in all, it is suggested that the phenotype associated 
with ERCCJ deficiency is more characteristic of the consequences of cell cycle arrest 
and premature ageing than simple DNA repair deficiency. This idea was further 
supported by the phenotypic similarity between the ERCC1 mutants and that reported 
for mice overexpressing the cyclin-dependent kinase inhibitor p21 in hepatocytes. As 
one of the principle effectors of p53, overexpression of p21 leads to cell cycle arrest 
in G2 (Wu et al., 1996). 
It is worth noting that our original knockout and the two Dutch mutants could 
potentially give rise to transcript with the ability to encode more than the amino-
terminal half of ERCC 1. It remains possible that whilst these targeting strategies 
have resulted in the inactivation of the NER capacity of ERCC1 a further as yet 
undetermined function remains intact. Analysis of different, laboratory generated, 
ERCC 1-deficient rodent cell lines has shown some phenotypic heterogeneity 
supportive of this idea (Busch et al., 1997). Whilst most ERCC1 mutants are 
sensitive to both UV and mitomycin C (cross-linking agent), some were only 
sensitive to one of these mutagenic agents. Our second knockout line carries a 
deletion of coding sequences from the N-terminal region, which may reveal 
additional phenotypic consequences resulting from inactivation of any secondary 
ERCCJ functions. Initial analysis of these nulls has confirmed the essential 
phenotypic features of the other ERCC1 null strains. More detailed analysis, of what 
may be the only true ERCC1 null, may be required to reveal any subtle phenotypic 
variations. 
Embryonic fibroblasts derived from our original null and the two Dutch mutant 
ERCC1 lines were shown to be hypersensitive to UV, with virtually no incision 
following irradiation, confirming that the null animals were indeed NER deficient. 
More detailed analysis carried out on fibroblasts from our original null line has 
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shown that the cells were only mildly sensitive to the cross-linking agent mitomycin 
C, suggesting that ERCC1 is not essential for the recombination mediated repair of 
interstrand cross-links in mouse cells or that this function is not effected by the 
targeting (Melton et al., 1997). The fibroblasts were not deficient in the homologous 
recombination pathway. In mouse cells the GI arrest induced by UV irradiation is 
less extensive than in human cells, consequently replication proceeds along an 
unrepaired template. To prevent the accumulation of strand breaks at these 
unrepaired lesions, a mechanism of illegitimate recombination is employed which 
leads to increased incidence of chromatid exchanges. The frequency of these 
exchanges was reduced in ERCCJ null fibroblasts relative to wild type cells, 
suggesting that ERCC 1 may normally play a role in the promotion of these 
recombination events. 
It has been shown that ERCC1 -deficiency is indeed compatible with development to 
term in the mouse, however the gestation period in man is significantly longer and as 
such the consequences of the analogous deficiency may be developmentally lethal in 
humans. Whilst the ERCCJ-deficient animals have provided a useful system in 
which to investigate ERCC 1 function in vivo, the short lifespan of the animals has 
precluded a number of further studies such as exploring the possible role of ERCCJ 
in carcinogenesis. 
1.25 Project Aims 
In the limited number of cells and tissues studied to date it has been reported that 
ERCC1 is expressed constitutively, but at low abundance. It would seem logical for 
the expression of ERCC1 to be altered where there was a. greater biological demand 
for the protein. We speculated that biological demand on ERCC1 would perhaps be 
greater in the skin, as it receives the greatest exposure to UV. We originally produced 
ERCC1-deficient mice, by targeted inactivation of the ERCC1 gene in mouse 
embryonic stem cells, with the intention of studying the mechanisms involved in the 
UV-induction of skin cancer. Such studies were precluded by the severe phenotype 
associated with ERCC1 deficiency in the mouse. The mice are born severely runted 
and die, before weaning, with liver failure. The principal aims of the work presented 
in this thesis, were: 
1 .To study the pattern of ERCCJ expression in mouse tissues to determine if a tissue 
specific pattern of expression was evident. 
2. To extend the lifespan of the ERCCJ nulls so as to be able to study the 
consequences of ERCC1 deficiency in other tissues, such as the skin, in adult mice. 
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Materials 
2.1 Laboratory reagents and suppliers: 
BDH Ltd.: dimethyldichiorosilane, hydrochloric acid, Sarkosyl NL30, xylene, xylene 
cyanol. 
Boehringer Mannheim UK Ltd.: deoxyribonucleotides, proteinase K, 3'/5' RACE 
Kit. 
The Boots Company plc: paraffin oil. 
Difco Laboratories: agar, bacto-tryptone, bacto-yeast extract. 
Fisher Scientific UK Ltd.IFisons Scientific Equipment: 3M blotting7 paper, boric acid, 
butanol, calcium chloride, citric acid, disodium hydrogen orthophosphate, disodium 
hydrogen orthophosphate, EDTA, filter paper, glacial acetic acid, hydroxyquinolin, 
isoamyl alcohol, isopropanol, sodium acetate, sodium chloride, sodium citrate, 
sodium hydroxide, sodium dihydrogen orthophosphate, potassium acetate, 
trichioroacetic acid. 
Gibco BRL Life Technologies Ltd.: lOObp DNA marker ladder, agarose, formamide, 
guanidine hydrochloride, Hind ifi digested ? DNA marker ladder, phenol, Tris, low 
melting point agarose, NACS columns, hybridisation bags, urea. 
ICN Biomedicals Ltd.: Dulbecco's PBS tablets. 
Millipore (UK) Ltd.: disposable sterile filters, Immobilon P. 
National Diagnostics: ecoscint A. 
New England Nuclear Life Science Products: Genescreen Plus. 
Promega (UK) Ltd.: oligo dT, random hexamers, RNasin. 
Qiagen Ltd.: tip 500 columns. 
Sigma-Aldrich Company Ltd.: bovine serum albumin, bromophenol blue, dextran 
sulphate, DTT, ethidium bromide, ficoll, formaldehyde, glycerol, herring sperm 
DNA, IPTG, mineral oil, MOPS, new methylene blue, NP-40, parafilm M, PMSF, 
sodium bicarbonate, thymidine, Triton X- 100, Tween 20, X-Gal. 
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2.2 DNA /RNA modifying enzymes 
Boehringer Mannheim UK Ltd.: Kienow polymerase, M-MuLV reverse transcriptase, 
restriction endonucleases. 
Gibco BRL Life Technologies Ltd.: bacterial alkaline phosphatase, restriction 
endonucleases, T4 DNA kinase, Taq DNA polymerase. 
New England Biolabs (UK) Ltd.: restriction endonucleases, T4 DNA ligase. 
2.3 Radioactive reagents 
Amersham International plc.: Redivue [a- 32P]-dCTP (-3000 Ci/mmole, lOmCiImI). 
2.4 Antibiotics 
Sigma-Aldrich Company Ltd.: ampicillin, penicillin G, streptomycin. 
2.5 Mammalian cell culture reagents 
Becton Dickinson Labware: plasticware. 
Difco Laboratories: trypsin. 
Gibco BRL Life Technologies Ltd.: foetal calf serum, Glasgow's Modified Eagle 
Medium (BHK21), horse serum, L-glutamine, new-born calf serum, non-essential 
amino acids, sodium bicarbonate, sodium pyruvate. 
Sigma-Aldrich Company Ltd.: b-mercaptoethanol. 
2.6 Bacterial culture reagents 
Difco Laboratories: agar, bacto-tryptone, bacto-yeast extract 
2.7 Oligonucleotides 
All oligonucleotides were synthesised by the Oswel DNA service. The sequences of 
all primers used are given in Table 2.1. 
Table 2.1 Oligonucleotides 
CODE SEQUENCE (5'-3') DESCRIPTION 
033M CCAGTGTTGAAGTTTG ERCC1 exon 4 (429-448) 
TGCG  
035M CGAAGGGCGAAGTTC ERCC1 exon 5 (598-579) 
TTCCC  
159M TAGCCAGCTCCTTGA ERCCJ exon 6(657-638) 
GAGCC 
529N GGTGCAGTCAGCCAA ERCC1 exon 6 (683-664) 
GATGC 
N1138 CTTCCTCCTGGTGGGT ERCCJ exon 1 (161-142) 
GGTCC 
Exon 1 TGAGGGCTGTGGCCG ERCC1 exon 1(140-110) 
ACTTTCCTCGTCCTT 
H4395 CATGCCATGGACCCT ERCC1 cDNA 5'end 
GGGAAGGACGAG (99-119) 
H4396 GAAGATCTTCTCGAG ERCC1 cDNA 3'end 
TCATCGAGGCACTTTG (996-977) 
AGG 
Oligo dT anchor GACCACGCGTATCGA 5'/3' RACE 
TGTCGACTTTTTTTTT (Boehringer Mannheim) 
TTTTTTTV 
PCR anchor GACCACGCGTATCGA 5'/ 3' RACE 
TGTCGAC (Boehringer Mannheim) 




2.8 Bacterial culture media 
Luria Broth (LB): 1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, and 0.5% 
(w/v) NaCl, adjusted to pH 7.2 with NaOH. 
Luria Agar: 1.5% agar, 1% (wlv) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, and 
0.5% (w/v) NaCl, adjusted to pH 7.2 with NaOH. 
Terrific Broth (TB): 1.2% (w/v) bacto-tryptone, 2.4% (w/v) bacto-yeast extract, 0.4% 
(v/v) glycerol, 170mM potassium dihydrogen orthophosphate, and 72mM 
dipotassium hydrogen orthophosphate. 
When required, ampicillin was added immediately prior to use, to a final 
concentration of 100Jg/rnl. 
2.9 Mammalian tissue culture media 
Glasgow's Modified Eagle's Medium (GMEM) (McPherson, 1962, with 
modifications by W. House, Medical Research Council Institute of Virology, 
University of Glasgow, 1964) was used as the base culture medium for mouse and 
human fibroblast cell lines. 
Freezing medium for long term storage of cells consisted of the appropriate 
supplemented culture medium with additional DMSO and FCS to final 
concentrations of 10% (vlv) and 20% (v/v) respectively. 
Fibroblast culture medium: 10% (v/v) FCS, 1X non-essential amino acids, 1mM 
sodium pyruvate, 25U/ml penicillin, 25pg/ml streptomycin, in GMEM. 
MJCRE culture medium: 10%(v/v) NCS, 1X non-essential amino acids, 1mM sodium 
pyruvate, 25U/ml penicillin, 25ig/ml streptomycin, in GMEM. 
Ere 
2.10 Solutions and buffers 
bacterial alkaline phosphatase buffer: 530mM Tris-HC1 pH 7.5, 95mM M902, 
5OmMDTT 
Carnoy fixative: 3 parts methanol, 1 part glacial acetic acid 
CA: 24 parts chloroform, 1 part isoamyl alcohol 
Citrate buffer: 8.55% sucrose, 5% DMSO, 40mM tn-sodium citrate, pH 7.6 
denaturation buffer: 0.5M NaOH, 1.5M NaCl 
dialysis buffer: 10mM Tris-HC1 (pH7.5) 0.1mM EDTA (pH7.5) 
electroporation buffer: 21mM HEPES, 5mM D-glucose, 8mM Na2HPO4, 5mM KC1, 
140mM NaC1 
FACS stock solution: 3.4M tn-sodium citrate, 0.5M Tris —HC1, 1% NP40, 
0.52mg/mi spermine tetrahydrochioride, pH 7.6 
FACS Solution A: 30jig/ml trypsin in stock solution 
FACS Solution B: 0.5mg/mi trypsin inhibitor, 0.1mg/mi ribonuclease inhibitor in 
stock solution 
FACS Solution C: 0.42mg/mi propidium iodide, 1mg/mi spennine tetrahydrochioride 
in stock solution 
formalin: 4% (v/v) formaldehyde in phosphate buffered saline 
formamide sample buffer: 2.3X MOPS, 50% de-ionised formamide, 11% 
formaldehyde 
injection buffer: 10mM Tris pH7.5, 0.1mM EDTA pH 7.5 
lOX kinase buffer: 50mM Tris-HC1 pH 7.5, 100mM M902, 100mM DTT, 10mM 
ATP, 0.5 jig/mI BSA 
lOX MOPS: 200mM 3-(N-morpholino) propane-suiphonic acid (MOPS), 50mIvI 
sodium acetate, 10mM EDTA, pH 7.0 
neutralising buffer: 3M NaCl, 0.5M Tris-HC1, pH 7.0 
northern blot stripping solution: 0.01% (wlv) SDS, 0.01X SSC 
oligo labelling buffer: SOjil solution A, 125ji1 solution B, 75p1 solution C 
Solution A: 1.25M Tris-HC1 pH 8.0, 0.125M MgC12, 25mM 13-mercaptoethanol, 
0.5mM each of dGTP, dATP and dTTP. 
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Solution B: 2M HEPES buffer adjusted to pH 6.6 with NaOH. 
Solution C: Random hexadeoxyribonucleotides OD260 nm=90 units/ml in TE 
P1: 50mM Tris-HC1 pH 8.0, 10mM EDTA, 100ig/m1 RNase A 
P11: 20mM NaOH, 1% (w/v) SDS 
Pifi: 2.55M potassium acetate pH 4.8 
PCA: 25 parts redistilled phenol, 24 parts chloroform, 1 part isoamyl alcohol 
lox PCR: 50mM KC1, 1.5mM M902, 10mM Tris-HC1 pH 8.3, 0.01% (w/v) gelatin, 
0.45% (v/v) Triton X-100, 0.45% (v/v) Tween 20 
QBT: 750mM NaC1 pH 7.0, 50mM MOPS, 15% (v/v) ethanol, 0.15% (v/v) Triton X- 
100 	 - 
QC: 1M NaC1 pH 7.0, 50mM MOPS, 15% (v/v) ethanol 
QF: 1.25M NaC1 pH 8.2, 50mM MOPS, 15% (v/v) ethanol 
iox RT buffer: 500mM Tris-HC1 pH 8.3, 60mM M902, 400mM KC1, 10mM DTT 
5X sample buffer: 20% (v/v) glycerol, 100mM EDTA, 0.1% (w/v) bromophenol blue 
20X SSC: 3M NaCl, 0.3M tn-sodium citrate, pH 7.0 
Southern blot stripping solution: 1% (w/v) SDS, 0. lx SSC 
5X T4 DNA Ligase: 250mM Tris-HC1 pH7.6, 50mM M902, 5mM ATP, 5mM DTT, 
25% (w/v) polyethylene glycol-8000 
iox TBE: 0.9M TrisHCl, 0.9M boric acid, 20mM EDTA 
tail buffer: 400mM NaCl, 10mM Tris-HC1, 3mM EDTA, 1% (w/v) SDS 
TE buffer: 10mM Tris-HC1, 1mM EDTA, pH 8.0 
transformation buffer: 50mM CaC12, 10mM Tris-HCI 
2.11 Bacterial strains 
The E. coli strain DH5a was used for thepropagation of all plasmids. The genotype 
of DH5a is: supE44, • lacUl69 (0 801acZ. MiS), hsdRi7, RecAl, endAl, gyrA96, 
thi-1, and was first described by Hanahan (1983). 
2.12 Plasmids 
The plasmids used are presented in Table 2.2 
Table 2.2 Plasmids 
PLASMID DESCRIPTION REFERENCE 
pBluescript II Cloning vector Thummel et al., 1988 
pTZME Mouse ERCC1 cDNA van Duin et al. 1988 
pMFG Retroviral vector Dranoff et al., 1993 
pTTR EX1V3 Transgene vector Yan et al. 1990 
P91 Mouse actin cDNA Minty et al., 1991 
pGAPDH Mouse GAPDH cDNA Fort et al., 1985 
pHPT5 Mouse HPRT cDNA Konecki et al., 1982 
2.13 Mammalian cell culture lines 
The cell lines used are presented in Table 2.3. 
Table 2.3 Mammalian cell lines 
CELL LINE DESCRIPTION REFERENCE 
PF 20 Immortalised wild type Melton et al., 1998 
mouse embryonic fibroblast 
cell line.  
PF24 Immortalised ERCCJ- Melton et a!, 1998 
deficient mouse embryonic 
fibroblast cell line.  
CH09 Wild-type Chinese hamster Wood and Burki, 1982 
ovary cell line.  
CH043-3B ERCC1-deficient Chinese Wood and Burki, 1982 
hamster ovary cell line.  
Keratinocyte (WT) Mouse wild type Melton, unpublished 
keratinocytes data 
Keratinocyte (WT) ERCCJ -deficient mouse Melton, unpublished 
keratinocytes data 
jiCRE Retroviral 	packaging 	cell Dranos 	and 	Mulligan, 




2.14 Growth of E. Coli 
Cells were grown at 37°C either in suspension in LB or TB with shaking, or on the 
surface of Luria agar plates. Cells grown on Luria agar plates supplemented with 
ampicillin were incubated at 30°C to prevent growth of satellite colonies. 
2.15 Storage of E. Coli 
For long term storage, 900il of a fresh culture, grown overnight in LB supplemented 
with antibiotic where necessary, was mixed with lOOpl DMSO, and frozen at -70°C. 
Cells were recovered by scraping the surface of the frozen culture with a sterile 
inoculating loop and streaking onto a Luria agar plate. 
For short term storage (4-6 weeks) bacteria were streaked onto Luria agar plates, and 
stored at 4°C. 
2.16 Transformation of E. coli 
Bacteria were transformed with plasmid DNA by the method of Mandel and Higa 
(1970) with the modifications by Dagert and Ehrlich (1974). An inoculating loop was 
used to scrape bacterial growth from a fresh Luria agar plate of E. Coli and was 
added to 50m1 of LB supplemented with MgCl 2 to a final concentration of 20mM. 
Cells were grown with vigorous shaking at 37°C until the OD600 nm of the 
suspension equalled 0.2, and the cells were in log phase growth. The cells were 
chilled on ice for 5 minutes, and then spun down at 1,500rpm for 15 minutes at 4°C. 
The pellet was gently resuspended in 20mJ ice-cold transformation buffer, incubated 
for 30 minutes on ice, subsequently re-pelleted at 1,500rpm for 15 minutes at 4 °C, 
and finally resuspended in 2ml ice-cold transformation buffer. The suspension of 
competent cells was then incubated on ice for a minimum of 2 hours prior to use. 
Approximately lOng of plasmid DNA in a volume of 5-10il was added to 100il of 
competent cells, which were then incubated on ice for 30 minutes. Following heat 
shock at 37°C for 5 minutes, 400p1 of warm LB was added, and the mixture 
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incubated at 37 °C for 1 hour to allow expression of antibiotic resistance. Thereafter, 
the cells were spread onto Luria agar plates with ampicillin selection, and incubated 
overnight at 300C. 
Where appropriate, 30il of 2% (w/v in dimethylformàmide) X-Gal and 20pl of 
lOOnilvi IPTG were also spread over the surface of the plate to enable blue-white 
colour selection of colonies containing recombinant plasmids. 
Mammalian cell culture 
2.17 Growth of mammalian fibroblasts 
Mammalian fibroblasts were maintained in supplemented GMEM at 37°C in a 5% 
CO2 atmosphere in a humidified tissue culture incubator (Forma Scientific). 
To passage cells, the medium was aspirated, the bottom of the flask or dish rinsed 
with 1-2m1 of trypsin (0.05% w/v), then a further 1-2m1 of trypsin added and 
incubated at 37°C until the cells had become detached. Thereupon 5 volumes of 
medium were added, the cell suspension transferred to a sterile 50m1 tube, and cells 
pelleted by 5 minutes centrifugation at 1,300rpm. The supernatant was discarded, and 
the cells resuspended in an appropriate volume of medium, and an aliquot transferred 
into a tissue culture flask. 
For long term storage, cells were kept in liquid nitrogen. Cultures to be frozen were 
trypsinised, spun down, the supernatant removed, and cells resuspended in ice cold 
freezing medium. lml aliquots were placed at -20°C for 2 hours, then transferred to - 
70°C overnight, before removal into liquid nitrogen. Frozen aliquots were thawed 
rapidly at 37°C and diluted in 9m1 of medium, before being pelleted by centrifugation 
at 1,300rpm for 5 minutes. The supernatant was discarded, the cells resuspended in 
an appropriate volume of medium, and transferred into a flask. 
2.18 Transfection of ijiCRE cells 
Cloned DNA sequences were introduced into the retrovirus producer cell line using a 
calcium phosphate precipitation protocol with a glycerol shock, as follows. A 
confluent 90mm dish of WCRE cells were split 1:10 the day before the transfection. 
Added to an Eppendorf tube containing 0.5m1 HBS was l0pg of retroviral vector 
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DNA and 1.Op.g of a selectable marker construct and then 31pJ of 2M CaCl2. The 
solution was left to precipitate at room temperature for 40 minutes. The medium was 
aspirated from the NICRE dish and the calcium phosphate precipitate added to the 
cells and left at room temperature for 20 minutes, with frequent rocking of the dish. 
Following this, 5m1 of medium was added back to the dish and the cells incubated at 
37°C for 4 hours. The medium was once again aspirated from the dish and this time 
replaced with 2.5m1 of 15% glycerol in HBS (vlv) and incubated at 37°C for 3.5 
minutes. The glycerol was then aspirated and the dishes rinsed with 5m1 of medium 
and then cultured overnight in non-selective medium. The following day the medium 
was aspirated and replaced with medium containing appropriate selection. 
2.19 Retroviral infection of mouse fibroblasts 
In an attempt to optimise the viral titre from the retroviral producer cell line WCRE, 
the harvesting of the supernatant was timed to coincide with the cultures reaching 
confluence. To ensure that they were actively dividing, the target cells were spit 1:20 
on the day prior to the infection. The viral supernatant was removed from the cells 
using a syringe and filtered through a 0.45 micron filter. Polybrene was added to the 
supernatant to a final concentration of 8ig/ml. The medium was aspirated from the 
target cells and replaced with the viral supernatant. The infection was allowed to 
proceed for 6 hours at 37°C. The viral supernatant was then replaced with normal 
medium. 
2.20 Electroporation 
In order to achieve transient expression of cloned DNA sequences in cultured 
mammalian cells, a linearised ERCC1 minigene vector was introduced by co-
electroporation with a selectable HPRT minigene construct under the control of the 
mouse phosphoglycerate kinase (PGK-1) gene promoter. Cells to be electroporated 
were trypsinised, pelleted by centrifugation, and 5.OX 106  cells were resuspended in 
0.8ml of electroporation buffer. The suspension was mixed with 120ig of plasmid 
DNA in 100il sterile distilled water, and transferred into an electroporation cuvette 
(0.4cm electrode, Bio-Rad). The cuvette was slotted into a Gene Pulser (Bio-Rad), 
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and the cells pulsed at 300V, 500jiFd capacitance. After 10 minutes incubation at 
room temperature, the cells were added to 20mls supplemented GMEM and 
transferred to a flask. After culturing overnight, the medium was changed to selective 
medium containing HAT. 
2.21 UV survival assays 
To measure UV survival of cultured cells, 10 5 cells were plated per 30mm dish. The 
following day the medium was aspirated from the dishes and replaced with 0.2 ml of 
sterile PBS and the dishes were UV irradiated (254nm) at a fluence of 0.15 J m 2  s 1 . 
The medium was then replaced and the dishes were incubated for a further five days 
when the cells were fixed in Carnoy fixative and stained with Crystal Violet. The 
degree of cell growth was then determined by extracting the dye from the stained 
cells using 70% ethanol and measuring the optical density at 575nm. Each UV 
dosage was done in duplicate and survival was determined relative to unirradiated 
control dishes as the ratio of the mean OD I mean OD of cells in unirradiated dishes. 
Nucleic acid isolation 
2.22 Small-scale preparation of plasmid DNA 
A modification of the - method described by Ish-Horowicz and Burke (198 1) was used 
to prepare amounts of plasmid DNA up to 10tg. Bacteria were grown overnight at 
37°C in 5m1 LB or TB supplemented with ampicillin to a final concentration of 
SOp g/rnl. '1.5m1 of the culture was transferred to a microfuge tube, and the cells 
pelleted by centrifugation for 5 minutes. The pellet was resuspended in lOOp! of 
solution P1, and the cells lysed by addition of 200pl of solution P2 with 5 minutes 
incubation on ice. 150p1 of cold solution P3 was added, with gentle mixing, and the 
tube incubated on ice for a further 15 minutes. Precipitated chromosomal DNA, SDS 
and protein were sedimented by centrifugation for 10 minutes in a microcentrifuge, 
and the supernatant, containing the plasmid DNA, removed to a fresh tube. The 
supernatant was centrifuged again for a further 10 minutes to remove residual debris, 
and then plasmid DNA was precipitated by addition of iml cold ethanol. Following 
10 minutes centrifugation, the nucleic acid pellet was washed twice with 70% (vlv) 
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ethanol, vacuum dried, resuspended in 50.tl sterile distilled water and stored at - 
20°C. 
2.23 Large scale preparation of plasmid DNA (Quiagen prep.) 
For preparation of larger amounts of plasmid DNA, up to 500j.tg, a column 
purification method was employed. Bacteria were grown for 24 hours at 37°C in 
50m1 of TB supplemented with ampicillin to a final concentration of 100ig/ml. Cells 
were pelleted by spinning at 4,000rpm for 20 minutes at 4°C. The pellet was 
resuspended in lOml of solution P1 supplemented with RNase to a final 
concentration of 0.5ig/ml, and the cells lysed by addition of lOmi of solution P2 
with 5 minutes incubation at room temperature. lOmi of cold solution P3 was added, 
with gentle mixing, and the tube incubated on ice for a further 20 minutes. 
Precipitated chromosomal DNA, SDS and protein were sedimented by centrifugation 
at 16,000rpm for 10 minutes at 4°C. The supernatant was removed promptly, filtered 
and applied to a Qiagen-tip 500 column, previously equilibrated with lOmi of QBT 
buffer. After washing twice with 30m1 QC buffer, the plasmid DNA was eluted from 
the column with 15m1 QF buffer. 12m1 of isopropanol was added to precipitate the 
DNA, which was then spun down at 10,000rpm for 10 minutes at 4°C. The DNA 
pellet was resuspended in 400111 of sterile distilled water, prior to transfer into an 
microfuge tube, whereupon the DNA was reprecipitated with 40111 of P3 and imI of 
cold absolute ethanol. Following 10 minutes centrifugation, the nucleic acid pellet 
was washed twice with 70% (v/v) ethanol, vacuum dried, resuspended in 200pl 
sterile distilled water and stored at -20°C. 
2.24 Preparation of mammalian genomic DNA 
DNA was prepared from mouse tail samples, tissue samples and fibroblasts by the 
same method. Cultured cells were harvested by scraping in ice cold PBS, and pelleted 
by centrifugation at 1,300rpm for 5 minutes. Cell pellets and tissue samples were 
digested overnight at 37°C in 750111 tail buffer supplemented with proteinase K to a 
final concentration of 280g/m1. The supernatant was extracted twice with 750111 
PCA and vigorous shaking, and subsequently once with 750111 CA to remove traces 
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of phenol. The DNA was precipitated for 10 minutes at room temperature by addition 
of 750tl of isopropanol. Following 10 minutes centrifugation, the nucleic acid pellet 
was washed twice with 70% (v/v) ethanol, vacuum dried, resuspended in 200il 
sterile distilled water and stored either at 4°C in the short term or at -20°C for longer 
periods. 
2.25 Preparation of mammalian RNA (RNAzol' B method) 
A modification of the method described by Chomczynski and Sacchi (1987) was 
used for the isolation of total RNA from all cultured cells and tissues. The method 
used the commercially available reagent RNAz01TM  B (Biogenesis Ltd.) and followed 
the protocol supplied by the manufacturers. Briefly, approximately 300mg of tissue 
was homogenised with 6m1 RNAzolTm B using an Ultra-Turrax T25 homogeniser 
(IKA-Laboratechnik). Cultured cells were lysed directly in the culture dish by the 
addition of RNAzol' B (imi per 3.5ml petri dish) and the RNA was solubilised by 
pipetting the lysate a few times. The RNA was extracted by the addition of 0. imi 
chloroform per lml of homogenate, followed by vigorous shaking of the mixture for 
15 seconds prior to placing on ice for 5 minutes. The suspension was then 
centrifuged at 12000g for 15 minutes at 4°C. The aqueous phase was transferred to a 
fresh tube and the RNA precipitated by the addition of an equal volume of 
isopropanol. The RNA was left to precipitate at 4°C for at least 15 minutes and then 
pelleted by centrifugation at 12000g. The RNA pellet was then washed in 8mls 70% 
ethanol by vortexing followed by centrifugation at 7500g for8 minutes at 4°C. The 
pellet was allowed to air dry before being resuspended in 200p1 of sterile distilled 
water for storage at -70°C. 
2.26 Estimation of DNA concentrations 
DNA samples were diluted in imi of distilled water and the absorbency at 260 and 
280nm measured in a spectrophotometer (Perkin-Elmer, Lambda 15, UV/VIS 
Spectrophotometer). Double stranded DNA of concentration 50ig/m1 has an 
0D260nm = 1.0. The ratio OD260nm/OD280nm gives an estimate of nucleic acid 
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purity. A value of around 1.8 indicates that the preparation is not significantly 
contaminated with protein or phenol. 
2.27 Estimation of RNA concentrations 
RNA samples were diluted in lml of distilled water and the absorbency at 260 and 
280nm was measured in a spectrophotometer (Perkin-Elmer, Lambda 15, UV/VIS 
spectrophotometer). An OD260 nm = 1.0 represents an RNA concentration of 40 
Vg/ml. The ratio OD260nmIOD280nm  gives an indication of nucleic acid purity. A 
value of OD260nm/OD280nm = 2.0 indicates a pure preparation of RNA. 
DNA manipulation 
2.28 Restriction of DNA with endonucleases 
DNA was digested with 10 units of the desired endonuclease per jig of DNA using 
buffer and temperature conditions recommended by the manufacturer. For double 
digests involving enzymes with different recommended buffers, reactions were either 
carried out using an intermediate buffer, or DNA was digested in two sequential 
digests separated by a DNA purification procedure. Digestion reactions were 
terminated by heating at 65°C for 10 minutes, phenol extraction, or by the addition of 
5X sample buffer for agarose gel electrophoresis. 
2.29 Dephosphorylation 
Bacterial alkaline phosphatase (BAP) is a phosphomonoesterase that hydrolyses 3' 
and 5' phosphates from DNA and RNA. It is suitable for removing 5' phosphates 
prior to end labelling and for dephosphorylating linearised plasmid vectors prior to 
insert ligation. Approximately ing of DNA, in 90pl of sterile distilled water, was 
mixed with lOp! of lOX BAP buffer and 66 units of BAP. The reaction mix was 
incubated for one hour at 65°C, following which the DNA was purified by phenol 
extraction to remove all traces of the enzyme. 
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2.30 Phosphorylation and ligation of PCR products 
In the process of cloning PCR products it was necessary to phosphorylate their 5' 
termini by means of a kinase reaction. Reactions were performed on gel purified PCR 
products in lOpl volumes containing lpl lox kinase buffer, and lpl of T4 DNA 
kinase. Following incubation at 37°C for 11/2  hours, a further ipi of lOX kinase 
buffer was added, along with linearised plasmid vector DNA and 2 units of T4 DNA 
ligase. The total volume was made up to 20p1 with sterile distilled water, and the 
ligation reaction incubated overnight at 15°C, after which it was used to transform 
competent E. coli. 
2.31 Blunt-ending of DNA fragments 
Overhanging ends, generated by restriction endonucleases were converted to blunt 
ends by 'filling-in' using the Kienow fragment of E. coli DNA polymerase I. 
Approximately lpg of DNA, in 39p.l sterile distilled water, was mixed with 5p1 lOX 
nick translation buffer, 5j.tl of 5mM dNTP's and 6 units of Kienow. The reaction mix 
was incubated at room temperature for 1 hour and the reaction stopped by phenol 
extraction. 
2.32 Ligation 
Linearised vector and insert DNA fragments were gel purified as described (in 
section 2.34) prior to ligation. Approximately 200ng of insert DNA was ligated in a 
reaction with vector to insert DNA concentrations at a 3:1 molar ratio. Ligations were 
carried out in a 20t1 reaction volume containing 4p1  of SX T4 ligase buffer and 2 
units of T4 DNA ligase and incubated overnight at 15°C. Products of the ligation 
reaction were then used to transform E. coli. 
Electrophoresis of nucleic acids 
2.33 Electrophoresis of DNA in agarose gels 
DNA fragments were separated on 0.8-2% (w/v) electrophoresis grade agarose gels 
containing O.Spg/ml ethidium bromide and 1X TBE. DNA samples were mixed with 
1/5 volume of 5X sample buffer prior to loading. Electrophoresis was carried out 
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horizontally at 30-100V in a lx TBE buffer system. Hind ifi digested bacteriophage 
? DNA marker ladder and a lOObp DNA ladder were used as size markers. After 
electrophoresis, DNA was visualised by UV illumination. 
2.34 Recovery of DNA from agarose gels 
If DNA was to be recovered from agarose gels, low melting point agarose was used, 
and the desired section of gel excised following electrophoresis. An equal volume of 
IX TBE, 0.2M NaCl was added, and the gel melted at 65°C. lt.tl  of glycogen was 
added to act as a carrier, and increase the proportion of DNA ultimately recovered. 
Next, an equal volume of redistilled phenol saturated with 1X TBE , 0. 1M NaCl was 
added, the mixture vortexed until an emulsion was formed, then spun down in a 
microfuge for 5 minutes. The aqueous phase was removed into a fresh tube, and 
100l of butanol added to remove traces of phenol. The mixture was vortexed, then 
spun down for 1 minute and subsequently the butanol layer discarded. 1/10th volume 
3M sodium acetate pH 5.0 and 21/2  volumes of cold absolute ethanol were added, and 
the DNA precipitated at -70°C for 20 minutes. Following 10 minutes centrifugation, 
the nucleic acid pellet was washed twice with 70% (v/v) ethanol, vacuum dried, and 
resuspended in 10.il sterile distilled water. 
2.35 Purification of DNA for pronuclear injections 
Approximately 100tg of plasmid was digested with a suitable restriction enzyme 
under appropriate buffer conditions. The restriction digest was electrophoresed 
slowly at 50V overnight on a large agarose gel without the addition of ethidium 
bromide. Following electrophoresis, a full length slice of the gel was cut and stained 
with ethidium bromide to enable the position of the linear DNA fragment to be 
determined and then isolated. The gel slice was then placed into dialysis tubing with 
a small volume of the electrophoresis buffer for electro-elution at 100V for 1 hour. 
The buffer was then collected from the tubing and the DNA precipitated with 1/10th 
volume 3M sodium acetate and 21/2  volumes absolute ethanol. The pellet was 
washed in 70% ethanol, dried, resuspended in lOOpi of TE + 0.5M NaCl. The DNA 
was then purified by chromatography on a NACS PREPACTm Cartridge (GIBCO 
BRL). The column was equilibrated with 0.5M NaCl in TE, prior to the loading of 
the DNA. After washing, the DNA was eluted in lml of 2M NAC1 in TE. 
The purified DNA was then dialysed against 2 litres dialysis buffer for 36 hours with 
one change of buffer. The DNA was recovered using a syringe and transferred to 
Eppendorf tubes for storage at -20°C. 
2.36 Electrophoresis of RNA in agarose gels 
RNA samples were electrophoresed on denaturing 1% (w/v) agarose gels containing 
0.5g/ml ethidium bromide, 1X MOPS and 0.66M formaldehyde. 20ig of total RNA 
in 20111 of sterile distilled water was added to an equal volume of formamide sample 
buffer and 1/4  volume of 5X sample buffer. Samples were heated for 5 minutes at 
65°C and snap chilled on ice immediately prior to loading. Electrophoresis was 
carried out in a 1X MOPS buffer system at 100V for 3-4 hours. 
Transfer of nucleic acids from agarose gels to membranes 
2.37 Transfer of DNA from agarose gels to membranes (Southern blot) 
This procedure was originally developed by Southern (1975) and modified by Smith 
and Summers (1980). For Southern analysis of genomic DNA, lOpg of DNA was cut 
with an appropriate restriction enzyme, and the resulting fragments were separated by 
agarose gel electrophoresis. The gel was soaked in denaturation buffer for 30 minutes 
preceding DNA transfer onto Genescreen Plus nylon membrane (New England 
Nuclear) by capillary action using denaturation buffer as the transfer medium (Reed 
and Mann 1985). A wick made of wet blotting paper was placed on a platform, with 
both ends of the blotting paper immersed in denaturing buffer in a reservoir 
underneath the platform. The gel was laid on top of the wick, bordered with cling 
film. A sheet of nylon membrane, previously equilibrated in denaturing buffer) was 
placed on top, overlaid by three sheets of moistened blotting paper and a stack of dry 
paper towels. A weighted glass plate was put on top of the paper towels. Transfer 
was allowed to proceed for 12-24 hours, after which time the membrane was 
neutralised for 30 minutes in neutralising buffer, and air-dried. 
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2.38 Transfer of RNA from agarose gels to membranes (northern blot) 
Following electrophoresis the gel was soaked for two 20 minute periods in lox ssc, 
with gentle agitation. Transfer was as described for DNA, except that iox SSC was 
used as the transfer medium. When transfer was complete, the membrane was rinsed 
in 2X SSC and baked for 2 hours at 80°C under a vacuum. 
Nucleic acid hybridisation 
2.39 Labelling DNA by random priming with hexadeoxyribonucleotide primers 
Radioactively labelled DNA was obtained using the randomly primed DNA labelling 
method (Feinberg and Vogelstein 1983). This method is based on the hybridisation of 
a mixture of hexanucleotides to the DNA, and allows small amounts of DNA to be 
labelled to high specific activities. Many sequence combinations are represented in 
the hexanucleotide primer mixture, which leads to binding of primer to template in a 
statistical manner. The complementary strand is synthesised from the 3'OH termini of 
the hexanucleotide primers using Kienow polymerase, simultaneously incorporating 
radiolabelled dCTP into the newly synthesised DNA strand. DNA fragments to be 
labelled were purified from agarose gels. Approximately lOng of DNA dissolved in 
32il of sterile distilled water was denatured by boiling for 5 minutes, followed by 
incubation at 37°C for 10 minutes. lOpl of oligo labelling buffer, 20pg of BSA, 
501iCi of a- 32P-dCTP and 2 units of Kienow polymerase were added, and the mixture 
incubated overnight at room temperature. 4.5mg of sonicated herring sperm DNA 
was added to the probe, which was then denatured prior to hybridisation by boiling 
for 5mm. 
2.40 Separation of unincorporated radionucleotides 
Unincorporated nucleotides were separated fromthe labelled DNA by 
chromatography on a NICK® Column (Pharmacia). The column was equilibrated 
with 400p1 TE before the labelling reaction was added to the column. The labelling 
reaction was run into the column by the addition of 400pi TE. The labelled DNA was 
then eluted into a fresh Eppendorf tube by the addition of a further 400.tl TE. 
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2.41 Hybridisation 
Membranes onto which DNA had been transferred were blocked by prehybridising in 
30m1 of 6X SSC, 1% (wlv) SDS, and 10% (w/v) dextran sulphate with 3.5mg of 
denatured sonicated herring sperm DNA for two hours placed in an oven at 65°C in a 
hybridisation bag (Gibco BRL). Hybridisation was performed by addition of 
denatured radiolabelled probe to the prehybridisation mixture, and incubation for a 
further 12-24 hours at 65°C. Membranes to which RNA was bound were treated 
identically, except that incubations were performed at 60°C. Following hybridisation, 
non-specifically bound DNA molecules were removed by washing. The membrane 
was first immersed in 2X SSC at room temperature for 5 minutes with agitation, and 
then twice in 2X SSC, 1% (wlv) SDS for 30 minutes at either 65°C or 60°C. Finally 
the membrane was rinsed in 0.1X SSC for 10 minutes at room temperature, and 
sealed in a plastic bag to prevent drying out. Radioactive DNA molecules bound to 
the membrane were then visualised by autoradiography or phosphorimagery. 
2.42 Removal of probes and re-use of blots 
Radiolabelled DNA probes hybridised to nucleic acids immobilised on nylon were 
removed by the method described in the manual supplied with Genescreen Plus 
membranes. Southern filters were boiled three times for 10 minutes, with gentle 
shaking, in 0.1X SSC, 1% (w/v) SDS. Northern filters were washed five times for 3 
minutes in hot 0.1X SSC, 0.0 1% (w/v) SDS. The blots were then autoradiographed to 
confirm that dehybridisation was complete. Filters could then be dried and 
hybridisation repeated as above. 
2.43 Autoradiography 
Autoradiography was used to visualise, on film, radioactive molecules hybridised to 
the membrane. Autoradiography was performed using Cronex (Du Pont) X-ray film 
in a cassette with intensifying screens (Cronex Lightning Plus, Du Pont). Cassettes 
were stored at -70°C during exposure to slow the reversal of activated bromide 
crystals to their stable form and give an enhanced signal. 
2.44 Phosphorimagery 
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Phosphorimagery was performed using a storage phosphor screen (Molecular 
Dynamics). After exposure of the screen, signals were visualised using a Molecular 
Dynamics phosphorimager, and analysed with ImageQuant software (Version 3.3). 
2.45 DNA sequencing 
DNA sequencing was performed using an ABI PRISM dye terminator cycle 
sequencing reaction ready kit (Perkin-Elmer Corporation), on an Omnigene thermal 
cycler (Hybaid Ltd.). Extension products were then separated on an ABI PRISM 377 
DNA sequencer (Perkin-Elmer). 
Approximately 0.4tg of double stranded template DNA was mixed with 3.2pmoles 
of the required oligonucleotide primer and 8.t1 of terminator ready reaction mix in a 
final volume of 20jil. The reaction mixture was overlaid with a drop of mineral oil 
before thermal cycling as follows: 96°C for 30 seconds, 50°C for 15 seconds, 60°C 
for 4 minutes, repeated for 25 cycles. 
Extension products were purified by the addition of 2.Oj.il 3M sodium acetate pH 5.0, 
50i11 absolute ethanol, and incubation on ice for 10 minutes followed by 15 minutes 
centrifugation. The pellet was washed with 70% (v/v) ethanol, vacuum dried and 
stored dry at 4°C before electrophoresis. Electrophoresis was performed by the DNA 
sequencing facility within the Institute of Cell and Molecular Biology. 
2.46 Amplification of DNA by the polymerase chain reaction 
All PCRs were carried out in 50111 volumes in 1X PCR buffer supplemented with 
EDTA, to a final concentration of 0.4mM, and dNTPs, to a final concentration of 
0.1mM, and 2.5 units of Taq DNA polymerase. Approximately lOOng of DNA was 
used per reaction, along with 300ng of each primer. Cycle conditions varied for 
different primers pairs, generally, denaturation was carried out at 94°C for 1 minute, 
followed by 1 minute at an appropriate annealing temperature, and synthesis at 72°C 
for 30 seconds to 2 minutes. 35-40 cycles were carried out for all genotyping PCRs. 
All experiments were carried out using a Techne PHC-2 thermal cycler. 
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2.47 Rapid screening using PCR 
To facilitate the rapid screening of colonies of cultured mammalian cells, a PCR-
based strategy that bypassed the need for DNA purification was employed 
(McMahon and Bradley 1990). When colonies were picked from dishes to be 
transferred into multiwell plates, half of each colony (circa 1,000 cells) was 
transferred into a 1.5m1 microfuge tube. The cells were pelleted for by centrifugation 
for 30s, and the medium removed using a pipette. The pellet was resuspended in 40il 
IX PCR buffer to which proteinase K had been added to a final concentration of 
0. lmg/ml, and incubated at 65°C for two hours. The proteinase K was inactivated by 
heating at 90°C for 15 minutes, and lOp! of sample used as a template for PCR. 
2.48 RT-PCR 
Reverse transcription was carried out on 20pg of total RNA. To denature the RNA, 
samples were heated at 70°C for 2 minutes and then snap cooled on ice. Reverse 
transcription was carried out at 43°C for 1 hour in 1X RT buffer with 0.5j.tl RNasin, 
dNTPs to a final concentration of 1.25mM, O.lp.g of random hexamers, 25ig of 
oligo-dT, and 30 units of reverse transcriptase. The reaction was then heated at 75°C 
for 1 minute snap cooled on ice , before a second round of reverse transcription was 
carried out by the addition of a further 0.5p1 RNasin and 30 units of reverse 
transcriptase. After incubation at 43°C for 1 hour the reaction was diluted in 200p1 of 
TE and stored at 4°C. For subsequent procedures l0jil of the total cDNA pool was 
used. 
2.49 3' RACE 
Characterisation of the 3' end of the ERCC1 cDNAs was performed using 5'! 3' 
RACE Kit (Boehringer, cat. no. 1734792). All reagents used in the procedure were 
supplied by the manufacturer, excluding the allele specific primers. A detailed 
protocol supplied by the manufacturer was followed throughout the procedure. An 
overview of the principles involved in 3' RACE and an abridged protocol are 
presented in this section. The method exploits the naturally occurring poly(A)-tail of 
messenger RNAs as a target site for PCR primers. First strand cDNA synthesis is 
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started from the poly(A)-tail using an oligo dT-anchor primer. The oligo dT-anchor 
primer is in actual fact a mixture of dT primers with a single non T at the 3' end, the 
primer then binds to the inner end of the poly(A)-tail. The same primer codes for 
three restriction sites at the 5' end to facilitate subsequent cloning of any PCR 
products. After this synthesis, the cDNA is amplified by PCR using a PCR anchor 
primer, which is specific for the last twenty-two nucleotides at the 5'end of the oligo 
dT-anchor primer, and a forward primer specific for ERCC-1 (033M). The resultant 
PCR product was used for subsequent characterisation by cloning and restriction 
analysis. 
Figure 2.1 An overview of 3'RACE. 
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Characterisation of the 5' end of the ERCC1 cDNAs was performed using a 5'/ 3' 
RACE kit (Boehringer, cat. no. 1734792). All reagents used in the procedure were 
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supplied by the manufacturer, excluding the relevant ERCC1 specific primers. The 
detailed protocol supplied by the manufacturer was followed throughout the 
procedure. For the purposes of illustration, an overview of the principles behind the 
technique along with an abridged version of the protocol are presented in this section. 
(See Figure 2.2) 
The procedure requires the amplification of unknown DNA sequences from a 
messenger RNA (mRNA) template between known internal sequences and the 
unknown sequences of the 5' end of the rnRNA. This method is referred to as RACE, 
the rapid amplification of cDNA ends and was first described by Frohmann et al. 
(1994). 
The first strand of cDNA was synthesised from total RNA using a primer specific for 
ERCC1 (035M), AMV reverse transcriptase and deoxynucleotides. The resultant 
cDNA was then purified from unincorporated primers and deoxynucleotides using 
the High Pure PCR Purification Kit component of the RACE Kit. A homopolymeric 
A-tail was added to the 3' end of the cDNA using terminal transferase. The tailed 
cDNA was then amplified by PCR using a second ERCC1 specific primer (N113 8)  
and an oligo dT-anchor primer. This cDNA was then amplified with a further round 
of PCR using a nested ERCC 1 (Exon 1) primer in combination with the anchor 
primer. The cDNA resultant at this stage was then cloned into a suitable vector to 
enable further characterisation by restriction analysis and sequencing. 
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Animal procedures 
2.51 Animal husbandry 
Mice were maintained in accordance with established animal care guidelines (Poole 
1989), and all procedures were licensed by the Home Office under the animals 
(Scientific Procedures) Act 1986. The mice were kept under a 12 hour light and 12 
hour dark cycle, with standard mouse diet and tap water. Genotyping was by PCR 
analysis carried out on the biopsied distal 1cm of tail, removed after the pups were 
weaned into single sex cages at 21 days. Individual cage members were identified by 
means of coded ear marking. 
2.52 Conventional transgenesis by pronuclear injection 
The protocol adopted for the generation of transgenic mice by injection of DNA 
directly into the pronuclei of fertilised mouse eggs is described in detail in 
Manipulating the Mouse Embryo by Hogan, Costantini and Lacy (1986). 
2.53 Superovulation of donor females 
In order. to increase the yield of fertilised eggs from each of the female donors it was 
necessary to induce super-ovulation by the administration of gonadotrophins. Up to 
eight female Fl hybrid CB6 mice aged between 4 and 6 weeks were injected 
intraperitoneally with 5 units of pregnant mare's serum (PMS) which mimics the 
endogenous follicle stimulating hormone (FSH). After a period of approximately 42 
hours the mice were then injected intraperitoneally with human chorionic 
gonadotrophin (hCG) which mimics luteinizing hormone (LH). Each female was 
then placed in a cage with a CB6 stud male and checked for a copulation plug the 
following morning. 
2.54 Recovery of fertilised eggs 
Plugged females were humanely culled by cervical dislocation before bilateral 
dissection of the oviducts. The oviducts were then transferred to a 35mm petri dish 
containing M2 medium. The eggs, and attached cumulus cells, were released using 
watchmakers forceps to tear open the oviduct. The eggs were then transferred to a 
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second petri dish containing M2 with hyaluronidase at about 300p.g/ml and incubated 
at room temperature to remove cumulus cells. After rinsing in a further dish of M2 
the fertilised eggs were transferred to a dish containing M16 and cultured at 37°C 
until required. 
2.55 Injection of mouse egg pronuclei 
All pronuclear injections were carried out using a Narishige micromanipulator 
system (Narishige Co Ltd.). Holding pipettes and injection needles were pulled from 
borosilicate glass capillaries (Clark Electromedical Instruments) using a Sutter 
Instruments Co. (model P-87) needle puller and a Research Instruments Ltd forge. 
Embryos were transferred to a drop of M2 on a coverslip, overlayed with mineral oil. 
Following injection the surviving eggs were transferred to an M16 drop and cultured 
at 37°C until required. 
2.56 Embryo transfers 
Eggs that survived injection were either transferred on the day of 'injection or after 
overnight culturing into the oviduct, of a 0.5 p.c pseudopregnant CB6 female. To 
compensate for the number of embryos not developing to term and thus avoiding 
very small litters, between 20 and 30 injected eggs were transferred into each 
pseudopregnant recipient. 
2.57 Tissue histology 
All tissue samples were fixed in 4% formalin for at least 48 hours and then stored in 
70% ethanol until sectioning. All sectioning and staining of :fixed tissues was 
performed by the Department of Pathology, University of Edinburgh. The tissues 
were embedded in paraffin wax and sectioned at 5pm onto microscope slides. The 
mounted sections were stained using haematoxylin and eosin for subsequent 
histological analysis. 
2.58 Fluorescence activated cell scanning 
Fluorescence activated cell scanning (FACScan) refers to the application of flow 
cytometry in the determination of the DNA content of a cell. A laser light (488nm) is 
used to excite fluorochrome molecules, causing them to emit light of a greater 
wavelength, which is detected by the FACScan. Propidium iodide is a commonly 
used DNA dye. The propidium iodide intercalates in the DNA double helix and 
fluoresces strongly red following exposure to laser light. The extent of the 
fluorescence varies according to the DNA content and is measured by the FACScan. 
In all cases the analysis was carried out on fresh tissue samples. A 0.5cm 3 tissue 
biopsy was homogenised using a sterile scalpel and suspended in lOOj.tl of citrate 
buffer. After adding 450ltl of FACS Solution A, the suspension was incubated at 
room temperature for 10 minutes with gentle mixing. The action of the trypsin was 
stopped and cellular RNA degraded by the addition of 325.tl of FACS Solution B and 
incubation at room temperature for 10 minutes. The nuclear DNA was then dyed with 
the fluorescent stain propidium iodide, by the addition of 250pJ  of FACS Solution C 
and incubation on ice for 10 minutes. The suspension was filtered through sterile 
gauze before analysis on a flow cytometer. 
The analysis was carried out using a Becton Dickson FACScan, and the resultant data 
analysed using Lysis II software. 
2.59 ATPase staining of Langerhans cells 
To identify phosphatase-positive cells, epidermal sheets were first fixed in cacodylate 
formaldehyde fixative (4% formaldehyde, 0.8M sodium cacodylate and 0.2M 
sucrose) and then washed three times for ten minutes in lOml of Trismal buffer 
(20mIvI Trismal maleate, 0.2M sucrose, pH 7.3). They were then incubated at 37°C 
for 30 minutes in Trismal buffer containing 20mM MgC1 2. 4mM Pb(NO3) and 
0.33mM ADP. After three washes in Trismal buffer, the samples were immersed in 
0.5% ammonium sulfide for 5 minutes and then washed 4 times in lOmi of distilled 
water before mounting in a 90% glycerol, 10% PBS medium. Stained cells were then 
counted microscopically. 
2.60 Mixed skin lymphocyte reaction 
Epidermal cells were prepared from mouse ears by incubation in a 1% trypsin 
solution. After counting, 0.5 x 105 epidermal cells were incubated, in 96 well plates 
at 37°C, with 105  spleen cells from strain C31-1 female mice in complete RPMI 
medium containing 10% foetal bovine serum. After 5 days in culture 0.7 pCi 
[H3]thymidine was added to the well. [H3]thymidine incorporation was measured 
when cells were harvested 24 hours later. The specific proliferative response was 
calculated as the mean of 5 replicate wells after subtracting the mean of the negative 
control consisting of EC cultured alone. 
2.61 Accumulation of Langerhans cells in the draining lymph nodes 
The draining, axillary and auricular lymph nodes were removed and pooled for each 
of the experimental groups. A single suspension of lymph node cells was prepared by 
mechanical disaggregation through a 200-mesh stainless steel gauze. The DC were 
purified by density gradient centrifugation. Briefly, 8ml of the cell suspension was 
added to a lOml conical tube and was underlayed with 2m1 of 14.5% metrizamide in 
RPMI-FCS medium. The tubes were then centrifuged for 15 minutes at 600g. The 
DC enriched population at the interface was collected, washed and resuspended in 
RPMI-FCS medium. The number of DC within this fraction was assessed 
morphologically by conventional light microscopy. The mean number of DC present 
within a lymph node was calculated. 
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Chapter 3 
Identification and molecular characterisation of a novel 
ERCCJ transcript in mouse skin 
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The mammalian genome contains an estimated 80,000 (Antequera and Bird, 1993) 
genes and by various mechanisms, including differential splicing, can encode an even 
greater number of polypeptides. Fortunately, in order for a cell to survive it is not 
required to express every single gene, all of the time. In many cases gene expression 
is determined to a great extent by biological requirement. This control of gene 
expression can vary from simple, expression or no expression, to various levels of 
expression depending on the individual cell type or tissue and the biological 
requirement for expression. 
It would not be unreasonable to imagine that ERCCJ expression could be altered in 
tissues where it would have a greater biological significance. The NER pathway, in 
which ERCC1 is involved, is known to be the principle pathway responsible for the 
removal of UV-induced DNA lesions and the tissue which receives the greatest 
exposure to UV is the skin. It might therefore be reasonable to expect that the 
expression of ERCC1 may display different properties in the skin in an attempt to 
deal with a more demanding role in that tissue. It was with this in mind that we 
decide to take a detailed look at the expression pattern of ERCCJ in mouse tissues. In 
the limited number cells and tissues studied to date it has been reported that ERCC1 
is expressed constitutively, but at low abundance: 
3.1 Identification of a novel ERCCJ transcript in mouse skin 
A panel of tissues from a wild type male mouse was analysed by northern blot 
analysis to investigate further the endogenous pattern of ERCCJ expression (Figure 
3.1). Total RNA (30ug) from each of the tissues was separated by electrophoresis, 
transferred onto a nylon membrane and the ERCCJ transcript detected by 
hybridisation to an ERCCJ cDNA probe. 
The ethidium bromide staining of the gel is presented in the lower panel and suggests 
that the amount of RNA loaded in each of the tracks was equivalent. The detection of 
ERCC1 mRNA by probing with ERCCJ cDNA is shown in the top panel. The 
normal 1.1kb ERCCJ transcript was evident in all tissues examined. By eye, the level 
of expression was lowest in the liver and generally low in all other tissues 
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Figure 3.1 Identification of a novel ERCC1 in mouse skin 
Northern blot analysis of tissue RNA from a wild type male mouse. Upper panel, 
total RNA was prepared from a selection of mouse tissues, electrophoresed on a 
1.4% agarose-formaldehyde gel, transferred onto a nylon membrane and probed with 
an 800bp BamHI fragment of the ERCC1 cDNA, corresponding to exons 1 to 8. The 
position of the 18S rRNA is indicated. Lower panel, ethidium bromide staining to 
















except for the testes, where the level of expression of this transcript was clearly much 
higher than in any of the other tissues. There was a suggestion of some heterogeneity 
in the size of the ERCC1 transcript detected within both the brain and heart, as seen 
by hybridisation to a higher molecular weight smear up from the normally discrete 
transcript signal. The pattern of expression seen in the skin was clearly different from 
any other tissue. In addition to the normal ERCC1 transcript, a second larger 
transcript was evident. In terms of abundance the novel ERCC1 transcript was the 
major transcript in skin. The size of the transcript extends beyond the upper limits of 
the heterogeneous smear identified in the brain and heart and there was no evidence 
to suggest expression of this transcript in any of the other tissues examined. The 
elevated level of expression observed in the testes may be as a consequence of the 
proposed role played by ERCC1 in recombination. 
3.2 The novel ERCCJ transcript is evident in some cultured cell lines 
Having identified a novel ERCCJ transcript in mouse skin it was important to us to 
see if the transcript was also evident in any cultured cells. Initial attempts to isolate 
good quality RNA from skin biopsies were often technically problematic, thought to 
be due to a greater abundance of nucleases associated with the tissue. Identifying an 
in vitro source of the transcript would greatly facilitate any subsequent efforts 
towards the molecular characterisation of the novel ERCC1 transcript and the 
elements affecting its expression. 
A panel of cultured cell lines, from those readily available in our laboratory was 
screened by northern blot analysis for the presence of the novel ERCCJ transcript 
(Figure 3.2). Total RNA was isolated from the SV40 transformed wild-type human 
fibroblast line MRC5V1, the HPRT-deficient mouse embryonic stem cell line HM 1, 
the mouse L-cell line RJK69 1, the wild-type Chinese hamster ovary cell line CH09, 
the ERCCI deficient Chinese hamster ovary cell line CH043 313, the transformed 
wild-type mouse embryonic fibroblast line PF20, the transformed ERCC1 deficient 
embryonic fibroblast line PF24, a wild-type mouse keratinocyte line Ker.(WT), an 
ERCC1 deficient mouse keratinocyte line Ker.(null) and a wild-type mouse primary 
neuronal culture HM134.4. The RNA was electrophoresed on a 1.4% agarose- 
74 
Figure 3.2 The novel ERCCJ transcript is present in some cultured cell lines 
Northern blot analysis of RNA samples from a range of cultured cell lines. Total 
RNA was prepared from a transformed human fibroblast cell line (MRC5V1), a 
mouse embryonic stem cell line (HMI), a mouse L cell line (RJK691), a wild-type 
mouse fibroblast line (PF20), an ERCC1 null fibroblast line (PF24), a wild-type 
mouse keratinocyte line (Ker.WT), an ERCCJ null mouse keratinocyte line (Ker. 
Null) and a wild type mouse neuronal culture (HMB4.4). Upper panel, RNA was 
electrophoresed through a 1.4% agarose-formaldehyde gel, transferred onto a nylon 
membrane and probed with an 800bp BamHI fragment of the ERCC1 cDNA, 
corresponding to exons 1 to 8. Positions of the 18S and 28S rRNAs are indicated. 
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formaldehyde gel, transferred onto a nylon membrane and ERCCJ transcript detected 
by hybridisation to a mouse ERCC1 cDNA probe. 
The ethidium bromide staining of the gel is presented in the lower panel and 
indicates that the amounts of RNA in each lane are essentially equivalent. The 
normal 1.1kb transcript was present in all lanes except for the ERCCJ-deficient 
fibroblasts and keratinocytes. The high molecular weight species evident in the null 
keratinocyte lanes was believed to be the transcript arising from the ERCC1 targeted 
-allele (McWhir et al., 1993), however, the targeted allele transcript was not evident 
in the PF24 lane. This could be a consequence of partial degradation of the RNA 
sample preventing detection of a higher molecular weight transcript normally present 
at very low abundance. The nature of the ERCC1 mutation in the CH043 3B cell line 
is such that a transcript is still evident although no functional protein is made 
(Hayashi et al., 1998). 
In the MRC5V 1 lane there appeared to be a number of additional larger transcripts, 
these did not correspond with the size of the novel ERCCJ transcript and were most 
likely due to contaminating DNA in the RNA sample. The transcripts in HMB 4.4, 
the neuronal culture, exhibited a degree of heterogeneity similar to that observed in 
mouse brain. The ERCCJ pattern of expression first identified in mouse skin was 
also mirrored in the wild-type mouse fibroblast and keratinocyte lanes. In these lanes 
the major transcript was again visibly larger than the normal 1.1kb transcript 
observed in other cell types. It was also evident from this blot, assuming equal 
loading of RNA, that the level of ERCC1 expression . in these two cell lines was 
higher than in any of the other cell lines tested, with expression apparently highest in 
the keratinocytes. 
3.3 Estimated size of the novel, skin specific ERCC1 transcript 
Further northern blot analysis was performed to provide an estimation of size for the 
novel skin specific ERCCJ transcript. Duplicate panels of total RNA from ES cells 
and mouse skin were electrophoresed on a 1.4% agarose-formaldehyde gel, 
transferred onto a nylon membrane and then the two panels were probed separately 
using an HPRT cDNA fragment and an ERCC1 cDNA fragment (data not shown). A 
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comparison between the size of the skin specific ERCCJ transcript and the size of the 
HPRT transcript detected in ES cells, showed that they were very similar. The HPRT 
mRNA is known to be 1.5kb (Costello, 93). Thus the novel ERCCJ transcript is 
approximately 400bp larger than the normal 1.1kb transcript. 
3.4 The size of the coding region of the ERCCJ skin specific transcript is 
unaltered 
Having identified a novel ERCC1 transcript of approximately 1.5kb it was necessary 
to discover the molecular basis for this difference in size. The first possibility we 
considered was that the skin specific transcript contained additional coding sequences 
and ultimately encoded a different skin-specific NER protein. RT-PCR was used to 
compare the size of the ERCC1 coding region of the normal transcript from ES cells 
with that of the larger skin specific transcript. 
Total RNA from ES cells and two separate wild-type mouse skin samples was 
reverse transcribed using an oligo-dT primer to generate a pool of cDNAs. The 
ERCC1 cDNA was then PCR amplified from these pools using primers specific for 
exons .1 and 10, electrophoresed on a 1% agarose gel and visualised by ethidium 
bromide staining. At this stage PCR products, of the predicted 900bp size, were 
clearly visible in the ES cell lanes and were faintly evident in only one of the skin 
sample lanes (data not shown). To confirm that the PCR products were ERCC1 
cDNA and not simply artefacts of PCR, Southern blot analysis was performed. The 
electrophoresed PCR products were denatured and transferred onto a nylon 
membrane, then probed using an ERCC1 cDNA probe (Figure 3.3). A schematic 
representation of the ERCCJ cDNA and the positions of the PCR primers is shown in 
the top panel. The detection of ERCCJ sequences by probing with ER CC] cDNA is 
shown in the lower panel. The Southern blot confirms, by hybridisation, that the PCR 
products resultant from RT-PCR analysis of total RNA from ES cells and mouse skin 
were ERCC1 cDNA. The absence of a positive signal in the second skin lane was 
probably due to technical difficulties experienced with initial attempts at the isolation 
of RNA from skin biopsies. It is possible that this RNA sample was slightly degraded 
and as a result the initial round of reverse transcription was not succesful 
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Figure 3.3 RT-PCR analysis of ERCC1 transcripts in ES cells and mouse skin 
a, the ERCC1 cDNA is represented schematically, with the relative positions of the 
ERCC1 primers shown. Scale, 1kb to 10 cm. b, Southern blot analysis of ERCC1 RT-
PCRs. Total RNA from ES cells and two separate wild-type mouse skin samples was 
reverse transcribed using an oligo-dT primer. The ERCCJ cDNA was then PCR 
amplified from these pools using primers specific for exons 1 (H4395) and 10 
(H4396), electrophoresed on a 1% agarose gel, transferred to a nylon membrane and 
probed with an ERCCI cDNA fragment spanning exons 1 to 8. 
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and consequently the second stage PCR failed. Where ERCCJ sequences were 
detected, in the ES cell lanes and in the first skin lane, it was evident that the 
products were the same size, the predicted 900bp. Whilst this result may indicate that 
the coding region of the skin specific transcript is equal in size to that of the normal 
transcript, it remains a formal possibility that the product amplified from the skin 
RNA was derived from the normal sized transcript which is also evident in this 
tissue. Furthermore, the analysis presented here fails to exclude the possibility of an 
exon being included in the skin specific transcript which lies either upstream or 
downstream of the known coding sequences 
3.5 Characterisation of the 3' end of the ERCC1 cDNA in mouse skin and ES 
cells 
The 3' UTR and poly(A) tail have been implicated in the mRNA stability and 
translational efficacy of a number of genes. It is generally accepted that the longer the 
3'UTR the more stable the mRNA. It was possible that the increased size of the skin 
specific transcript was the result of differential polyadenylation giving rise to a more 
stable ERCC1 transcript. Increasing the half-life of the transcript could be seen as one 
way of meeting the increased demands on the protein in skin, by enabling more 
protein to be translated. Furthermore the differential polyadenylation of ERCC1 
transcripts in fibroblasts has previously been reported (van Duin et al., 1987). 
The 3' ends of the ERCC1 cDNAs from ES cells and mouse skin were characterised 
using 3' RACE (rapid amplification of the cDNA ends) analysis. The method is 
essentially a modified RT-PCR protocol enabling the amplification of the 3' end of a 
cDNA where upstream sequence data are known. The method exploits the naturally 
occurring poly(A)-tail of mRNAs as a site for PCR priming. First-strand cDNA 
synthesis is performed using an oligo dT- anchor primer, which is actually a pool of 
oligo dT primers with a single non T nucleotide at the 3' end, forcing the primer to 
bind to the inner limit of the poly (A) tail. The anchor element is a stretch of 22 
nucleotides at the 5' end of the primer which contain restriction sites (Sail, Clal, and 
Miul) to facilitate subsequent cloning steps where required. Following the cDNA 
synthesis the 3' end of the cDNA of interest is amplified directly using a PCR anchor 
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primer in combination with a gene specific primer. The resultant product is suitable 
for cloning and subsequent restriction or sequencing. 
Total RNA samples (2.tg) from ES cells and mouse skin were reverse transcribed 
using the oligo dT- anchor primer. Without purification of the resultant cDNA pool, 
PCR amplification of the 3' end of the ERCCJ cDNA was performed. Using ipi of 
the cDNA reaction, PCR was performed with the anchor primer (a 22mer 
homologous to the 5' end of the oligo dT-anchor primer) and a primer specific for 
exon 4 of the ERCC1 cDNA (033M). The predicted size for the resultant PCR 
product was 664bp, from the published ERCC1 cDNA sequence, assuming the 
normal polyadenylation site was used (van Duin et al., 1988). Half of the resultant 
PCR product was then electrophoresed on a 1.2% agarose gel and visualised by 
ethidium bromide staining. To be able to distinguish between PCR products that 
were ERCC1 cDNA products and not simply artefacts of PCR, Southern blot analysis 
was performed. The electrophoresed PCR products were denatured and transferred 
onto a nylon membrane, then probed using an ERCC1 cDNA probe (Figure 3.4). 
Panel a, shows a schematic representation of the 3' RACE analysis performed on the 
ERCC1 cDNA. Panel b, the ethidium bromide stained gel showed an apparent 
difference between the PCR profiles resultant from the two cDNA sources. The ES 
cell lane contained a heterogeneous DNA smear, the largest of the clear bands was 
approximately 650bp. The PCR profile resultant from the mouse skin PCR showed 
an equally heterogeneous DNA smear, however, in this case the largest distinct band 
was visible at approximately 780bp. At this stage the PCR results suggested that the 
3' ends of the ERCC1 cDNAs in ES cells and mouse skin may be different. Panel c, 
the Southern blot analysis of the PCR products showed a distinctly different result 
from that seen after ethidium bromide staining. The ERCC1 probe hybridised to 
distinct bands in both the ES cell and mouse skin lanes. In ES cell lane the probe 
hybridised to the 650bp band and a smaller band of approximately 500bp. In the 
mouse skin lane the probe also hybridised to bands of 650bp and 500bp as well as a 
third band of approximately 400bp. The 780bp band visible after ethidium bromide 
staining did not hybridise with the ERCCJ probe and was therefore most likely an 
artefact of the PCR reaction. The Southern blot analysis of the PCRs showed that the 
Figure 3.43' RACE analysis of ERCC1 cDNAs in skin and ES cells 
a, A schematic representation of the principles of 3' RACE analysis is shown, cDNA 
was synthesised by reverse transcription of total RNA, using an oligo dT-anchor 
primer. The position of the variable nucleotide (A, C or G) is indicated as V. The 
ERCC1 cDNA was amplified using a primer specific for ERCC1 exon 4 in 
combination with an anchor primer. The PCR product was then visualised by gel 
electrophoresis. b, ethidium bromide stained gel of electrophoresed PCR products 
from 3' RACE analysis of ES cell and skin cDNAs. The 650bp product from ES 
cells, and an 780bp from skin are indicated. c, Southern blot analysis of the 3' RACE 
PCR products. Following electrophoresis, the PCR products were transferred to a 
nylon membrane and probed with an ERCC1 cDNA fragment corresponding to exons 
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3' end of the ERCC1 cDNA in mouse skin was not larger than the 3' end in ES cells. 
The smaller hybridising bands in skin and ES cells most likely represent artefacts of 
PCR rather than actual shorter ERCC1 transcripts. Once again, the products 
amplified from the skin RNA sample could have been derived from the normal 1.1kb 
ER CC] transcript which is also present in skin, at a much lower level than the 1.5kb 
transcript. However, the failure to detect a larger product in skin suggests that it is 
unlikely that the difference between the ERCCJ mRNAs is due to differential 
polyadenylation. 
3.6 Characterisation of the 5' end of the ERCCJ eDNA in mouse skin and ES 
cells 
So far it has been suggested that the increased size of the novel skin specific 
transcript was not due to additional sequences within the coding region or within the 
3' UTR. A simple process of elimination would then suggest that the difference 
between the two transcripts must lie at the 5' end. To investigate this hypothesis the 
5' ends of the ERCC1 cDNAs from ES cells and mouse skin were characterised using 
5' RACE analysis. 
Once again, 5' RACE is an RT-PCR based method which enables the 
characterisation of unknown 5' cDNA ends where internal cDNA sequence data are 
available. The first strand cDNA synthesis is carried out using a gene specific 3' to 5' 
primer, a homopolymeric A-tail is added to the 3' end of the cDNA by the action of 
terminal transferase. The tailed cDNA is then PCR amplified using a second gene 
specific primer, in combination with the oligo dT-anchor primer. A further round of 
PCR is carried out using the anchor primer in combination with a third nested gene 
specific primer. The resultant product is suitable for cloning and subsequent 
restriction analysis or sequencing. 
Total RNA samples (2jig) from ES cells, keratinocytes and mouse skin were reverse 
transcribed using a primer specific for exon 5 of the mouse ERCC1 cDNA (035M). 
The resultant cDNA pool was purified using a PCR product purification kit. The 
PCR product binds to a glass fibre platform within a microfuge tube in the presence 
of guanidine-thiocyanate, the unincorporated nucleotides and any protein or salt 
M. 
contaminants are removed by washing, before the PCR product is eluted in re-
distilled water. A poly(A)-tail was added to the 3' end of the first strand by the action 
of terminal transferase. A first round of PCR was carried out on 5p1  of the tailed 
cDNA using an ERCC1 primer specific for exon 1 113138) in combination with the 
oligo dT-anchor primer. The resultant PCR products were visualised by 
electrophoresis on a 1.5% agarose gel and ethidium bromide staining. At this stage 
there was an apparent difference of only -200bp between the strongest product 
visible from ES cells and the largest product from mouse skin (Figure 3.5b). A 
further round of PCR was performed, on the ES cell and skin PCR products, using a 
nested ERCC1 primer from exon 1 in combination with the anchor primer. The 
resultant PCR products were electrophoresed on a 1.5% agarose gel and visualised by 
ethidium bromide staining (Figure 3.5b). Panel a, shows a schematic representation 
of the ERCC1 cDNA and the relative positions of the primers used in the 5' RACE 
analysis are indicated. The positions of the transcriptional and translational start sites 
are also indicated for reference. The transcriptional start site indicated is that mapped 
for the human gene (van Duin et al., 1987) Panel b, the first panel shows the 
ethidium bromide stained gel of the first round PCRs, all lanes showed a 
heterogeneous smear of DNA. The strongest band in the ES cell lane was 
approximately 280b p. compared with a band of almost 450bp in skin. There was no 
evidence of this 450bp product in the keratinocyte lane. Following this observation 
the keratinocyte sample was not used for subsequent rounds of PCR. The ethidium 
bromide stained gel of the nested PCR showed an apparent difference between the 
PCR profiles from the ES cell and skin cDNA sources. The ES cell lane contained a 
single diffuse band of approximately 150 to 200bp. The PCR profile resultant from 
the mouse skin PCR again showed a heterogeneous DNA smear, however, in this 
case a distinct band was evident at approximately 550bp. An additional diffuse band, 
believed to be an artefact of PCR, was clearly evident at approximately iSObp. 
This apparent size difference of almost 400bp closely matches the size difference as 
estimated from the earlier northern blot analysis. The size of the 5' RACE product 
from ES cells maps it closely to the predicted transcriptional start site for the normal 
transcript, as previously determined for the human gene. The .1 5O-200bp RACE 
product was amplified from nt position +42, this would then map the end point to a 
nt position between -108 and -158. The transcriptional start site in humans was 
mapped to nt position -112. In contrast to the RT-PCR and 3' RACE analysis, the 5' 
RACE did reveal differences between the products evident in stem cells and skin. At 
the level of PCR fragment analysis it appears that the difference between the ERCC1 
skin specific transcript and the normal transcript may be linked to differences at the 
5' end of the mRNA. 
3.7 Cloning of the 5' RACE products from ES cells and mouse skin 
Multiple PCRs were performed on a dilution of the first round PCRs from both 
sources, in order to generate sufficient product for cloning. The PCRs for each source 
were pooled and separated by low melting point gel electrophoresis. The 150-200bp 
product was isolated and purified from the ES cell PCRs and the 550bp product was 
isolated and purified from the skin PCRs. The fragments were then cloned blunt 
ended into the Smal site of pBluescriptfl SK+. Recombinants were identified by 
blue/white colour selection and characterised by restriction enzyme analysis (not 
shown). The 5' RACE clone from ES cells was labelled ES! 5' RACE #1, and 
restriction analysis confirmed that the insert was approximately 200bp. In order to 
map the end point of the cDNA more precisely, the insert was sequenced (Figure 3.6) 
It was previously assumed that the transcriptional start site in mouse would be the 
same as that already determined for humans. As such the site for initiation of mouse 
ERCCJ transcription mapped to a position upstream of the start of the published 
mouse cDNA sequence (accession number: X07414 ) and within the published 
promoter sequence (accession number: X07413). With this in mind and for the 
purposes of illustration the sequence of the HMI 5' RACE clone, ES! 5' RACE #1, 
was aligned with a sequence compiled from the promoter region and the cDNA. The 
120 bases at the 5' end of the published cDNA sequence being identical to the 3' 
limit of the published promoter region (sequence alignments were performed using 
Wisconsin Package Version 9. 1, Genetics Computer Group (GCG), Madison, Wisc., 
and were carried out by Jill Douglas). Sequencing of the HMI 5' RACE clone 
revealed the size of the insert to be 189bp. The sequence was numbered from the 
Figure 3.5 5' RACE analysis of ERCC1 cDNAs in skin and ES cells 
a, A schematic representation of the ERCC1 cDNA and promoter region. The 
promoter region is indicated as a dotted box, the cDNA region as an open box. The 
relative positions of primers used for reverse transcription (035M) and subsequent 
rounds of PCR amplification (N 1138, Exon 1 and Anchor) are shown. The positions 
of the transcriptional (human gene) and translational start sites are indicated. Shown 
to scale: 1cm = lOObp. b, After reverse transcription using primer 035M and addition 
of a homopolymeric poly(A)-tail, the tailed ERCCJ cDNA was amplified using 
primers N1138 and the anchor primer. The PCR product was visualised by gel 
electrophoresis and ethidium bromide staining (first panel), the positions of bands of 
450bp in the skin and 280bp in the ES cell track are indicated. A further round of 
nested PCR was performed on these products using the Exon 1 and anchor primers. 
The second round PCR products were electrophoresed and visualised by ethidium 
bromide staining (second panel), the positions of bands of 200bp in ES cells and 
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translational start site, with the A of the ATG being +1. The Sequence analysis 
showed that the homopolymeric A-tail, of 14 nucleotides (nt), added by terminal 
transferase to the end of the cDNA, began at nt position -113. This mapped the 5' end 
of the ERCC1 eDNA in mouse ES cells to nt position -112. This coincides exactly 
with the position of the transcriptional start site previously determined for the human 
ERCC1 gene. The sequence alignment showed that the amplified ERCCJ sequence 
matched the published mouse sequences except for the last four 5' nucleotides. 
The 5' RACE clone from skin was labelled Skin! 5' RACE #17, and restriction 
analysis confirmed the insert was approximately 580bp. The insert was then 
sequenced in order to map the end point of the eDNA in skin more precisely. (Figure 
3.7) It was known that the transcriptional start site for the human ERCC1 mapped to 
a position upstream of the published cDNA sequence (accession number: X07414) 
and within the published promoter sequence (accession number: X07413). Once 
again, for the purposes of illustration the sequence of the skin 5' RACE clone, Skin! 
5' RACE #17, was aligned with a sequence compiled from the promoter region and 
the cDNA. (sequence alignments were performed using Wisconsin Package Version 
9. 1, Genetics Computer Group (GCG), Madison, Wisc., and were carried out by Jill 
Douglas). Sequencing of the skin 5' RACE clone revealed the size of the insert to be 
579bp. The 5' end sequence of the Skin! 5' RACE #17 insert was dominated by 
polypyrimidine/polypurine tracts (CT repeats). As previously, the sequence was 
numbered with the A of the translational start (ATG) being numbered +1. The 
Sequence analysis showed that a homopolymeric A-tail, of 16 nucleotides (nt), added 
by terminal transferase to the end of the cDNA, began at nt position -502. This 
mapped the 5' end of the ERCCJ cDNA in mouse skin to nt position -501, 389 nt 
upstream of the transcriptional start site mapped in mouse ES cells and human cells. 
This apparent difference fitted well with the predicted size, 1.5kb of the ERCC1 skin 
specific transcript, compared to the 1.1kb normal transcript. The sequence alignment 
showed that the amplified sequences matched the published sequences, except for a 
single base mismatch at nt position -31. In the 5' RACE clone the nt at this position 
was a T, compared with a C in the published sequence. This nt difference was not 
observed in the analogous region of the HMI 5' RACE clone and as such it most 
Figure 3.6 Sequence of the ES/ 5 1RACE #1 insert aligned with the published 
mouse ERCC1 promoter and eDNA sequences 
The sequence of the ES/ 5'RACE #1 insert was used to precisely map the end point 
of the 5' RACE product in ES cells. The sequence (HMlrace) was aligned with a 
composite of the published mouse ERCC1 cDNA and promoter sequences 
(promocDNA) (Accession numbers: X07414 and X07413). The sequence 
corresponding to the anchor primer is shown in red, the sequence corresponding to 
primer Exon 1 is shown in blue. The translational start site is shown in pink and is 
numbered +1. The position of the transcriptional start site (human) is indicated by an 
asterisk at nt -112. The sequence corresponding to the homopolymeric tail added by 
terminal transferase is underlined (single). The position of the four mismatched 
nucleotides are underlined (double). 
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-222 	 -173 
promocDNA AAGCTTCCAT CCGCCCCAAA CCACAGCGGT CCTCCAGGAC CATAGAGAGC 
HMlrace 
-172 	 -123 
prornocDNA AGCGCGAATA GAGTTCCCCG CTCTAACTCC TCCGGGGAGC AGCGAGACGA 
HMlrace 	 :TTTT 
-122 	* 	 73 
promocDNA GCGAAGGGCC AGAGGGCCGG AAGTGAGTCT AGCAGGAGTT GTGCTGGCTG 
HM1 race TTTTTTTTT GAGCGGCCGG AAGTGAGTCT AGCAGGAGTT GTGCTGGCTG 
-72 	 -23 
promocDNA TCCTGGCGTT GTGTCGCCTC TGTTTCCCCC CGTGGTATT CCTCTAGGC 
HM1 race TGCTGGCGTT GTGTCGCCTC TGTTTCCCCC CGTGGTATTT CCTTCTAGGC 
-22 	 +1 	 28 
promocDNA ATCGGGAAAG ACCAGGCCCC AG GACCC TGGGAAGGAC GAGGAAAGTC 
HM1 race ATCGGGAAAG ACCAGGCCCC AGATGGACCC TGGGAAGGAC GAGGAAAGTC 
29 	 42 
promocDNA GGCCACAGCC CTCA 
HNlrace GGCCACAGCC CTCA 
likely reflects a PCR error. The 5' end of the cDNA in mouse skin extends beyond 
the limit of the published mouse promoter sequence, as such it was not possible to 
verify the integrity of the sequence using database searches. Subsequently a genomic 
clone encompassing this region was isolated within our laboratory (Kan-Tai Hsia, 
unpublished data.).The 1053bp genomic fragment encompassed all but 9nts, from nt 
-231 to nt -223, of the skin 5' RACE clone. This has enabled sequence alignment and 
comparisons to be made between the genomic clone and the sequence of the Skin! 5' 
RACE #17 insert. The genomic fragment contained stretches of CT repeats; a (CT)34 
beginning at nt -428 and a (CT)4 at nt -358. The sequence of the Skin! 5' RACE #17 
insert matched the sequence at the 3' end of the genomic fragment between nts -351 
and nt -232. Upstream of nt -351 the two sequences become quite divergent. The 5' 
RACE clone contains the (CT)4 repeats but, although it does have a 
polypyrimidine/polypurine tract at the 5' end, it does not align perfectly with the 
adjacent (CT)34 repeats of the genomic fragment. In the Skin/5' RACE #17 insert, the 
absolute number of CT repeats was greater although the tracts were disrupted. In 
addition to the (CT)4 repeat shared with the genomic fragment, the Skin/5' RACE 
#17 insert also had (CT)6, (CT)7, (CT)5, (CT)8 and a (CT)30 repeat only 7 nt 
downstream of the 5' end point of the skin cDNA. 
In summary, the 5' limits of the HM  and skin 5' RACE clones have been mapped 
by sequence analysis of the cloned RACE fragments. The 5' end of the normal 
ERCC1 cDNA from ES cells was positioned at nt -122, which matches the 
transcriptional start site reported for the human ERCC1 gene. The 5' end of the skin 
5' RACE clone was mapped to nt position -501, 389nts upstream of the 
transcriptional start site used for the normal ERCC1 transcript. This suggests that the 
transcription of ERCC1 in skin may be driven by an alternative upstream promoter 
element not utilised in other tissues. Sequence analysis of the skin 5' RACE clone 
revealed an extensive tract of CT repeats at the 5' limit of the clone, the functional 
significance of such sequences will be discussed later. 
W. 
Figure 3.7 Sequence of the Skin! 5'RACE #17 insert aligned with the published 
mouse ERCC1 promoter and eDNA sequences and unpublished 5' flanking 
sequences 
The sequence of the Skin] 5'RACE #17 insert was used to precisely map the end 
point of the 5' RACE product in skin. The sequence (skin) is shown aligned with a 
composite of the published mouse ERCC1 cDNA, promoter sequences 
(5'promcDNA) (Accession numbers: X07414 and X07413) and the 3' end of the 
unpublished 5' flanking sequence. The 3' end of the unpublished 5' flanking 
sequence is shown in italics. The sequence corresponding to the anchor primer is 
shown in red, the sequence corresponding to primer Exon 1 is shown in blue. The 
translational start site is shown in pink and is numbered +1. The position of the 
transcriptional start site (human) is indicated by an asterisk at nt -112. The CT repeat 
tracts in both sequences are underlined, genomic sequence: broken underline, insert 
sequence : double underline. A single mismatch between the 5'RACE sequence and 
the published elements of the composite sequence is shown in bold type. Mismatches 
with the unpublished 5' flanking sequence are not indicated. 
-537 	 -488 
5'promcDNA - - ------------GTGA GTCAATGTCT 
skin 	- 	 TTTTTTTTTT TTTTTCTT TTCTCTCTC 
-487 	 -438 
5' promcDNA GTGGGCTGAG TCCACCCACG CTTACAGGGA AGGGCGTCCT CTGAAATCTC 
skin TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC 
-437 	 -388 
S'promcDNA ACCTCCCTCC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC 
skin TCTGTGTGTG TCTCTCTCTC TCTCTCTGTC TCTCTCTCTG TCTCTCTCTC 
-387 	 -338 
S'promcDNA TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCCT 'VrCCTCCTTT 
skin TCTCTGTCTC TCTCTCTCTT TGTCTCTGTC TCTCTCTCCT TTCCTCCTTT 
-337 	 -288 
S'promcDNA CCCTCCCCCA CCTCCTTTGA TCATCACTGC GCCCGATCTG GAGTCTGGGA 
skin CCCTCCCCCA CCTCCTTTGA TCATCACTGA GCCCGATCTG GAGTCTGGGA 
-287 	 -238 
5' promcDNA AGCGCTTAAG AGGCCCTTGG AACACAACTA CTTGAAGTCA AAGTCTCCCA 
skin AGCGCTTAAG AGGGCCTTGG A1CACAACTA CTTGAAGTCA AAGTCTCCCA 
-237 	 -188 
S'promcDNA GCTACC ---- -----AAGCT TCCATCCGCC CCAAACCACA GCGGTCCTCC 
skin GGTACCAAGA TGCACAAGCT TCCATCCGCC CCAAACCACA GCGGTCCTCC 
-187 	 -138 
5 , promcDNA AGGACCATAG AGAGCAGCGC GAATAGAGTT CCCCGCTCTA ACTCCTCCGG 
skin AGGACCATAG AGAGCAGCGC GAATAGAGTT CCCCGCTCTA ACTCCTCCGG 
-137 	 * 	 -88 
5' promcDNA GGAGCAGCGA GACGAGCGAA GGGCCAGAGG GCCCGAAGTG AGTCTAGCAG 
skin GGAGCAGCGA GACGAGCG?A GGGCCAGAGG GCCGGAAGTG AGTCTAGCAG 
-87 	 -38 
5' promcDNA GAGTTGTGCT GGCTGTGCTC GCGTTGTGTC GCCTCTGTT CCCCCCGTGG 
skin GAGTTGTGCT GGCTGTGCTG GCGTTGTGTC GCCTCTGTTT CCCCCCGTGG 
-37 	 +1 	 13 
5' promcDNA TATTTCCTTC TAGCCATCGG GAAAGACCAG GCCCCAG GACCCTGGGA 
skin TATTTCTTTC TAGGCATCGG GAAAGACCAG GCCCCAGATG GACCCTGGGA 
14 	 42 
promocDNA AGGACGAGGA AAGTCGGCCA CAGCCCTCA 
skin AGGACGAGGA AAGTCGGGCA CAGCCCTCA 
3.8 Detection of the skin specific ERCC1 transcript using a probe isolated from 
the mouse skin 5' RACE clone (skin/5' RACE #17) 
Having characterised the 5' end of the ERCC1 cDNA in mouse skin using 5' RACE 
analysis it was important to confirm the integrity of the result. Evidence that the 5' 
RACE clone was actually cDNA derived would be gained by demonstrating that the 
5' end of the RACE clone was suitable for use as a transcript specific probe for the 
1.5kb skin transcript. 
The previously described sequencing of both 5' RACE clones enabled restriction 
sites to be mapped for each of the cloned fragments. With this information it was 
possible to identify a region of cDNA unique to the skin clone (skin/5' RACE #17). 
A 430bp SalJJBfaI fragment, which shared only 14bp of homology with the ES cell 
cDNA 5' end, was identified as a suitable probe (Figure3.8). Panel a, shows a 
schematic representation of the 5' end region of the mouse ERCCJ cDNA, the 
positions of the translational start site and the location of the ERCC1 primers are 
indicated for reference. The relative positions and sizes of the 5' RACE clones from 
both sources are shown along with a representation of the fragment identified as a 
suitable probe. 
Total RNA (30ug) from ES cells, wild type mouse heart and ERCCJ heterozygous 
keratinocytes was separated by electrophoresis, transferred onto a nylon membrane 
and the ERCC1 transcript detected by hybridisation to the SalIfBfaI 5' RACE probe 
(Figure 3.8). The membrane was then stripped and reprobed using an ERCCJ cDNA 
probe spanning exons 1 to 8. An ERCCJ heterozygous keratinocyte RNA was used 
for this blot to further test the specificity of the transcript specific probe. As detailed 
in the introduction, there is known to be a 2.8kb transcript associated with the ERCCI 
targeted allele in ES cells. It was predicted that this transcript should be detected in 
ERCC1 heterozygous keratinocytes at 3.2kb 
Panel b, the ethidium bromide stained gel is shown in the first panel. The RNA 
loading in each lane appeared reasonably well matched. The second panel shows the 
filter probed with the SalIfBfaI 5' RACE fragment. It was seen that, as predicted, the 
fragment did not hybridise with anything in the ES cell lane. In the heart lane there 
was a suggestion of a faint signal, equal in size to the skin specific transcript. This 
ce 
Figure 3.8 Northern blot analysis using a probe specific for the novel ERCC1 
skin specific transcript 
a, Shows a schematic representation of the 5' end of the ERCCJ cDNA and promoter 
region. The promoter region is indicated as a dotted box, the cDNA region as an open 
box. The relative positions of the RT-PCR primers are indicated for reference, and 
the translational start site (ATG) is also indicated. The relative positions and sizes of 
the cloned 5'RACE products from ES cells and skin are shown below. The region of 
the skinl5'RACE #17 insert used for the probe is also indicated. B, BfaI; S, Sall 
Shown to scale 1cm =lOObp. b, northern blot analysis. Total RNA (30pg) from ES 
cells, heart and ERCC1 heterozygous keratinocytes was electrophoresed through a 
1.4% agaro se-formaldehyde gel (first panel), transferred onto a nylon membrane and 
probed with a 430bp SalIJBfaI fragment from Skin/5'RACE #17 (second panel) 
before being stripped and reprobed with an 800bp BaniHI fragment of the ERCC1 
cDNA, corresponding to exons 1 to 8 (third panel). Positions of the 1.45kb and 1.1kb 
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signal could be explained as a consequence of contamination from the neighbouring 
lane of keratinocyte RNA. A more likely explanation is, however, that the signal 
arises from the heterogeneous smear associated with the ERCC1 transcript in heart. 
This smear may represent a degree of heterogeneity with ERCCJ transcriptional 
initiation in the heart. Similar results were seen when this fragment was used to probe 
brain RNA, which also results in an heterogeneous smear when probed with a cDNA 
fragment (data not shown). In the third, ERCC1 heterozygous keratinocyte lane, the 
probe hybridised strongly with a transcript of 1.5kb. There was no evidence of 
hybridisation to any smaller transcripts. A larger transcript in the region of 3.0kb, was 
also evident in this lane as predicted for the targeted allele. The final panel shows the 
same membrane, this time probed using an ERCCJ cDNA probe spanning exons 1 to 
8. The normal 1.1kb transcript was detected in each of the lanes. In the heart there 
was also the typical heterogeneous smear above the normal transcript. The 
keratinocyte sample exhibits the distinctive skin specific pattern of expression, where 
the 1.5kb transcript was clearly the major species and was detected at greater levels 
of abundance than the 1.1kb transcript. The transcript from the targeted allele was 
also evident. 
These results add significant weight to the evidence already presented, from the 5' 
RACE analysis, that the size difference observed between the normal and skin 
specific ERCCJ transcripts is due to differences at the 5' end of the transcript. 
Furthermore, the northern blot analysis has suggested that the although the pattern of 
expression in skin and keratinocytes is clearly distinct from the pattern seen in brain 
and heart, the 1.5kb transcript was also present in these tissues at very low 
abundance. 
3.9 Lack of UV inducibility of the novel ERCC1 skin transcript 
Identifying a novel transcript for ERCCJ was in its own right an interesting result. 
The tissue specificity of the novel ERCCJ transcript added a much greater biological 
significance to the discovery. As previously mentioned, the skin is the body's first 
line of defence against the harmful effects of UV irradiation. The NER pathway, in 
which ERCC1 is involved, is the principal repair mechanism for removing UV 
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induced DNA lesions. In this context the skin specific expression pattern of the novel 
ERCC1 transcript seems perfectly logical. Therefore it would also seem reasonable to 
imagine that a gene involved in the repair of UV induced DNA damage might itself 
be UV inducible. It has been reported that the expression of the normal transcript is 
not induced by UV in Hela cells (van Duin et al., 1987). To investigate the biological 
significance of the novel ERCCJ transcript in skin, we decided to see if this 1.5kb 
transcript was UV inducible. 
Twelve adult male BalbC mice were anaesthetised by intraperitoneal injection of 
Hypnorm and Hypnovel. Whilst under anaesthesia a 6cm 2 area of the back was 
shaved, exposing the skin directly to the UV source. Anaesthesia was used to prevent 
mice from being shaded from the UV source as a consequence of huddling 
behaviour. The shaved backs of the mice were then exposed to a single 2000 Jm 2 
dose of UVB light. The average minimal erythemal dose for mice being 1500 Jm 2 
To investigate induction of the ERCCJ gene expression, animals were culled and 
total RNA was extracted from the areas of shaved dorsal skin at various time points 
after the UV. irradiation. Three animals were culled immediately after anaesthesia and 
shaving to serve as non irradiated controls. Total RNA was extracted from three 
irradiated animals at: 3, 6 and 24 hours after UV irradiation. Northern blot analysis 
was performed to determine whether ERCC1 mRNA levels were altered following 
UV irradiation. Total RNA (30ug) from each of the skin samples was separated by 
electrophoresis, transferred onto a nylon membrane and the ERCC1 transcript 
detected by hybridisation to an ERCCJ cDNA probe. The membrane was later 
stripped and reprobed using a mouse hypoxanthine phosphoribosyl transferase 
(HPRT) cDNA probe to standardise for any variations in RNA loading in each lane 
(Figure 3.9). Panel a, the detection of ERCCJ mRNA by probing with ERCC1 cDNA 
is shown in the top panel. The normal pattern of expression was evident in each 
sample; the 1.5kb transcript remained the major transcript relative to the I.M. The 
lower panel shows the HPRT reprobe of the filter to standardise for loading. At first 
glance it appeared that the level of ERCC] was unchanged, relative to the controls, at 
3 and 6 hours after irradiation. It then appeared to be elevated twenty-four hours after 
irradiation. It can be seen that this apparent elevated level of ERCCJ correlated with 
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Figure 3.9 Lack of UV induction of ERCCI in skin 
a, northern blot analysis of skin RNA from UV irradiated mice. Upper panel, total 
RNA was prepared from the dorsal skin of mice at various time points after receiving 
a UVB dose of 2000 Jm 2 , electrophoresed on a 1.4% agarose-formaldehyde gel, 
transferred onto a nylon membrane and probed with an 800bp BamHI fragment of the 
ERCCJ eDNA, corresponding to exons 1 to 8. Lower panel, the filter was then 
stripped and reprobed with a mouse HPRT cDNA probe. The positions of the 18S 
and 28S rRNAs are indicated. b, phosphorimager analysis of ERCC1 expression 
following UV irradiation. The values from the phosphorimage were obtained using 
the ImageQuant V3.3 image analysis package. The signal values represent thearea, in 
arbitrary units, under the peak corresponding to the ERCC1 and HPRT mRNA bands. 
The ratio represents the value of the ERCC1 signal divided by the value of the HPRT 
signal, i.e. the standardised ERCCJ value. The % control is the mean mRNA level in 
irradiated samples relative to the non irradiated controls, expressed as a percentage. 
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an elevated HPRT signal in the same lanes which suggests disproportionate loading 
of RNA in these lanes. Phosphorimagery was used to quantify the level of ERCCJ 
relative to the HPRT signal (Figure 3.9). The ratio of the ERCC1 signal to the HPRT 
signal was calculated for each of the twelve samples and the mean of the three ratios 
from each time point was used for comparisons between the groups. The control 
group, which received no UV irradiation, represents the normal level of ER CC] 
expression in skin and the mean ratio of this group (0.49) was regarded as the normal 
level (100%). The mean ratio of the samples taken 3hrs after irradiation was 0.36 or 
73% of normal, for the samples taken 6hrs after irradiation the mean of the ratios was 
0.21 or 43% of normal, and finally for the samples taken 24hrs after irradiation the 
mean of the ratios was 0.48 or 97% of normal. It was clear that, at the time points at 
which samples were taken, there was no evidence of increased expression of ERCCJ 
in skin. The pattern of expression that had emerged did show some changes in the 
abundance of ER CC] in the skin. After irradiation the level of ERCCJ appeared to 
fall; to 73% of the normal level after 3hrs and then further to 43% of the normal level 
after 6hrs, before returning to 97% of the normal level 24hrs after irradiation. This 
apparent reduction in the level of ERCCJ may reflect an increase in the rate of 
turnover of the ERCCJ mRNA as the cells attempt to deal with lesions induced by 
the UV irradiation. The expression returns to the normal level after 24hrs, 
presumably once the insult has been dealt with. In summary, although the levels of 
ERCC] appeared to be affected by UV, the expression of the ERCC] skin specific 
transcript was not induced by UV irradiation as determined by northern blot analysis. 
3.11 Discussion 
The expression pattern of a gene is, by and large, determined by the biological 
function and demand on the protein that the gene encodes. Patterns of gene 
expression take many forms including: tissue specific patterns of expression; where 
genes are only switched on in certain tissues or cell types; inducible gene expression, 
where the expression of a gene is switched on or elevated in response to biological 
demand or environmental stresses; constitutive expression, where genes are 
expressed at all times in all tissues. Mouse ERCCJ has been reported as being 
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expressed in all tissues and cells at low abundance. The gene gives rise to a major 
transcript of 1.1kb, with differential splicing resulting in a smaller transcript of 1.0kb 
and differential polyadenylation giving rise to transcripts of 3.4 and 3.8kb (van Duin 
et al., 1988). 
We have identified and characterised a novel mouse ERCCJ transcript. Northern blot 
analysis of mouse tissues has revealed that the pattern of ERCCJ expression in skin 
differed from all other tissues examined, although the normal 1.1kb transcript is 
evident in skin, the major transcript was an estimated 1.5kb. This novel transcript 
was also identified in a number of cultured cell lines including: embryonic fibroblasts 
and as one might expect, mouse keratinocytes. The presence of a skin specific 
transcript in embryonic fibroblasts may reflect the manner in which the embryonic 
fibroblast cell cultures are established; essentially whole embryos at day 12.5 
gestation are disaggregated and cultured in vitro. As such the resultant fibroblasts 
may be derived from a range of tissues including the dermis, and thus some cells may 
express genes in a 'tissue specific' manner. The apparently higher level of expression 
of the novel ERCC1 transcript observed in keratinocytes compared to the PF20 cells 
may be due to the heterogeneous origins of the cells that make up the fibroblast cell 
line, if the transcript is 'skin specific' and if the cells are not all of a dermal 
derivation they may not all be capable of expressing the novel transcript, whereas the 
keratinocytes are by their nature all of a dermal derivation and thus all capable of 
expressing the skin specific transcript. As mentioned above, there are a number of 
transcripts associated with ERCCJ, however none of these other transcripts has been 
associate with a tissue specific pattern of expression. This skin specific pattern of 
expression may have arisen in order to meet a greater biological demand for NER in 
the skin. As the skin is the body's first line of defence against environmental UV 
irradiation, it is reasonable to assume that the incidence of UV induced lesions is 
higher in skin than, for instance, in the kidneys. It would therefore seem reasonable 
that the expression of a gene involved in the removal of such lesions is altered to 
meet the possible increased biological demand. Although skin specific transcripts 
have not been reported for any of the other NER genes characterised so far, this may 
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simply be because this tissue is seldom chosen for such analysis due to difficulty with 
the RNA extraction. 
An ERCCJ cDNA with altered coding sequences, the result of alternative splicing of 
exon 8, has previously been described (van Duin et al, 1986). We have used RT-PCR 
to demonstrate that the size of the coding region of the skin specific transcript 
matched that of the normal 1.1kb transcript of ES cells. Similarly, although 
differentially polyadenylated ERCC1 transcripts have been reported (van Duin et al., 
1987), we have shown that the skin specific transcript is not the product of 
differential polyadenylation. Using 3' RACE analysis it was shown that the 3' RACE 
products from the normal transcript was the same size as the 3' RACE product from 
skin. 
Using. 5' RACE we have demonstrated that the increased size of the skin specific 
ERCC1 transcript is most likely due to differential initiation of transcription, 
probably utilising an, as yet, uncharacterised upstream promoter. The transcriptional 
start site of the normal ERCC1 transcript in mouse was shown to be at the same 
nucleotide position as that reported for humans, nt -112 (van Duin et al., 1987). It 
was noted that the last 4 nts at the 5' end of the ES cell 5' RACE clone (GAGC) did 
not match the published sequence for that region (AGAG). Whilst this may reflect 
genuine differences between the mouse strains used in each case, it is more likely that 
the sequence divergence was an artefact of the PCR amplification. The sequence 
obtained from the corresponding region of the skin 5' end did match the published 
sequence. The 5' RACE analysis carried out using skin RNA mapped the 5' end of 
the tissue specific cDNA to nt position -501, 389 nts upstream from the 
transcriptional start site of the normal transcript. This is in agreement with the 
estimated size of the skin specific transcript as being almost 1.5kb. Sequencing of the 
skin 5' RACE clone revealed a striking number of CT repeats at the 5' end, but the 
absolute number of repeats was apparently less extensive in a cloned genomic DNA 
fragment spanning the region. Whilst it is possible that the sequence heterogeneity 
and the increase in the absolute number of CT repeats could be an artefact of the RT-
PCR, an alternative explanation is that the number of repeats are, in this instance, a 
reflection of the different mouse strains from which the genomic fragment (129/01a) 
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and skin 5' RACE clone (BalbC) were derived. Differences in the sizes of the 
ERCC1 introns as well as additional restriction fragment length polymorphisms have 
previously been reported between these strains (Selfridge et al., 1992). 
CT repeats are abundant in eukaryotic genomes and have been implicated in a 
number of biological mechanisms. In Drosophila, CT repeats have been shown to 
have a role in the regulation of the transcription of genes for two heat shock proteins, 
hsp26 and hsp7O. The double-stranded (CT) ,,/(AG),, has been shown to be a binding 
site for the GAGA transcription factor (GAF)(Wilkins and Lis, 1998). It is believed 
that the binding of GAF to the CT element plays an important role in the 
maintenance of DNase I hypersensitive sites in the promoters, which are themselves 
important for heat-induced expression (Lu et al, 1993). Although CT repeats are 
abundant in rodents, the GAF has yet to be detected in mouse. In promoters that lack 
a TATA box, CT repeats can act as initiator elements and in many cases are 
sufficient to drive gene expression (Weis and Reinberg, 1992). The promoter of the 
chicken malic enzyme gene lacks a TATA box and uses multiple transcription 
initiation sites (Hodnett et al., 1996). It has been suggested that the (CT) 7 tract within 
the promoter region may function as an alternative promoter in certain tissues or at 
specific stages of development. It is believed that the ability of the CT repeats to 
form non-B-DNA structures is of greater functional significance than the binding of 
any specific protein to the sequence. Increasing the extent of the CT repeats, which 
increased the likelihood of non-B-DNA structures forming, was shown to increase 
the transcription level of a reporter gene (Xu and Goodridge, 1998). In this context it 
is very probable that the CT repeats associated with the ERCCJ gene play an 
important role in the regulation of transcription although the sequences that control 
the skin specific expression are likely to be located upstream of CT tracts. 
The sequence divergence between the genomic fragment and the 5' end of the skin 
RACE clone does cast some doubt over the exact site of transcriptional initiation in 
skin. Further analysis of the 5' end of the skin specific transcript, using either primer 
extension or RNase protection analysis would be required to confirm the exact site of 
transcriptional initiation in skin. However the result of the 5' RACE analysis in skin 
was supported by the demonstration that 430bp from the 5' end of the Skin! 5' RACE 
#17 insert acted as a transcript specific probe for the 1.5kb transcript, confirming that 
this region shares homology with the skin specific transcript. 
Finally, we have shown that the novel ERCCJ transcript was not induced by UV 
irradiation. Although the UVC induction of the Ligase I gene, which is involved in 
NER, has previously been reported (Montecucco et al, 1995), this result was in 
accordance with findings that other NER genes including, XPA and XPB, or the 
normal ERCC1 transcript are not induced following UV irradiation (reviewed in 
Hoeijmakers, 1993). We did observe an apparent increase in the turnover of the 
ERCC1 mRNA following irradiation, perhaps as more protein is made to meet the 
increased biological demand. 
This work constitutes the first report of a skin specific transcription pattern 
associated with a gene involved in NER. The exact mechanism by which this pattern 
of expression is controlled remains to be elucidated. We speculate the tissue 
specificity is determined by sequences within a recently isolated genomic fragment, 
which may harbour an upstream promoter. 
Chapter 4 
Use of an ER CC] minigene to complement DNA repair 
deficiency in cultured cells 
OR 
Eukaryotic gene expression is driven by promoter sequences that are generally 
located upstream of the transcriptional initiation point. It is with these promoter 
sequences that the basal transcription factors interact in order that the RNA 
polymerase can then bind. The polymerase responsible for synthesising 
heterogeneous nuclear RNA, the precursor to mRNA, is RNA polymerase H. Within 
any promoter there are a number of elements that can determine the efficiency with 
which the promoter will drive gene expression. The 'classical promoter' elements 
include: the TATA box, the CAAT box and the GC box. The TATA box (consensus 
sequence: TATA(T/A)A(T/A)), generally located about 30 nucleotides upstream of 
the transcriptional initiation site, is implicated in the determination of the start site. 
The CAAT box (consensus sequence: GGCCAATCT), located about 80 nucleotides 
upstream from the transcriptional start site, is believed to be involved in controlling 
the frequency of transcription initiation. The GC box (consensus sequence: 
GGGCGG) is often present in multiple copies within promoters and binds the 
transcription factor Sp 1. 
The characterisation of the mouse ERCCJ promoter has been reported (van Duin et 
al., 1988). It was shown that the ERCC1 promoter, located within 170bp upstream of 
the transcriptional start site, lacked any clearly identifiable classical promoter 
elements such as CAAT or TATA boxes. It was shown that 170bp of 5' genomic 
sequence was able to drive expression of a complete human ERCCJ cDNA fragment, 
as measured by the correction of the DNA repair defect associated with CH043-3B 
cells. This finding is in keeping with the promoters of other NER genes including 
XPA (van Oostrom et al., 1994). We have just described (Chapter 3) the 
identification of a novel skin specific ERCC1 transcript which arises as the result of 
transcription initiating at a point upstream of the currently published promoter 
sequence. This suggests that expression of the ERCCJ skin specific transcript is 
under the control of an upstream promoter not previously characterised. 
The aim of the work described here was, to construct a functional ERCC1 minigene 
which could be used subsequently to identify the control elements responsible for the 
skin specific pattern of ERCC1 transcription, by conventional deletional analysis. 
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4.1 Construction of an ERCC1 minigene 
As previously shown, the normal 1.1kb ERCCJ transcript is also expressed in skin 
but is much less abundant than the 1.5kb skin specific transcript. As such, using the 
5' flanking sequence from the mouse ERCCJ gene with a reporter gene, such as 
chioramphenicol acetyl transferase (CAT), would not have been suitable for the 
identification of the control elements required for the skin specific pattern of 
expression. It has been shown that the promoter associated with the normal transcript 
lies within 170bp of the initiation site, so, depending on the mechanism for the skin 
specific expression and the cell type in which the assay was performed, CAT 
expression might still be predicted from a deleted promoter incapable of driving the 
skin specific pattern of expression if the 170bp promoter remains intact. Using gene 
fragments readily available in our laboratory an ERCC1 minigene was constucted in 
order to define the elements responsible for the skin specific pattern of expression. A 
minigene was constructed in which a 1.05kb stretch of 5' flanking sequence was 
linked on to an ERCC1 gene fragment and the 3' end of the ERCC1 cDNA which 
carries the polyadenylation signal. Due to the uncertaintity that remains, at this stage, 
about the, precise transcriptional start site in skin it remains a formal posibility that 
some of the necessary elements for the skin specific pattern of expression may lie 
upstream of the 5' flanking sequence utilised in this minigene. The 1.05kb 5' 
flanking sequence used in the minigene construct was cloned and sequenced by Kan-
Tai Hsia (Figure 4.1). The nucleotide sequence of this region showed that the 
fragment contained a number of interesting sequence motifs, including a stretch of 25 
CA repeats at the 5' end in addition to the CT repeats, described earlier (Chapter 3), 
at the 3' end. As with CT repeats, CA repeats are widespread in the genome and are 
believed to play a role in chromatin structure. More significantly, it was found that 
this fragment contained a clearly identifiable TATA box at nt position 456 
(TATATAA) and the consensus sequence for a GC box, which binds the 
transcription factor Spi, at nt position 305 (GGGCGG). This is the first time that 
classical promoter elements have been identified in association with an ERCC1 
promoter (Hsia, unpublished data). The TATA box in this fragment is located at 
approximately 322bp upstream of the putative transcriptional initiation site in skin, as 
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Figure 4.1 Nucleotide sequence of the mouse ERCCJ 5' flanking region 
The nucleotide sequence of the mouse ERCC1 5' flanking region (pRK1.05). The 
stretch of CA repeats is shown in red. Consensus sequences for GC and TATA boxes 
are shown in yellow and green respectively. The nt position for initiation of 
transcription in skin is shown in pink. The CT repeat tract is shown in blue. Data 
kindly provided by Kan-Tai Hsia. 
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1 	 60 
GAATTCACAG CGTAGGCATG TGCTTGTACA CACACACACA CACACACACA CACACACACA 
61 120 
CACACACACA cACACACACC TAAACTAG GAAAAcATTA AAAAAGATAT AGAGGGATTA 
121 180 
CATATGATGA CCTTTGGGCG TGCCCTCTCT CAATACACGPk AGACCAAAAG AAAATGGAGA 
181 240 
ATACGTTGGT AAATGCATGC AAAATTTTAA ATGGAGAATT TTTAAAAGTA TGAACTCGAA 
241 300 
GGAAAGATTT GCAGCCTAPkT GAAGTGACTA ACAGCATCAG CCCTTAAGCA TCACTCCAAC 
301 	 360 
AAAT 	TAATCAAAAG ATGCTCATCT CCTTTTCCTC CCCCTTTTTA ATTTAAAAAA 
361 	 420 
ACCGTTGAAT TGCTCATTTC GAAAPAATGG GCAAAGGATA TGAGCCAATC TTTGTTAAAA 
421 480 
GGAATAGGCA AAGGAAATGA GCAAGAACAA AAAAATATAT AAGACCATTA AACTATTTCC 
481 540 
TTAGCAATCA CAGAACTACA AGTTGGAACG GGGTGAAACT GTCCTTCCAG GAAATGAGTC 
541 600 
ATACTAAGTC ATTCATGGGG CCCAGGTCTC GGAACACAGG TGTCCCTTCC TTCAGGAAGC 
601 660 
TCGTCCTCAC ACCCCAGCTG GGTCAGGTGC TCCCCCTAAC ACGGGCTCAA TGTCCTCTGG 
661 720 
GCTCTCCCTT CCCGACCCTG CCCGCTCTGG GTTGTCCCTG TCTGACTGTC CCACTGGACT 
721 780 
TTAPLGCCACA GCTGTCGGTA TCAGTCCCTG CTTGGGATGC AAGTGGGGAA TGGCTTAGAA 
781 840 
TTAGTGAGTC AATGTCTGTG GGCTGAGTCC ACCCACGCTT ACAGGGAAGG GCGTCCTCTG 
841 900 
AAATCTCACC TCCCTCCTCT CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT 
901 960 
CTCTCTCTCT CTCTCTCTCT CTCTGTCTCT CTCTCCTTTC CTCCTTTCCC TCCCCCACCT 
961 1020 
CCTTTGATCA TCACTGAGCC GGATCTGGAG TCTGGGAAGC GCTCAAGAGG GCCTTGGAAC 
1021 1053 
ACAACTACTT GAAGTCAAAG TCTCCCAGGT ACC 
determined by the 5' RACE analysis. Typically TATA boxes are situated about 25bp 
upstream of the startpoint, this may suggest that the sequence motif identified in the 
5' flanking fragment is simply coincidental and does not function as a TATA box, or, 
alternatively the 5' end point determined by the 5' RACE analysis is not exact. 
The cloning strategy used to construct the ERCC1 minigene is shown schematically 
in Figure 4.2. The minigene was derived from three parental plasmids available 
within our laboratory. The 5' flanking region believed to harbour the upstream 
promoter was isolated as a 1.05kb SstJJKpnI fragment from a genomic subclone, 
pRK1 .05 (provided by Kan-Tai Hsia). This was hooked up to a 9.3kb KpnI fragment 
of the gene carrying exons 1 to 7, isolated from the genomic subclone pKpnl 9.3 
(provided by Kan-Tai Hsia). The KpnI site within exon 7 was utilised to add on the 
3' end of the cDNA carrying exons 7 to 10, the polyadenylation signal and a short 3' 
UTR, as a 300bp KpnIIEcoRI fragment, in Bluescriptil SK+. Recombinants were 
identified by blue/white colour selection and subsequently characterised by 
restriction analysis. A single positive clone was identified and the integrity of each of 
the cloning sites was confirmed by sequencing (data not shown). The resultant 
minigene, ERCC1 MG #13, was 10.4kb and could be linearised by restriction at the 
Nod site in the Bluescriptil SK+ polylinker. 
4.2 Expression of the ERCC1 minigene (ERCCI MG #13) in DNA repair 
deficient mouse embryonic fibroblasts (PF24) 
As described earlier, the spontaneously transformed embryonic fibroblast cell line 
(PF24) was derived from an ERCC1 deficient embryo and has been shown to be 
hypersensitive to UV as a consequence of DNA repair deficiency. It has been shown 
that the pattern of ERCCJ expression observed in wild type embryonic fibroblasts 
(PF20) matches the pattern observed in skin and keratinocytes. As such the PF24 cell 
line was regarded as suitable for the in vitro study of the expression pattern of the 
minigene. Northern blot analysis after transfection of the PF24 cell line with the 
minigene construct would enable us to determine if all the sequence elements 
necessary for the skin specific pattern of expression were present within the 
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Figure 4.2 Construction of the ERCC1 minigene (ERCCJ MG #13) 
a, The 5' flanking sequence clone pRK 1.05 was cut with SstI and KpnI to liberate 
the insert. Drawn to scale: lcm=lOObp. b, The exon 7 to 10 region of the cDNA 
subclone pBluescriptll SK+ EX4-10 (RI), was isolated as a 300bp KpnIJIEcoRI 
fragment. Drawn to scale: lcm=lOObp. c, The 9.3kb KpnI genomic fragment carrying 
exons 1 to 7 was isolated from pKpn 9.3. Drawn to scale: lcm1kb. d, Each of the 
isolated fragments were cloned into SstJl EcoRI cut pBluescriptll SK+. Drawn to 
scale lcm=lkb. 
Plasmid backbone shown as thin line. 5'Flanking sequence shown as stippled box. 
cDNA sequence shown as hatched box. Exons shown as numbered open boxes. 
Introns shown as thick line. Restriction sites used for cloning and subsequent analysis 
shown as follows: EcoRI; E, BamHI; B, Bglll; Bg, KpnI; K, PstI; P. SstI; S, NotI; N. 
Restriction sites cut for cloning or later linearising are indicated by X. 
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minigene. This was essential before any deletional analysis of the promoter could be 
carried out. 
The original ERCCJ gene targeting took place in the HPRT-deficient ES cell line, 
HMI (Selfridge et al., 1992). Consequently, a proportion of the ERCC1-deficient 
animals generated from the targeted ES cell line also carried the X-linked, non-
functioning HPRT allele from the HM 1 cell line. It has been established that the 
ERCC 1-deficient PF24 cell line was derived from an HPRT-deficient male embryo 
(Melton unpublished data) a factor which was exploited in the gene transfer 
experiments described here. HPRT catalyses an early step in the purine salvage 
pathway in mammals. It is possible to select for HPRT activity in vitro, using 
medium supplemented with hypoxanthine, aminopterin and thymidine (HAT). As 
aminopterin inhibits de novo synthesis of purines and pyrimidines, HPRT activity is 
required for cells to bypass the aminopterin-induced metabolic block by utilising the 
hypoxanthine and thymidine in the purine and pyrimidine salvage pathways. This 
enables HPRT minigenes to be used as selectable markers. 
PF24 cells were co-transfected with the ERCC1 MG #13 and the PGK driven HPRT 
minigene, PGKHPRT, in a 3:1 ratio, respectively. Both vectors were linearised with 
NotI prior to transfection. Stably transfected cells were identified by culturing in 
HAT selective medium. Individual colonies were then picked and screened by PCR 
for the presence of the ERCC1 minigene. Details of the PCR assay used to 
distinguish between wild type and targeted alleles are presented in Figure 6.2 
(Chapter 6). The PCR primers 033M and 035M give rise to a 600bp product from 
exons 4 to 5 of the wild type allele and fail to generate a product from the targeted 
allele. Using this primer pair when screening transfected PF24 cells can only give rise 
to a PCR product if the ERCC1 minigene is present; exons 4 and 5 are present within 
the minigene in their wild type configuration. Out of twelve colonies screened, all 
were found to be positive for the presence of the ERCC1 minigene (data not shown). 
Six of the twelve positive clones were expanded in culture for northern blot analysis 
(Figure 4.3). 
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Figure 4.3 ERCC1 minigene (ERCC1 MG #13) expression in repair-deficient 
embryonic fibroblasts (PF24) 
Northern blot analysis of RNA from minigene-positive PF24 cell lines. Upper panel, 
total RNA was prepared from the minigene transfected cell lines PF24/MG#2, 
PF24/MG#4 and PF24/MG#6, a wild type mouse embryonic fibroblast cell line 
(PF20), an ERCCJ-deficient mouse embryonic fibroblast cell line (PF24) and a 
mouse ES cell line (HMI). The RNA (30pg) was electrophoresed on a 1.4% 
formaldehyde-agarose gel, transferred onto a nylon membrane and probed with an 
800bp BaniHI fragment of the ERCCJ cDNA corresponding to exons 1 to 8. 
Positions of the 18S and 28S rRNAs and estimated transcript sizes are indicated. 






C C C 
= 
N N N N N N 	N N 








Total RNA was isolated from six minigene positive PF24 cell lines, PF24IMG#1-#6, 
the wild type PF20 cell line, the parental PF24 cell line and the HMI ES cell line. 
The RNA (30pg) was separated by gel electrophoresis, transferred onto a nylon 
membrane and ERCC1 transcripts detected by hybridisation to an ERCCJ eDNA 
probe. 
The ethidium bromide staining of the gel is presented in the lower panel and 
indicates that the amounts of RNA in each lane are, by eye, equivalent. Only the 
normal 1.1kb transcript was present in HM 1 lane, whereas the skin specific pattern of 
expression was evident in the PF20 lane. Once again, as described in chapter 3.2, 
there was no evidence of a transcript from the targeted allele in the PF24 lane, 
perhaps due to partial degradation of the RNA sample preventing the detection of 
higher molecular weight species present in low abundance. Multiple transcripts were 
evident in each of the minigene positive lanes, however, the predicted skin specific 
pattern of expression, the presence of an abundant 1.5kb transcript, was not readily 
detected. In each of the lanes there was a suggestion of weak signals from hybridising 
mRNA at the predicted sizes of 1.1kb and 1.5kb, but not in the proportions normally 
detected in skin or the PF20 cell line. In addition to these weakly hybridising bands 
there were much stronger signals of higher molecular weight evident in each of the 
lanes. In lanes 1, 3, 5, and 6 there were two additional strongly hybridising bands, 
estimated to be in the region of 3.2kb, present in equal proportions to each other. In 
lane 4 only the smaller of the two additional transcripts was evident. In lane 2 the 
larger of the two additional bands was clearly detected and there was evidence of 
hybridisation to a band equal in size to the smaller additional band. Although these 
transcripts do not fit the size predictions, the pattern of expression evident in lane 
two, a higher molecular weight species present in greater abundance than the lower 
molecular weight species, is reminiscent of the skin specific pattern of expression. 
4.3 Expression of the ERCC1 minigene corrects the UV sensitivity of ERCCJ-
deficient fibroblasts (PF24) 
The northern blot analysis described above confirmed that the ERCCJ minigene was 
being transcribed, but the transcripts detected did not fit the predicted sizes and 
aberrant processing of the mRNA could not be ruled out at this stage. It was therefore 
necessary to establish that the minigene transcripts gave rise to fully functional 
ERCC 1 protein. Rescue of the PF24 UV sensitivity following transfection of the cells 
with the ERCCJ minigene would confirm the functionality of the minigene construct. 
Three of the minigene positive cell lines were expanded in culture for use in UV 
sensitivity experiments. The selected lines, PF24IMG#2, PF24IMG#4 and 
PF24/MG#6 all displayed different patterns of minigene expression at the level of 
northern blot analysis (see Figure 4.3). They were selected to investigate whether 
there was any correlation with any of the patterns and gene function. For the UV 
experiments, 2x104 cells were plated in small dishes and cultured overnight before 
being irradiated with various doses of UV irradiation. The dishes were maintained in 
culture until control dishes, not exposed to UV, reached confluence. At this point the 
cells were fixed and stained to quantify the UV sensitivity of the minigene positive 
cell lines. The UV survival curves obtained are presented in Figure 4.4. The graph 
illustrates the survival in terms of the cells surviving each dose of UV irradiation as a 
percentage of the untreated controls. The graph shows that the minigene positive 
PF24 cell lines were not sensitive to UV. The survival profile of the UV sensitive, 
non-transfected PF24 cells showed that 79% of the cells survived the UV dose of 
1.25 Jm 2, 46% survived the 2.5 Jm 2 dose, 26 % survived the 3.75 Jm 2, and 10 % 
survived the highest dose of 5 Jm 2. In the case of the wild type PF20 cell line, the 
survival profile indicates that 100% of the cells survived the highest dose of 10 Jm 2 . 
The survival profile of the cell line PF24/MG #4 only showed a slight degree of UV 
sensitivity at the highest UV dose, with 93% survival at the 5 Jm 2 dose. The 
PF24IMG#6 cell line showed a similar resistance to the UV irradiation with 94 and 
90% survival at the lower UV doses of 1.25 and 2.5 Jm 2. At the higher doses of 3.75 
and 5 Jm 2 survival of 94 and 77% was observed. The PF24IMG#2 cells survival 
profile showed that at the lower doses of 1.25 and 2.5 Jm 2 the survival was 88 and 
86%, whilst at the higher doses of 3.75 and 5 Jm 2 the survival was measured at 76 
and 73%. 
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Figure 4.4 Correction of the UV sensitivity of ERCC1 -deficient fibroblasts 
(PF24) by following transfection with an ERCC1 minigene (ERCC1 MG #13) 
The UV survival curves for wild type (PF20), ERCC]-deficient (PF24) mouse 
fibroblasts and three minigene-positive PF24 cell lines are shown. Each point 
represents the mean of two separate experiments. Circle, P1720; hexagon, PF24; 
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Thus the expression of the minigene in each of the cell lines analysed was seen to 
correct the UV sensitivity of the repair deficient PF24 cells to near wild type levels. 
There were no significant differences between the survival profiles of the minigene 
positive cell lines and as such it was not possible to consider any correlation between 
any of the observed patterns of minigene expression and gene function. 
4.4 Expression of the ERCC1 minigene (ERCC1 MG #13) in ERCCJ-deficient 
Chinese hamster ovary cells (CH043-3B) 
In addition to using the ERCC1 minigene in experiments designed to identify the 
sequences required for the skin specific pattern of expression it was also important to 
consider whether the minigene was expressed appropriately in other cell types. The 
cell types in which only the 1.1kb transcript is expressed include mouse ES cells and 
CHO cells. As ERCC1 -deficient mouse ES cells were not available it would not have 
been possible to assess whether expression of the minigene in ES cells gave rise to a 
functional protein. An ERCC1-deficient CHO cell line was available for such 
analysis to be carried out. The aim of the work described in this section was to 
determine if, when expressed in CHO cells, the minigene would only give rise to the 
normal 1.1kb transcript. 
The human ERCCJ gene was originally cloned by virtue of its ability to complement 
the UV sensitive CHO cell line, CH043-313. The ERCC1-deficient status provided an 
ideal environment to test whether the mouse minigene was capable rescuing the UV 
sensitivity in another species. Recently it was shown that the molecular basis of the 
ERCC1 defect in CH043-313 cells was a point mutation resulting in an amino acid 
exchange at the 98th residue. Although the cells are ERCC1-deficient, expression of 
the gene gives rise to a transcript of normal size and at wild type levels (Hayashi et 
al, 1998). The fact that the mouse ERCCJ cDNA probes hybridised with the hamster 
transcript meant that it would be less straightforward to detect expression of the 
minigene where the endogenous transcript was still present. It was felt that, as 
transgenes are generally present in multiple copies, an apparent increased abundance 
of the 1.1kb transcript might be sufficient to indicate minigene expression in the first 
instance. A secondary method for confirming transgene expression over the 
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endogenous gene would then be appropriate. The DNA mediated gene transfer was 
carried out using a spontaneously occurring HPRT-deficient clone, CH043-3B(TG1) 
derived from the CH043-3B cell line (Melton et al, 1998). This enabled an HPRT 
minigene to be used as a selectable marker in a co-transfection with the ERCCJ 
minigene. A pilot study showed that the PCR assay used for the detection of the 
minigene, the 600bp exon 4 to 5 product, was specific for the mouse sequences of the 
minigene and did not give a positive result for CH043-3B DNA (data not shown). 
CH043-3B(TG1) cells were co-transfected with the ERCCJ MG #13 and the PGK 
driven HPRT minigene, PGKHPRT. Both vectors were linearised with Not! prior to 
transfection. Stably transfected cells were identified by culturing in selective HAT 
medium. Individual colonies were then picked and screened by PCR for the presence 
of the ERCC1 minigene. Out of twelve colonies screened, all were found to be 
positive for the presence of the ERCCJ minigene (data not shown). Six of the twelve 
positive clones were expanded in culture for northern blot analysis (Figure 4.5). 
Total RNA was isolated from six minigene positive CH043-3B(TG1) cell lines, 
CH043-3B(TG1) IMG42, 4, 6, 7, 10 and 11, the wild type CHO-9 cell line and the 
parental CH043-3B cell line. The RNA (30jig) was separated by gel electrophoresis, 
transferred onto a nylon membrane and ERCCJ transcripts detected by hybridisation 
to a mouse ERCCJ cDNA probe. 
The ethidium bromide staining is presented in the lower panel and suggests that, by 
eye, the two control tracks CHO-9 and CH043-3B are overloaded relative to the 
other samples. The detection of ERCCJ mRNA by probing with the mouse ERCC1 
cDNA is shown in the upper panel. The normal 1.1kb transcript was evident in every 
lane. Allowing for the apparent overloading of the two control tracks there was no 
evidence to suggest that the level of this transcript was elevated in any of the 
minigene positive cell lines. There were no additional distinct transcripts evident in 
lanes CH043-3B(TG1)IMG#2, 6, 10 and 11. In the CH043-3B(TG1)IMG#7 and 4 
lanes an additional transcript, estimated at 1.5kb, was discernible. In summary, 
despite each of the cell lines being minigene positive, as determined by PCR, it 
appeared that the mouse ERCCJ minigene was not expressed in all of the CHO cell 
lines. 
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Figure 4.5 ERCC1 minigene (ERCC1 MG #13) expression in repair-deficient 
Chinese hamster ovary cells (CH043-3B(TG1)) 
Northern blot analysis of RNA from minigene-positive CH043-3B(TG1) cell lines. 
Upper panel, total RNA was prepared from the minigene transfected cell lines 
CH043-3B(TG1)IMG#2, 4, 6, 7, 10, 11, a wild type Chinese hamster ovary cell line 
(CH09), and the parental ERCC1-deficient Chinese hamster ovary cell line (CH043-
3B(TG1)) The RNA (30j.tg) was electrophoresed on a 1.4% formaldehyde-agarose 
gel, transferred onto a nylon membrane and probed with an 800bp BamHI fragment 
of the ERCC1 cDNA corresponding to exons 1 to 8. Positions of the 18S and 28S 
rRNAs and estimated sizes of distinct transcripts are indicated. Lower panel, 








































4.5 The UV sensitivity of ERCC1-deficient CHO cells (CH043-3B) is corrected 
by expression of the mouse ERCCJ minigene (ERCCJ MG#13) 
The northern blot analysis described above, suggested that the mouse ERCC1 
minigene was not expressed in the majority of the cell lines tested. Expression was 
detected in two cell lines by virtue of the transcript being different in size from the 
endogenous hamster transcript. It remained possible that the minigene was indeed 
being expressed appropriately, at low levels, in the other cell lines and that the 
presence of the endogenous hamster transcript prevented it from being detected. if 
this was the case, and assuming that the minigene was producing a functional protein, 
it was predicted that rescue of the CH043-313 UV sensitivity would be evident in 
those cell lines where the minigene was being expressed in the manner suggested. To 
investigate further whether there was rescue of UV sensitivity, two of the cell lines 
were expanded in culture for use in UV sensitivity experiments. The cell lines 
selected were, CH043-3B(TG1)IMG#2 which did not appear to be expressing the 
minigene at the level of northern blot analysis and CH043-3B(TG1)/MG#7 in which 
an additional transcript was detected.. 
For the UV experiments, 2x10 4 cells were plated in small dishes and cultured 
overnight before being irradiated with various doses of UV irradiation. The dishes 
were maintained in culture until control dishes, not exposed to UV, reached 
confluence. At this point the cells were fixed and stained to quantify the UV 
sensitivity of the minigene positive cell lines. The UV survival curves obtained are 
presented in Figure 4.6. The graph illustrates the survival in terms of the cells 
surviving each dose of UV irradiation as a percentage of the untreated controls 
The UV survival curve of the CH043-313 cell line illustrated its sensitivity to UV. 
The curve showed that although 92% of cells survived the 1.25 Jm 2 dose, survival 
was reduced to 61 and 41 % at the higher UV doses of 3.75 and 5 Jm 2 and only 2% 
survived a UV dose of 10 Jm 2 . The CH043-3B(TG1)/MG#2 cell line exhibited a 
comparable degree of UV sensitivity. In this case 88% of cells survived the 1.25 Jm 2 
dose, survival was reduced to 43 and 23% at the higher UV doses of 3.75 and 5 Jm 2 
and 4% of the cells survived the 10 Jm 2 dose. The CH043-3B(TG1)IMG#7 cell line 
did not appear to be sensitive to UV. In this case there was no cell death after the 
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Figure 4.6 Correction of the UV sensitivity of ERCCJ-deficient Chinese hamster 
ovary cells (CH043-3B(TG1)) following transfection with an ERCC1 minigene 
(ERCC1 MG #13) 
The UV survival curves for wild type (CH09), ERCCJ-deficient (CH043-3B(TG1)) 
Chinese hamster ovary cells and two minigene-positive CH043-3B(TG1)cell lines 
are shown. Each point represents the mean of two separate experiments. Circle, 
CH09; hexagon, CH043-3B (TG 1); triangle, CH043-3B (TG 1 )/MG#7; inverted 















1.25 Jm 2 dose, survival at the higher UV doses of 3.75 and 5 Jm 2 was 98 and 93% 
and 90% of the cells survived the highest UV dose of 10 Jm 2. This is in keeping with 
the survival curve of the wild type CHO-9 cells, which showed 91% survival at the 
1.25 Jm 2 dose, 95 and 91 % survival at the 3.75 and 5 Jm 2 doses and 85% survival 
at the highest dose of 10 Jm 2 . 
In summary, in the cell line where expression of the minigene was apparent, the UV 
sensitivity associated with the DNA repair deficient CHO cells, CH043-313, was 
rescued. The cell line in which only the endogenous transcript was evident remained 
sensitive to UV irradiation. 
4.6 Expression of the ERCC1 minigene (ERCCJ MG #13) in cultured ERCC1-
deficient mouse keratinocytes 
We have already shown that the pattern of ERCC1 expression observed in cultured 
mouse keratinocytes matched the pattern of expression seen in skin (Chapter 3). The 
major transcript in keratinocytes is the skin specific 1.5kb transcript. As such, 
keratinocytes were considered as an appropriate cell type to investigate further the 
elements involved in the control of this expression pattern using the ERCC1 
minigene. As with the PF24 cell line, the ERCC1-deficient keratinocytes (Ker.(-/-)) 
isolated in our laboratory were found to be HPRT-deficient (Melton, unpublished 
data). Once again this permitted the use of an HPRT minigene as a selectable marker 
in co-transfections with the ERCCJ minigene (ERCCJ/MG#13). Due to the technical 
difficulty associated with the successful culturing of mouse keratinocytes, all the 
culturing required for these experiments was carried out by Ann-Marie Ketchen. 
ERCC1-deficient keratinocytes were co-transfected with the ERCCJ MG #13 and the 
PGK driven HPRT minigene, PGKHPRT. Both vectors were linearised with NotI 
prior to transfection. Stably transfected cells were identified by culturing in selective 
HAT medium. Individual colonies were then picked and screened by PCR for the 
presence of the ERCC1 minigene, as described in section 4.2. Out of six colonies 
screened, 3 were identified as ERCC1 minigene positive and were expanded in 
culture for northern blot analysis (Figure 4.7) 
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Figure 4.7 ERCC1 minigene (ERCC1 MG #13) expression in repair-deficient 
murine keratinocytes (Ker.(-/-)) 
Northern blot analysis of RNA from minigene-positive Ker(-/-) cell lines. Upper 
panel, total RNA was prepared from the minigene transfected cell lines Ker.(-/-) 
JMG#3, 4 and 5, a wild type murine keratinocyte cell line(Ker.(WT)), and the 
parental ERCC1-deficient murine keratinocyte cell line (Ker.(-/-)) The RNA (30tg) 
was electrophoresed on a 1.4% formaldehyde-agarose gel, transferred onto a nylon 
membrane and probed with an 800bp BamHI fragment of the ERCCJ cDNA 
corresponding to exons 1 to 8. Positions of the 18S and 28S rRNAs and estimated 
sizes of distinct transcripts are indicated. Lower panel, ethidium bromide staining to 







Total RNA was isolated from three minigene positive Ker.(-/-) cell lines, Ker.(-/-) 
JMG#3, #4 and #5, the wild type keratinocyte cell line and the parental ERCCJ-
deficient keratinocytes. The RNA (30p.g) was separated by gel electrophoresis, 
transferred onto a nylon membrane and ERCC1 transcripts detected by hybridisation 
to a mouse ERCCJ cDNA probe. 
The ethidium bromide staining of the gel is presented in the lower panel and 
indicates that the amounts of RNA in each lane are, by eye, essentially equivalent. 
Transcripts arising from the targeted ERCC1 alleles were evident in the Ker.(-I-) 
lane, the size estimated for these transcripts was 3.2kb. In the wild type keratinocyte 
lane there were bands evident at 1.5kb and 1.1kb as expected. The expression 
patterns seen in the minigene positive lanes did not reflect the wild type pattern of 
expression. There was a band of approximately 3.2kb evident in each of the minigene 
positive lanes. Whilst the size of this band matches the size of the transcript from the 
ERCC1 targeted alleles, the signals were noticeably stronger in the minigene positive 
lanes and as the ethidium staining of the gel did not suggest that these lanes were 
overloaded relative to the Ker. (-I-) lane, it is probable that the bands corresponded to 
minigene transcripts. A further transcript of approximately 1.5kb was evident in the 
Ker(-/-)IMG#4 lan, this fitted the predicted size for the skin specific transcript. 
There was no strong evidence of a hybridising species at 1.1kb in this lane and as 
such the normal pattern of ERCCJ expression in keratinocytes was not obvious. In 
the Ker. (-/-)IMG#3 lane there were also additional transcripts evident, in this case 
none of the transcripts fitted the size predictions for correct expression of the 
minigene. 
In summary, although ERCCJ minigene expression was clearly detectable, the 
patterns of minigene expression seen in cultured keratinocytes did not reflect the 
normal pattern of ERCC1 expression associated with this cell type. 
4.7 The UV sensitivity of cultured ERCC1-deficient mouse keratinocytes is 
corrected by expression of the mouse ERCC1 minigene (ERCC1 MG#13) 
The northern blot analysis described above, suggested that the minigene was being 
expressed in cultured mouse keratinocytes. However, as the transcripts did not fit the 
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predicted sizes it was possible that the mRNAs detected, resulted from aberrant 
splicing of the minigene introns and as such would not be able to encode a fully 
functional protein. Rescue of the UV sensitivity associated with the Ker.(-/-) cell line 
would be indicative of the functionality of the minigene construct in keratinocytes. 
The keratinocyte UV survival assays were performed by Ann-Marie Ketchen. 
The three minigene positive cell lines were expanded in culture for use in UV 
sensitivity experiments. For the UV survival experiments, 2x10 4 cells were plated in 
small dishes and cultured overnight before being irradiated with various doses of UV 
irradiation. The dishes were maintained in culture until control dishes, not exposed to 
UV, reached confluence. At this point the cells were fixed and stained to quantify the 
UV sensitivity of the minigene positive cell lines. The UV survival curves obtained 
are presented in Figure 4.8 
The graph illustrates the survival in terms of the cells surviving each dose of UV 
irradiation as a percentage of the untreated controls. The UV sensitivity of the 
ERCC1-deficient cell line(Ker.(-/-)) was illustrated by its survival curve. The curve 
showed 43 and 5% survival after UV doses of 1.25 and 2.5 Jm 2. The wild type 
keratinocytes were not sensitive to these UV doses. The survival curve showed 96 
and 92% survival following UV doses of 1.25 and 2.5 Jm 2 and 88, 86% survival 
after UV doses of 3.75 and 5 JM 2 and 82% survival following the highest UV dose 
of 10 Jm 2 . Each of the minigene positive cell lines had survival profiles similar to 
the wild type pattern. In the case of the Ker(-/-)IMG#3 cell line the survival profile 
showed 100% survival following UV doses of 1.25 and 2.5 Jm 2 and 97, 96% 
survival after UV doses of 3.75 and 5 JM 2 and 94% survival following the highest 
UV dose of 10 Jm 2. The survival curve of the Ker.(-/-)IMG#4 cell line revealed 81 
and 67% survival following UV doses of 1.25 and 2.5 Jm 2 and 69, 85% survival 
after UV doses of 3.75 and 5 JM 2 and 60% survival following the highest UV dose 
of 10 Jm 2 . Finally, the survival profile of the Ker.(-/-)IMG#5 cell line displayed 100 
and 92% survival following UV doses of 1.25 and 2.5 Jm 2 and 95, 87% survival 
after UV doses of 3.75 and 5 JM 2 and 80% survival following the highest UV dose 
of lOJm 
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Figure 4.8 Correction of the UV sensitivity of ERCC1 -deficient murine 
keratinocytes (Ker.(-/-)) following transfection with an ERCC1 minigene 
(ERCC1 MG #13) 
The UV survival curves for wild type (Ker.(WT)), ERCCJ-deficient (Ker.(-/-)) 
murine keratinocytes and three minigene-positive Ker. (-/-)cell lines are shown. Each 
point represents the mean of two separate experiments. Circle, Ker.(WT); hexagon, 
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In summary, it was apparent that the minigene positive cell lines, identified by PCR, 
were not sensitive to UV irradiation. The minigene transcripts detected by northern 
blot analysis were thus capable of encoding an ERCC1 protein capable of fulfilling 
its role in NER. 
4.8 Transcription of the ERCC1 minigene initiates at the upstream start site 
The northern blot analysis carried out on each of the transfected cell lines has 
indicated that the ERCC1 minigene is expressed in each of the different cell types. 
Although the UV survival data indicated that the transcripts were functional, in each 
case the resultant transcripts have not fitted with predicted sizes and the molecular 
basis of these size differences has not been determined. As a result it has not been 
possible to determine, from these blots, whether the upstream transcription initiation 
site, in the minigene construct, was being used. The use of the upstream 
transcriptional start site would be confirmed where any of the transcripts identified in 
the transfected cell lines hybridised to the 430bp SalJIBfaI 5' RACE probe (chapter 
3.8). This probe is specific for the transcripts initiating at the upstream start site. 
Total RNA (30jig) from selected minigene positive cell lines from each cell type was 
separated by electrophoresis, transferred onto a nylon membrane and ERCC1 
transcripts detected by hybridisation to the SalLfBfaI 5' RACE probe (Figure 4.9). 
The filter was then stripped and reprobed using a mouse ERCCJ cDNA fragment 
spanning exons 1 to 8. 
The aim of this analysis was to demonstrate that amongst the various minigene 
transcripts detected by the earlier northern blots, some were the result of transcription 
initiating at the upstream start site due to the inclusion of distal promoter elements in 
the minigene construct. By a comparison of which bands were detected using the 5' 
end probe and then the cDNA probe it was possible to identify which of these 
transcripts, if any, were the result of transcription from the upstream start site. The 
upper panel shows the filter probed with the exon 1 to 8 cDNA probe that hybridises 
to all ERCC1 transcripts, irrespective of the site of transcriptional initiation. The 
lower panel shows the filter probed with the fragment specific for 
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Figure 4.9 Identification of minigene transcripts initiating at the upstream start 
site 
Northern blot analysis of RNA from selected minigene-positive cell lines. Lower 
panel, total RNA (30tg) from wild type murine keratinocytes (Ker.(WT)), ERCCJ-
deficient keratinocytes (Ker.(-/-)), minigene positive keratinocyte cell lines (Ker.(-/-) 
IMG#3, 4 and 5), minigene positive embryonic fibroblast cell lines (PF24IMG#2, 4 
and 6) and minigene positive Chinese hamster ovary cell lines (CH043-
3B(TG1)IMG#7 and 2) was electrophoresed on a 1.4% formaldehyde-agarose gel, 
transferred onto a nylon membrane and probed with a 430bp SalJIBfaI 5' RACE 
fragment. Upper panel, the filter was then stripped and reprobed using an 
800bpBamHI fragment of the ERCCJ cDNA corresponding to exons 1 to 8. Positions 
of the 18S and 28S rRNAs and estimated sizes of transcripts are indicated. 
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transcripts initiating at the upstream start site. In the null keratinocyte lane transcripts 
arising from the targeted alleles were evident in both cases. In the case of the wild 
type keratinocytes only the 1.5kb transcript was detected when probed with the 5' 
end probe, whilst the 1.1kb transcript was also detected by the cDNA probe. In the 
minigene positive keratinocyte lanes a single distinct band of approximately 3.2kb 
was evident in each of the lanes when probed with the 5' end probe. When probed 
with the cDNA probe there were additional smaller transcripts evident in the Ker.(-/-
)IMG#3 and #4 lanes. Using the exon 1 to 8 probe, the minigene positive PF24 cell 
lines showed a complex pattern of transcripts involving two bands at approximately 
2.8 and 3.2kb. In the PF24IMG#6 cell line both of these bands are evident, in 
PF24IMG#4 only the 2.8kb band was detected and in PF24IMG#2 only the 3.2kb 
was detected. When probed with the 5' end fragment specific for transcripts from the 
upstream start site, only the 3.2kb bands in the PF24IMG#2 and #6 lanes were 
evident, suggesting that this transcript begins at the upstream start site. The 2.8kb 
transcript, presumably from the downstream start site, was not detected in the 
PF24JMG#4 and #6 lanes using this probe. The cDNA probe detected only the 
endogenous 1.1kb transcript in the CH043-3B(TG1)IMG#2 lane whereas in the 
CH043-3B(TG1)IMG#7 lane an additional band of approximately 1.5kb was also 
evident. When probed using the 5' end probe there was no band evident in the 
CH043-3B(TG1)IMG#2 lane, however there was evidence of the band at 1.5kb. This 
would suggest that the mouse ERCCJ minigene transcript identified in CHO cells 
initiated at the upstream start site. 
In summary, this analysis has shown that for keratinocytes and mouse embryonic 
fibroblasts there is evidence to suggest that transcription of the mouse ERCC1 
minigene does initiate at the upstream 'start site in keeping with the pattern of 
transcription seen in wild type cells. However the apparent use of this transcriptional 
start site when the minigene was expressed in CH043-313 cells does not concur with 
the normal pattern of ERCCJ expression in wild type CHO-9 cells. Possible 
explanations for the aberrant sizes of the minigene transcripts will be discussed later. 
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4.9 Discussion 
The transfection of cloned genes or their minigene derivatives into eukaryotic cells is 
a powerful and convenient tool for studying the control of gene expression. The use 
of minigenes is often necessary when the size or structure of a particular gene means 
that it is not amenable to simple cloning and transfection procedures. The HPRT 
minigene, used as a selectable marker in this chapter, is a good example of this 
problem. The endogenous mouse HPRT locus spans approximately 33kb and would 
not be suitable for use as a marker gene in that form, whereas, the PGKHPRT 
minigene was only 2.7kb and could be linearised without disruption of the coding 
sequences. It was deemed necessary to construct a mouse ERCC1 minigene as the 
locus spans 15kb and was not available as a single cloned genomic fragment. 
The primary goal of the work described in this chapter was to develop a functional 
ERCC] minigene for subsequent use in conventional deletional analysis of the 
promoter region. These studies are often carried out using the promoter region of the 
gene of interest coupled to a CAT reporter gene and the level of CAT enzyme 
activity detected is indicative of promoter activity (Li et al., 1991). However, this 
approach could not be used to identify the sequences responsible for the skin specific 
pattern of expression that we have described, as the normal transcript driven by the 
170bp promoter element is also present in skin. As such, it was predicted that CAT 
enzyme activity would continue to be detected from this promoter after the deletion 
of the upstream promoter. The CAT reporter gene assay could have been employed if 
the normal 1.1kb transcript was not evident in skin or cell lines displaying the skin 
specific pattern of ER CC] expression. 
We have described the construction of a mouse ERCCJ minigene. This involved 
combining the cloned 5' flanking sequence, believed to harbour the upstream 
promoter, with a cloned genomic fragment spanning exons 1 to 7, hooked onto the 3' 
end of the ERCCJ cDNA including exons 7 to 10 and a short 3' UTR carrying the 
polyadenylation signal. The final size of the minigene was 10.6kb compared to 15kb 
of the endogenous locus. Given the limitations of using RACE analysis, alone, for the 
definition of the precise transcriptional start site in skin, it remains possible that the 
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5' flanking sequence included in the mingene did not harbour the complete promoter 
required for the skin specific expression pattern. 
The minigene construct was used for the stable transfection of three different 
ERCCJ-deficient cell types including: the ERCCJ-deficient CHO cell line CH043-
3B as well as ERCCJ-deficient embryonic fibroblast (PF24) and murine keratinocyte 
(Ker.(-/-)) cell lines derived from ERCCJ-deficient mice generated in our laboratory 
(McWhir et al., 1993). In each case where the minigene was being expressed, as 
determined by northern blot analysis, we observed complete rescue of the UV 
sensitive phenotype associated with each cell type. This confirmed that the minigene 
was capable of complementing the DNA repair defect in each of the cell types tested. 
The correction of the repair deficiency associated with CH043-3B using the human 
and mouse ER CC] cDNAs driven by the SV40 early promoter has been reported 
(van Duin et al., 1986 and 1988). The successful use of an XPA minigene to 
complement the repair defect in xeroderma group A cells has been demonstrated 
(Myrand et al., 1996). The 4.2kb XPA minigene included 1.6kb of 5' flanking 
sequence and 0.3kb of 3' flanking sequence. RT-PCR analysis showed that the 
minigene expression was at wild type levels but northern blot analysis of the 
minigene transcript was not reported, so it was not clear if the minigene transcripts 
were of the predicted size. 
Although the UV survival assays showed that the minigene was capable of encoding 
a functional ERCC1 protein, northern blot analysis revealed that, in each of the cell 
types analysed, the pattern of minigene expression did not reflect the pattern of 
expression seen with the endogenous gene in wild type cells of each type. The wild 
type embryonic fibroblasts and keratinocytes both display the skin specific pattern of 
expression; where the 1.5kb transcript is the major species but the 1.1kb transcript is 
still clearly detectable. In wild type CHO cells only the 1.1kb transcript is detected. In 
general, the minigene transcripts, estimated in the region of 3.2kb for the 
keratinocytes and fibroblasts and 1.5kb for the CHO cells, were larger than the 
expected 1.1 and 1.5kb. One possible explanation for the increased size of the 
minigene transcripts was aberrant splicing of introns from the pre-mRNA. This is 
however unlikely, as such RNAs would not be capable of encoding functional 
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proteins and it was demonstrated that the minigene did complement the DNA repair 
defect associated with each of the cell types. It remains possible that correctly spliced 
transcripts of the predicted sizes were present at such low levels that although they 
were capable of rescuing the UV sensitivity, they were not detectable by northern 
blot analysis. 
Northern blot analysis using a probe specific for transcripts initiating at the upstream 
start site suggested that some initiation of minigene transcription was from this site, 
or at least upstream of the 1.1kb transcript start site. It is unlikely that the increased 
sizes of the transcripts were the result of transcription initiating from a site even 
further upstream as this would have extended beyond the 5' end of the minigene 
construct in order to produce the observed size differential of almost 1.7kb. There 
have been several reports of minigene expression studies that have used RNase 
protection assays or primer extension analysis to verify the initiation site of minigene 
transcription (Kiledjian and Kadesch, 1991 and Prochownik and Orkin, 1984). Such 
assays could not have been used to map the transcriptional initiation site of the 
mouse ERCC1 minigene in the mouse embryonic fibroblasts or murine keratinocytes. 
As detailed in the introduction, the targeted alleles present in these cells are believed 
to give rise to non-functional fusion transcripts and as such the 5' ends of the 
transcripts from these alleles could not be distinguished from the 5' ends of minigene 
transcripts. Recently, a second ERCCJ -deficient embryonic fibroblast cell line, which 
does not produce any transcripts from the targeted alleles, has become available in 
our laboratory (Hsia, unpublished data). Future ERCC1 minigene expression studies 
will be performed using this cell line so that RNase protection and primer extension 
assays can be performed where necessary. It is possible that such analysis could be 
applied to the minigene transcripts evident in the CHO cells as the 5' end sequences 
would vary between the two species. The northern blot analysis of the minigene 
transcript detected in the transfected CHO cells suggested that the transcript had 
initiated upstream of the normal initiation site for transcription in CHO cells. RNase 
protection analysis could be used to verify if the upstream transcriptional initiation 
site was being used in this instance. 
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The process of 3' end formation in mRNA molecules involves cleavage of the pre-
mRNA and then addition of the poly(A) tail. Studies of Chinese hamster 
dihydrofolate reductase (DHFR) minigenes showed that minigene constructs lacking 
the three endogenous polyadenylation sites were capable of transferring DHFR gene - 
function (Venolia et al., 1987). The discrete minigene mRNAs detected, did not 
match the sizes of the endogenous transcripts. It was suggested that polyadenylation 
of the DHFR minigene was occurring via recruitment of polyadenylation sites within 
the host genome or carrier plasmid DNA. It is most probable that the increased size 
of the minigene transcript observed here is due to incorrect polyadenylation. The 3' 
end of the minigene construct consists of exons 7 to 10 and a stretch of 3' UTR 
(48bp) including the polyadenylation signal derived from a cDNA clone. It is 
possible that there are genomic elements of the 3' UTR absent from this construct 
that are necessary for faithful and efficient polyadenylation of the ERCC1 mRNA. 
The differential polyadenylation of ERCC1 has been described (van Duin et al., 
1987) and suggests that there maybe additional sequences downstream that are 
involved in determining the site of polyadenylation. To achieve the appropriate 
polyadenylation it may be necessary to construct another minigene incorporating a 
more extensive 3' UTR, or alternatively substitute the polyadenylation site with a 
stronger poly(A) site such as the rabbit beta-globin poly(A) site. The human 
calcitoninl CGRP-I pre-mRNA is processed in a tissue-specific manner into either 
calcitonin(CT) or calcitonin gene-related peptide (CGRPI). The respective mRNAs 
are the product of differential splicing and polyadenylation at either the fourth or 
sixth exons. It was reported that polyadenylation did not occur at the fourth exon of a 
human calcitonin minigene in vitro. Subsequent studies revealed that whilst 
polyadenylation at this site remained inefficient in vitro, there was a requirement for 
specific downstream sequences located within 39 nt of the cleavage site for optimal 
polyadenylation. When the exon 4 polyadenylation site was replaced with the rabbit 
beta-globin poly(a) site, efficient polyadenylation was observed (van Oers et al., 
1994). Similarly, improved expression of a human CD2 minigene was reported 
following the addition of extended 5' and 3' flanking sequences (Zhumabekov et al., 
1995) 
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In wild type embryonic fibroblasts and keratinocytes the 1.5kb transcript is more 
abundant than the 1.1kb. We have found that where there were two minigene 
transcripts detected, this characteristic difference in the relative abundance of each 
transcript was not apparent. It is possible that sequences which are involved in 
establishing this ratio are absent from the minigene construct. 
We have described the complementation of the DNA repair defect in three ERCCI-
deficient cell types using a mouse ERCCJ minigene. It was also shown that the 
pattern of minigene expression did not reflect the normal pattern of expression in 
each of these cell types with minigene transcripts being larger than predicted, 
probably due to aberrant polyadenylation. It would not be prudent to proceed with 
deletional analysis of the promoter region whilst the expression pattern of the 
minigene is so far removed from the endogenous pattern of ERCC1 expression. 
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Chapter 5 
Retroviral-mediated correction of UV sensitivity 
associated with ER CC] deficiency 
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ERCCJ-deficient mice die severely runted before weaning, at three weeks of age, as 
the result of liver failure. The short lifespan of the ERCC1 null animals has greatly 
reduced the extent of analysis we have been able to carry out on the consequences of 
ERCC1 deficiency in other tissues. Increasing the lifespan of the ERCC1 null animals 
would enable studies such as: investigations into the consequences of ERCC1 
deficiency at later stages of development as well as any predisposition to cancers. 
As it stands, the ERCCJ null mouse acts as an animal model for NER deficiency. The 
nature of this model, a single gene defect primarily affecting a single organ, also 
provides a suitable model for the development of a retroviral gene therapy system. 
The retroviral-mediated introduction of a functional ERCC1 coding sequence into the 
liver of a null mouse was identified as a means of extending the lifespan of the null 
animals in order to facilitate the further investigations mentioned. This chapter 
describes the attempted retroviral-mediated gene transfer and rescue of the UV 
sensitive phenotype associated with ERCCJ deficiency in cultured cells in vitro prior 
to the development of a therapeutic in vivo strategy. 
In theory, gene therapy is quite simple: the introduction of corrective nucleic acid 
into a cell to alleviate a disease phenotype. In practice, numerous technical obstacles 
have had to be overcome before any clinical advances could be made. The major 
problems in this field of research have been the development of safe and efficient 
gene delivery systems. The advantage of retroviruses is that they can stably infect 
dividing cells by integrating into the host genome without expressing any 
immunogenic viral proteins. The integrated viral genome should, in theory, be 
maintained throughout the life of the host cell. As a result of extensive research, the 
retroviral gene delivery strategy is perhaps furthest along the road to reaching this 
goal. To create the safe retroviral vectors used in gene therapy, the life cycle of their 
naturally occurring counter parts are exploited. The normal life cycle begins when a 
retrovirus binds to and enters a cell where it injects its RNA genome and accessory 
proteins into the cytoplasm. The viral genome consists of three genes: gag, poi and 
env, which are processed into a number of polypeptides for replication, 
encapsidation, infection and reverse transcription. There are also three noncoding 
regions: the two long terminal repeats required for viral integration and gene 
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expression thereafter, and the psi (N')  sequences necessary for packaging of the viral 
genome into virions. Once in the cytoplasm, reverse transcriptase from the virus, 
converts the viral RNA genome into DNA, which in turn enters the cell nucleus and 
integrates into the genome. Once integrated into the cell's genome the viral DNA 
directs the synthesis of viral proteins and RNA, utilising the transcription and 
translation machinery of the host cell. The resultant proteins once again encapsidate 
the viral RNA to form new virus particles which bud from the cell and go on to 
repeat the cycle. 
The structure of a retroviral vector is essentially simple, comprising the 5' and 3' 
long terminal repeats (LTRs), a packaging sequence and the coding sequence of the 
gene of interest. The coding regions for the viral genes, gag, poi and env are deleted. 
For propagation of the recombinant virus it is necessary to provide the additional 
essential viral elements in trans using a cell line known as a packaging cell line. The 
packaging cell line is engineered to stably express the viral proteins encoded by the 
gag, pol and env but lacks the packaging sequence required for encapsidation of the 
viral genome. This packaging sequence is, however, present on the transgene vector 
and as a result it is only the RNA from the vector becomes encapsidated, and released 
from the packaging cell as an infectious virus. This safe viral vector is capable of 
infecting appropriate target cells, where it can integrate and lead to expression of the 
therapeutic gene. The viral vector lacks the viral genes required for further replication 
and encapsidation, thus it is unable to reproduce. The target specificity of a viral 
vector is determined by using a packaging cell line expressing the env gene of a 
retrovirus with a known tropism. In this case the murine ecotropism was determined 
by using a packaging cell line expressing the env gene from the Moloney murine 
leukaemia virus (M0MLV). 
5.1 Production of recombinant ERCC1 retrovirus 
Recombinant ecotropic retroviruses containing ERCCJ coding sequences were 
produced using the murine leukaemia virus (MLV) derived, MFG viral vector 
(Dranoff et al., 1993) in combination with the viral packaging cell line NClI (Danos 
and Mulligan, 1988). In this system the NJCRE cell line, which stably expresses the 
retroviral proteins gag, pol and env is transfected with the retroviral vector encoding 
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the cDNA of interest. Expression of the cDNA is driven by the promoter activity of 
the LTR. As it is only the vector that includes the psi ('i')  packaging sequence, only 
the vector RNA is packaged into virions. The structure of the ERCC1 viral vector 
(EMFGI) and the strategy for viral infection of cultured cells is outlined in Figure 
5.1. 
The ERCCJ coding region was amplified by PCR from the plasmid pTZME using 
primers designed to introduce NcoI and BglII restriction sites, at the 5' and 3' ends 
respectively, required for later cloning into the pMFG plasmid. The sequence of the 
5' end primer was : 5' CATGC'CATGGACC,CTGGGAAGGACGAG 3', the 
position of the NcoI site was underlined, use of this cloning site ensured that the 
cDNA is inserted into pMFG in the correct reading frame. The sequence of the 3' end 
primer was: 5' GAA'GATCTTCTCGAGTCATCGAGGCACITTGAGG 3', the 
Bglll restriction sequence is underlined and the position of the translational stop 
codon is shown in italics. The PCR product was first cloned as a blunt ended 
fragment into the EcoRV site of Bluescript II SK+. The integrity of the coding 
sequence was confirmed by sequencing of the ERCClIBluescript clone (sequencing 
was performed by Carolanne McEwan). The ERCCJ cDNA was isolated as a NcoI / 
BglII fragment and cloned into NcoI/ BamHI cut pMFG. Recombinants were 
identified by conventional restriction analysis of DNA from ampicillin resistant 
bacterial colonies. The ATG of the NcoI site is the translational start site of the viral 
envelope gene and now acts as the start site for the cloned cDNA. Sequencing carried 
out across the cloning sites confirmed the integrity of each of the sites. A single clone 
was used for each of the experiments described here. 
The EMFGI vector was then used to stably transfect the NJCRE viral packaging cell 
line, resulting in the packaging of the EMFGI vector RNA into virions. Once 
transfected with the retroviral vector the cells should become retrovirus-producing 
cells. This approach was used to obtain four separate retrovirus producing cell lines; 
the first two lines EMFGI/NJCRE(GS) and EMFG/\VCRE were actually pools of 
NJCRE cells, transfected with and without a glycerol shock (GS) step, respectively. 
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Figure 5.1 Structure of the ERCC1 retroviral vector and strategy for retroviral 
infections 
cloning of the ERCC1 retroviral vector EMFGI shown schematically. The NcoJ/ 
Bglll restricted ERCC1 cDNA fragment (1015bp) was cloned into the NcoJJBamHI 
restricted pMFG vector (6.3kb). Dashed line, pUC19 plasmid backbone; solid line, 
MLV sequences including N'  packaging sequence; open boxes, MLV long terminal 
repeat (LTR) sequences; shaded box, ERCCJ cDNA. The vector is not shown to 
scale. 
strategy for retroviral infection of cultured ERCCJ-deficient cultured cells. The 
VCRE packaging cell line was stably transfected with the EMFGI vector which 
contains a Ni  sequence necessary for packaging of the vector RNA. The resulting 
infectious virus contains the ERCC1 retroviral-vector genome, which codes for 
ERCC1 but does not code for the gag, poi and env proteins and is therefore unable to 
replicate autonomously. The virus was harvested within the media in which the 
producing cells were cultured and applied to the ERCCJ-deficient target cells to 
permit infection to take place. After infection by the recombinant retrovirus 
phenotypic rescue was determined by reduced sensitivity to UV irradiation. 
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UV Survival Experiments 
At a later date the pool of cells arising from the transfection with glycerol shock was 
then plated at low density to enable individual colonies to be picked. Six out of the 
ten colonies picked contained EMFGI sequences, as determined by PCR detection of 
the ERCCJ coding region from the viral vector. The assay developed to identify cells 
that contained the retroviral vector exploited the fact that the viral vector contained 
the ERCC1 cDNA, which meant it was possible to use primers specific for exons 1 
and 10 to amplify the 950bp cDNA insert. The endogenous genomic sequences could 
not be amplified as the product would be too large (-15kb). Two of these PCR 
positive clones, EMFG1JJCRE #8 and EMFGIJIVCRE #9 were expanded for use as 
viral producing cell lines. 
5.2 UV survival of ERCC1-deficient fibroblasts (PF24) following retroviral-
mediated gene transfer 
The spontaneously transformed embryonic fibroblast cell line derived from an 
ERCC1-deficient embryo (PF24) has been shown to be hypersensitive to UV and 
completely lacking in NER activity (Mcwhir et al., 1993). Recombinant ERCCJ 
retroviruses from four virus producing cell lines, described in section 5.1 of this 
chapter, were used in an attempt to alleviate this UV hypersensitivity. 
In each case the virus producing cells were cultured in a single dish, until almost 
confluent, to optimise the yield of virus. The culture medium was changed on the day 
before the virus was collected. After overnight culturing the virus-containing medium 
was harvested from the producing cells and added to a dish of target PF24 cells. The 
target cells had been split on the previous day to ensure that the cells were actively 
dividing. The infection was allowed to proceed for 6 hours before the virus 
containing medium was replaced with normal culture medium. The infected PF24 
cells were expanded in culture for use in UV sensitivity experiments. For these 
experiments, 2x104 infected cells were plated in small dishes and cultured overnight 
before being irradiated with various doses of UV irradiation. The dishes were 
maintained in culture until control dishes, not exposed to UV, reached confluence. At 
this point the cells were fixed and stained to quantify • the UV sensitivity of the 
infected cells. The UV survival curves obtained are presented in Figure 5.2. The 
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graph illustrates sensitivity to UV in terms of the cells surviving each dose of UV 
irradiation as a % of untreated controls. The graph shows that the infections carried 
out using virus from the EMFGL' NJUCRE producing line had only a minimal affect 
on the survival curve relative to the control PF24 survival curve. PF24 cells infected 
with virus from the EMFGIJ WUCRE (GS) producing line still exhibited sensitivity to 
UV irradiation but in this case the survival profile was clearly distinguishable from 
the repair deficient profile of PF24 cells. At the lower UV doses of 1.25 and 2.5 Jm 2 
the 98 and 78% survival of the infected cells was most reminiscent of the wild-type 
cells (PF20). At the higher UV doses of 3.75 and 5 Jm 2 the survival dropped to 33% 
and 7% respectively whereas survival of wild-type cells was unaffected. The survival 
curve for the PF20 cells showed 94 and 98% survival at the lower UV doses of 1.25 
and 2.5 Jm 2 and 100% survival at the two higher UV doses. It was possible that the 
modest degree of phenotypic rescue observed was due to a low viral titre resulting 
from the use of a pool of virus producing cells, in which a proportion of the pool may 
not have been producing any virus, rather than a pure clone from this pool. The repair 
deficient PF24 cells were then infected in an identical manner by recombinant virus 
harvested from the two producing lines, EMFGIJWCRE #8 and EMFGIJWCRE #9 
cloned from the EMFGI/ NJUCRE (GS) pool. However, the survival curves obtained 
following this approach showed little evidence of phenotypic correction of UV 
sensitivity. The survival profile of the cells infected by EMFGJINJCRE #8 showed 83 
and 36% survival the lower UV doses of 1.25 and 2.5 Jm 2 . At the higher doses of 
3.75 and 5 Jm 2 survival fell to 14 and 4%. Similarly, the survival profile of the cells 
infected by EMFGIIWCRE #9 showed 84 and 34% survival at the lower UV doses of 
1.25 and 2.5 Jm2. At the higher UV doses of 3.75 and 5 Jm 2 survival of 9 and 3% 
was observed. 
In summary, the UV sensitivity of PF24 was seen to be partially corrected following 
retroviral-mediated gene transfer by viruses from the producing cell line EMFGIJ 
1IJUCRE (GS). 
135 
Figure 5.2 UV sensitivity of ERCC1 fibroblasts (PF24) following retroviral 
mediated gene transfer 
The UV survival curves for wild type (PF20), ERCC1-deficient (PF24) mouse 
fibroblasts and PF24 cells following retroviral infection from four separate viral 
sources are shown. Each point represents the mean of two separate experiments. 
Circle, P1720; hexagon, PF24; triangle, PF24+EMFGLICRE (GS); square, 
PF24+EMFGJJjJCRE; inverted triangle, PF24+EMFGJIWCRE #8; diamond, 
PF24+EMFGIINJCRE #9. 
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5.3 UV resistant cells within pools of infected cells are corrected to wild-type 
levels 
It was necessary to investigate further whether the limited degree of phenotypic 
correction observed thus far was a consequence of low viral titre or, alternatively, 
was due to some other factor which prevented the recombinant virus from bringing 
about complete phenotypic rescue. It was necessary to determine whether all the cells 
within pools of infected PF24 displayed the same modest degree of UV resistance or 
had some of the cells been corrected to the wild-type levels seen in PF20. Cells 
infected by recombinant virus from the EMFGI /CRE (GS) pool, which gave the 
best level of phenotypic correction thus far, were plated at low density and exposed 
to UV doses of between 3.5 and 5Jm 2. The irradiated cells were maintained in 
culture to enable UV resistant colonies to be identified and picked as clones. Each of 
the twelve UV resistant colonies picked were found to be positive, when screened by 
PCR, for the presence of the ERCC1 cDNA element of the EMFG vector (not 
shown). Two of these UV resistant clones, PF24/UVR #4 and #12, were expanded in 
culture for use in UV survival experiments. The UV survival curves obtained are 
presented in Figure 5.3. The graph illustrates sensitivity to UV in terms of % cells 
surviving at each UV dose. It is clear that the two PF24/ UVR clones exhibit a wild-
type pattern of UV resistance as seen by the similarity to the survival curve of the 
PF20 cells. 
Thus the recombinant virus produced by the cell line EMFGJ/ WUCRE (GS) is 
capable of infecting repair deficient PF24 cells and bringing about phenotypic 
correction to wild-type levels. 
5.4 Increased resistance to UV irradiation correlates with ERCCI transcription 
We have described the identification of UV resistant clones from within the pools of 
infected PF24 cells. It remained possible that the UV resistance of these clones was 
not a consequence of retroviral-mediated gene transfer. Such UV resistant clones 
could have arisen had the FF24 cultures been contaminated, at low levels, with the 
wild-type PF20 cells. PCR genotyping of the UV resistant clones confirmed that the 
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Figure 5.3 PF24 cells within infected pools are corrected to wild-type levels of 
UV sensitivity 
The UV survival curves for wild type (PF20), ERCCJ-deficient (PF24) mouse 
fibroblasts and UV resistant PF24 clones isolated from virally infected pools are 
shown. Each point represents the mean of two separate experiments. Circle, PF20; 
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cells were indeed ERCC] null (data not shown). It remained necessary to confirm 
that the retroviral-mediated gene transfer was responsible for the phenotypic 
correction. Evidence for this was gained by demonstrating that the observed 
correction of UV sensitivity correlated with the expression of a transgene derived 
ERCCJ mRNA. 
Northern blot analysis was performed on RNA extracted from each of the transduced 
PF24 cell lines, to demonstrate that the phenotypic correction observed in some of 
the cells was due to ERCCJ expression, resultant from the retroviral-mediated gene 
transfer (Figure 5.4a). Total RNA (30tg) from the wild-type mouse embryonic 
fibroblast cell line FF20, the parental ERCCJ-deficient mouse embryonic fibroblast 
cell line PF24 and the transduced cell lines PF24+EMFGJJWCRE #8, 
PF24+EMFGIIIVCRE (GS), its UV resistant derivatives PF24/UVR #4 and 
PF24/UVR #12, was electrophoresed on a 1.4% agarose-formaldehyde gel, 
transferred onto a nylon membrane and ERCCJ transcript detected by hybridisation 
to a mouse ERCC1 cDNA probe. The blot was later stripped and reprobed using a 
GAPDH probe to standardise for any variations in RNA loading in each lane. 
The lower panel shows the GAPDH reprobe of the filter to standardise for loading. 
The detection of ERCCJ mRNA by probing with ERCC1 cDNA is shown in the 
upper panel. The normal pattern of ERCC1 expression was evident in the wild type 
PF20 lane, the 1.5kb major transcript and the normal 1.1kb transcript present at a 
lower abundance. In the FF24 lane there was no evidence of any mRNA species 
hybridising with the ERCC1 probe. As expected, there was no suggestion of any 
hybridising transcripts in the PF24+EMFGIJijJCRE #8 lane. This was in keeping with 
the fact that these cells had not shown any degree of phenotypic correction as 
determined by UV survival. In the lanes of both of the UV resistant clones there was 
clear evidence of ERCCJ hybridising bands at about 2.8kb, which matches the 
predicted size for an EMFGI transcript. Additional, larger hybridising species, 
believed to be retroviral pre-mRNA, were also evident in each of the lanes. In the 
PF24+EMFGIJijCRE (GS) lane there was evidence of these transcripts at a much 
lower abundance, presumably reflecting the proportion of the cells within the pool 
that had been infected by the recombinant retrovirus. Fhosphorimagery was used to 
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Figure 5.4 The UV resistance of transduced clones correlates with ERCC1 
transcription 
northern blot analysis of RNA from transduced PF24 cell lines. Upper panel, total 
RNA was prepared from the transduced cell lines PF24+EMFGL'jiCRE (GS), 
PF24/UVR #4, PF24/UVR #12, PF24+EMFGJJ1IJCRE #8, wild type PF20 and the 
ERCCJ-deficient P1724. The RNA was electrophoresed on a 1.4% formaldehyde-
agarose gel, transferred onto a nylon membrane and probed with an 800bp BamHI 
fragment of the ERCC1 cDNA corresponding to exons 1 to 8. Positions of the 18S 
and 28S rRNAs and estimated transcript sizes are indicated. Lower panel, the blot 
was then stripped and reprobed using a GAPDH cDNA fragment to standardise for 
RNA loading in each lane. 
phosphorimager analysis of ERCC1 transcript levels in the transduced pool and 
UVR clones. The values from the phosphorimage were obtained using the 
ImageQuant software V3.3 image analysis package. The signal values represent the 
area, in arbitrary units, under the peak corresponding to the -2.8kb transcript. The 
ratio represents the value of the ERCCJ signal divided by the value of the GAPDH 
signal, i.e. the standardised values. The level of ERCCJ transcript in the pool relative 
to the two clones is indicated. 
determination of the number of transduced cells in the infected pool. The number 
of UV resistant cells in the infected pool was determined by the number of colonies 
formed after exposure of 100000 cells to UV doses of 3.75 and 5 Jm 2. The 
percentage survival was then corrected relative to the plating efficiency of 
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quantify the amount of retroviral transcript present in the RNA from the infected pool 
relative to the UV resistant clones (Figure 5.4b). This analysis showed that the level 
of the ERCC1 transcript in the infected pool lane was 5.3% of the average level of 
transcript evident in the UV resistant lanes. The phosphorimage analysis also showed 
a two-fold variation in the level of expression evident the two UV resistant clones 
The level of ERCC] expression detected in the pool of infected cells could be 
regarded as an indirect indication of viral titre. Where the level of expression in the 
pool was measured at 5.3% of that in the clones it was estimated that somewhere in 
the region of only 5.3% of the cells in the pool had been infected by the retrovirus. 
Evidence to support this idea was gained from a cell plating experiment performed 
using the pool of infected cells. To determine the plating efficiency of the 
pF24+EMFGII'qJCRE (GS) cells, 1000, 500 and 200 cells were plated (in duplicates) 
and maintained in culture for one week. At this point the cells were fixed and stained 
to enable the number of colonies on each plate to be counted. The plating efficiency 
was determined by expressing the number of resultant colonies as a percentage of the 
number of cells plated. The plating efficiency for the cells of the infected pool was 
measured as 4.25% (data not shown). In parallel, 10 5 cells were plated and cultured 
overnight prior to UV irradiation, in order to determine the actual proportion of cells 
in the pool that had been infected by retrovirus, and were therefore UV resistant. The 
dishes (in triplicate) were exposed to UV doses of 3.75 Jm 2 and 5 Jm 2, the UV 
doses from which the UV resistant clones were picked, then maintained in culture for 
one week. At this point the cells were fixed and stained and the number of colonies 
on each plate was counted (Figure 5.4c). The number of surviving colonies was used 
to determine the percentage of plated cells surviving. This figure was then adjusted 
relative to the plating efficiency of these cells by expressing the % cells surviving 
relative to the control plating efficiency (i.e.(% surviving cells / % plating efficiency). 
The result of this analysis showed that the average percentage of corrected cells in the 
pools surviving the UV dose of 3.75 Jm 2 was 4.3%. Suggesting that 4.3% of the cells 
in the pool were UV resistant as a result of retroviral mediated gene transfer. This 
figure is in accordance with the 5.3% correction estimated after the northern blot 
analysis The average percentage of cells in the pool surviving 5 Jm 2 was 1.76%. It 
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was first predicted that if cells were infected by retrovirus the observed correction 
would be to wild type levels of UV resistance as seen with the UV resistant clones. 
As such, the lower percentage survival of cells at the higher UV dose was not 
expected. This reduced survival at a UV dose of 5 Jm 2 may have been a reflection of 
heterogeneity in the levels of ERCC] being expressed in infected cells. It remained 
possible that the level of expression in some cells was not sufficient to confer 
resistance to the higher dose of UV. The earlier northern blot analysis performed on 
the UV resistant clones supported the, idea of variation in the levels of ERCCJ 
transcript between clones. 
In summary, we have demonstrated that the observed phenotypic correction 
following retroviral-mediated gene transfer correlates with the expression of an 
ERCC1 mRNA. Further, the abundance of this ERCCJ mRNA appears to correlate 
with the degree of correction observed within the pool of infected cells and the 
subsequent UV clones derived from it. The level of ER CC] transcript detected in the 
infected pool was in accordance with the proportion of the cells within the pool that 
were resistant to a UV dose of 3.75 Jm 2 . 
5.6 Discussion 
The Achilles heel of gene therapy is currently gene delivery, the inability to deliver 
genes efficiently with stable expression. The aim of any gene therapy is to introduce 
successfully a nucleic acid into a defective cell such that the expression of those 
sequences will result in the correction of the cellular defect. Although the absolute 
nature of the defect can greatly influence the most appropriate strategy for gene 
delivery, most current approaches utilise viral vectors as the delivery system. The use 
of retroviral vectors typically results in the stable transduction of the majority of 
target cells (Scharfmann et al., 1991 and reviewed in Smith 1995). The development 
of packaging cell lines that permit the production of high titres of replication-disabled 
recombinant virus (Danos and Mulligan, 1988) was crucial to the advancement of 
this technology. 
Using the MFG vector for the stable transfection of the NJCRE packaging cell line we 
have engineered a retroviral based system to produce ecotropic recombinant 
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retroviruses carrying the murine ERCCJ cDNA sequences. Using this system we 
have obtained four separate producing lines for the propagation of ERCC1 
retroviruses to be used in subsequent gene transfer studies. 
The ability of the recombinant retrovirus to bring about phenotypic correction of 
ERCCJ-deficient fibroblasts was demonstrated by the observed reduction of the UV 
sensitivity in transduced cells. The best phenotypic reversion was achieved using 
viruses harvested from pools of virus producing cells. The use of a glycerol shock 
step in the transfection of the packaging cell line resulted in a higher degree of 
correction when using the recombinant virus harvested from the pool of transfected 
cells. This is most likely due to. the improved efficiency of transfection of the 
packaging cells resulting in a higher viral titre. The ijiCRE packaging cell line was 
co-transfected with a selectable neomycin transferase marker gene and infections 
were carried out using the pools of cells that survived G418 selection. All of the cells 
in the pool should have contained the vector. When attempting to clone pure 
producing cell lines from the pools it was discovered that only 60% of the cells were 
positive for the retroviral vector. Furthermore when two of these cloned producing 
cell lines were used . in retroviral-mediated gene transfer experiments they failed to 
result in any discernible phenôtypic correction. Despite containing the retroviral 
vector sequences, these clones were apparently not producing therapeutic levels of 
recombinant retrovirus. It was not possible to linearise the retroviral vector prior to 
transfecting the NICRE packaging line, so integration of the vector would have been 
random rather than being through the ends of a linear fragment. It is possible that 
when randomly integrating into the genome, the viral vector was disrupted in such a 
way as to prevent the vector genome from being packaged. Any disruption or loss of 
the packaging sequence would have this affect. Together these factors suggest that 
the resulting viral titre in these experiments was far from optimal. As .an alternative 
to obtaining a producing line giving a higher titre of virus it would have been feasible 
to simply scale up the number of producing cells from which the virus was harvested. 
The successful transduction of target cells depends, to a certain degree, on the 
volume and concentration of virus that the target cells are exposed to and, as such, 
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this may have required the development of a technique to concentrate the virus. This 
would have been technically very difficult due to the fragile nature of retroviruses. 
Retroviral-mediated gene transfer has been used to correct the NER defect associated 
with fibroblasts isolated from XPD patients (Quilliet et al., 1996). In this case the 
MLV derived viral vector was propagated in the amphotropic ijiCRIP packaging cell 
line to permit infection of the human fibroblasts. The vector also carried a selectable 
neomycin transferase marker gene to permit G418 selection of transduced cells. The 
correction of the repair defect in the XPD cells was only assessed in cells that had 
survived G418 selection. In the absence of a selectable marker in our system, the 
analogous results from the PF24 correction studies would be those carried out on the 
UV resistant clones isolated from transduced pools, where the UV could be regarded 
as a substitute selection for transduction. In this light the results obtained from these 
studies compare favourably with reports of retroviral-mediated correction of the 
DNA repair defects of xeroderma pigmentosum cells belonging to complementation 
groups A, B and C, where phenotypic correction was determined after primary 
selection for the presence of vector sequences (Zeng et al., 1997). The ability to 
select for transduced cells prior to carrying out analysis of phenotypic correction is 
particularly useful in that it can permit in vitro studies to proceed where viral titre is 
low. 
This work was embarked upon as a means of developing a gene therapy strategy 
aimed at increasing the lifespan of the ERCCJ-deficient mouse. As such the goal of 
this study was to develop an efficient in vivo gene transfer technique using a 
retroviral vector. The use of the retroviral vector itself, whilst being particularly 
suited to the in vitro study described here, would have undoubtedly presented 
numerous technical hurdles when being used in vivo. It is a basic biological 
requirement that for retroviral infection to take place the target cell must be actively 
dividing. In the case of the ERCCJ - deficient mouse, the target cells were those of the 
normally quiescent liver. Whilst it is possible to induce a degree of cell division 
within the liver by partial hepatectomy, it would not have been possible to perform 
such surgery on the ERCCJ-deficient animals as they die before weaning. Without 
the active division of the target cells it is difficult to envisage how this system in its 
current state could be successfully used for retroviral-mediated gene transfer aimed at 
rescuing the ERCCJ mouse. It is now generally accepted that retroviral gene therapy 
is best suited to what are described as ex vivo gene therapy strategies, where target 
cells are removed from the patient and transduced in vitro before being transplanted 
back into the patient for repopulation. (Kay et al., 92 and Grossman et al., 94) 
If this work was to be taken on any further, possible improvements to this system 
would have to include improved 'targeting' of the retrovirus by introducing tissue 
specific promoter elements to bring about expression in a hepatocyte specific 
manner. However, it is likely that this would still require in utero transduction of the 
ERCCJ null hepatocytes in order to be most affective. It is difficult to imagine that 
the work required to overcome the technical hurdles posed by such a strategy would 
be justified by the potential outcomes in the event of any success. Realistically the 
phenotypic rescue of the DNA repair deficient ERCC1 null mice should be attempted 
using a non-retroviral strategy. 
Whilst it is clear that with time and further technological developments that 
retroviral-mediated gene transfer has a great deal to offer to the gene therapy 
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ERCC1 -deficient CHO cells (CH043-3B) and mouse embryonic fibroblasts (PF24) 
derived from ERCCJ-deficient mice have been shown to have a 100-fold elevated 
spontaneous mutation rate at the hypoxanthine phosphoribosyltransferase (HPRT) 
locus in addition to a higher level of genome instability, as indicated by an increased 
frequency of micronuclei (Melton et al., 1998). As such, we would speculate that 
ERCCJ-deficient mice might be more susceptible to UV induced skin cancers than 
wild type mice. The premature death of our ERCCJ -deficient mice has precluded any 
investigation relating to the incidence of skin cancers and ERCC1 deficiency. When 
the ERCC1-deficient animals were first described, in addition to the striking liver 
abnormalities, it was also reported that elevated levels of the tumour suppressor 
protein p53 were detected in the liver, brain and kidney (McWhir et al., 1993). The 
lethal liver phenotype of the ERCC1-deficient mice, which results in death before 
weaning, has greatly restricted studies of the consequences of ERCCJ deficiency in 
these and other tissues. It is clear that extending the life of ERCC1-deficient mice 
would permit some, if not all, of these studies to be completed. One approach to this 
problem, currently being pursued in our laboratory, is the use of CreIloxP mediated 
gene targeting, as described in the introduction chapter, to bring about the conditional 
inactivation of the ERCCJ gene in the specific organ or system of interest, whilst 
maintaining the expression of ERCCJ in the liver. However, this approach is time 
consuming, and reliant on the availability of additional transgenic mouse lines 
expressing Cre recombinase in tissue specific patterns. 
We speculate, that by restoring ERCCJ function in the liver, the lifespan of the 
ERCCJ-deficient mice would be extended significantly and that this extended 
lifespan would enable further studies of the consequences of ERCC1 deficiency in 
other tissues and systems. The work presented in this chapter describes the use of 
conventional transgenesis in the generation of a transgenic mouse line expressing 
ERCC1 specifically in hepatocytes and the consequences of crossing this transgene 
onto an ERCCJ-deficient background. 
Conventional transgenesis involves the microinjection of cloned DNA sequences into 
the pronucleus of a fertilised mouse egg. The eggs are then surgically transplanted 
into a pseudopregnant recipient female and allowed to develop to term. The injected 
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DNA becomes chromosomally integrated and is typically expressed in the resultant 
offspring. This approach has been used extensively to characterise the cis acting 
elements responsible for both tissue specific and stage specific expression of genes 
(Yan et al., 1990) Many cloned genes that have been introduced into the mouse 
germline in this manner have displayed appropriate tissue or stage specific patterns of 
expression. Integration of the transgene DNA often occurs at the one-cell stage and is 
consequently present in every cell, including the germ cells, of the transgenic animal. 
However, if integration occurs at a later stage the resultant animals are described as 
'mosaics' and some cells in the transgenic animal may not contain the transgene. The 
method by which the cloned sequences are introduced to the fertilised egg means that 
the number of copies of the transgene that become integrated into the genome can 
vary from 1 to several hundred (Robertson et al., 1996). Generally, the transgene 
copies become integrated in a head to tail arrangement at a single site of integration 
(Brinster et al., 1981 and Costantini and Lacy, 1981) although some integration 
events are more complex. 
6.1 Construction of an ERCCJ transgene regulated by the transthyretin (TTR) 
gene promoter 
Transthyretin (TTR) is a thyroid hormone transport protein that is normally secreted 
by hepatocytes into serum and by the choroid plexus epithelium into the cerebral 
spinal fluid. The protein is not present in significant amounts in any other tissues. 
Studies carried out in vitro identified the upstream sequences that were required for 
77R expression in hepatocytes (Costa et al., 1996). Subsequently, conventional 
transgenesis was used to determine whether these sequences were sufficient to direct 
cell specific expression in the liver and choroid plexus in vivo. It was found that the 
minimal sequences (300bp) required for expression in hepatocytes were sufficient for 
normal expression in the liver but lead to aberrant expression in regions of the brain 
other than the choroid plexus. When 3kb of upstream sequences were included, 
transgene expression in the brain was restricted to the choroid plexus. When more 
Figure 6.1 Structure of the transthyretin (TTR) regulated ERCC1 transgene 
(TTR/ERCCI #3) 
The structure of the 7TR/ERCC1 #3 transgene is shown schematically. The upstream 
(3kb) transthyretin regulatory region is shown by the diagonally striped box. Exons 
are represented by open boxes and are numbered. The first intron is shown as by the 
vertically striped box. The ERCC1 cDNA sequence is represented by the light 
stippled box. The SV40 3' end is represented by the dark stippled box. The plasmid 
backbone is shown as a thin line. The relative positions of the translational start 
(ATG) and the polyadenylation signal (AATAAA) are indicated. Restriction sites 
used in cloning and subsequent analysis are shown as follows: H, Hindifi; P. PstI; S, 






than 6 copies of the transgene were present, expression was reported in the salivary 
gland and gut of some lines, but this was not apparent in all mice of the lineage (Yan 
et al, 1990). This minigene construct was later adapted for use as a vector suitable for 
the liver specific expression of any cloned sequences. The introduction of several 
point mutations in the first and second exons resulted in the abolition of translational 
start sites and introduction of unique cloning sites within the TTR minigene. The use 
of this vector for the successful liver targeted expression of p21 (a cyclin-dependent 
kinase inhibitor) and a mutant p53 (a tumour suppressor) has been reported. (Wu et 
al., 1996 and Bowman et al., 1996). A 7TRp2l transgene was constructed by cloning 
the p21 cDNA into the second exon of the 7TR minigene backbone. Northern and 
western blot analysis of five lTRp21 transgenic mouse lines revealed that expression 
of the transgene was restricted to the liver. Based on this data, the transthyretin 
minigene vector (pTTRI exV3) was considered as an ideal means of targeting 
expression of ERCC1 to the liver using conventional transgenesis. 
The structure of the 1TRIERCCJ transgene is shown schematically in Figure 6.1. The 
exon 1 to 10 region of the ERCCJ cDNA was isolated as a 900bp XballHindffl 
fragment from ERCClfBluescript, this fragment includes only 5nt of ERCC1 
sequence upstream of the translational start signal and none of the ERCC1 3'UTR. 
The fragment was blunt-ended and cloned into the unique Stul site of pTTR exV3 
(kindly provided by Dr. T. Van Dyke). Initiation of transgene transcription and 
polyadenylation is determined by the 7TR regulatory sequences, whilst translation 
initiates from the ATG within the cloned cDNA fragment. Recombinants were 
characterised using restriction enzyme analysis. Two clones with the predicted 
structure were then sequenced to confirm the integrity of the translational start signal 
within the ERCCJ cDNA insert. A single clone, 7TR/ERCC1 #3 was used for all the 
experiments described in this chapter. 
6.2 A single PCR assay capable of distinguishing between three ERCC1 genes 
The PCR assay used for the routine genotyping of our ERCC1 breeding colony was 
also suitable for the genotyping of the 77'RIERCCl #3 transgenic line. The ability of 
this assay to identify both the wild type and targeted alleles in addition to the 
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Figure 6.2 PCR genotyping reaction that distinguishes between three ERCC1 
genes 
The products of PCR genotyping reactions for the ERCC1 wild type and targeted 
alleles and the transgene. Genomic DNA isolated from mouse tail biopsies was used 
as a template for PCRs carried out using primers 033M, 035M and M4956, and the 
products separated by electrophoresis. The 800bp product (from M4956 and 035M) 
is specific for the targeted allele(A), the 600bp product (from 033M and 035M) is 
specific for the wild type allele(WT), the 170bp product (from 033M and 035M) is 
specific for the transgene (TG). The strength of the endogenous wild type signal is 
reduced in the presence of transgene sequences. Transgene positive and negative 
samples of each ERCCJ genotype were used. The relevant areas of the three 
templates are shown schematically below. The relative positions of the primers 
giving rise to the product from each template are indicated. Exons are numbered and 
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transgene resulted in its use for all subsequent genotyping of 1TR/ERCC1 transgenic 
mice (Figure 6.2). The assay was performed as a single PCR reaction involving three 
primers (033M, 035M, and M4956). The 035M (ERCC1 exon 5) and M4596 (Neo 
cassette) primers gave an 800bp product specific for the targeted allele. The 033M 
(ERCCJ exon 4) and 035M (ERCC1 exon 5) primers gave a 600bp product specific 
for the wild type allele, no product was seen from the targeted allele as the distance 
between the two primer binding sites on this allele (3.0kb) was too great for efficient 
amplification under the cycle conditions used. The same primer pair did give rise to a 
170bp product specific for the transgene. It was observed that the 033M/035M 
product from the endogenous wild type allele became significantly weaker in the 
presence of the transgene, reflecting the propensity of the PCR reaction to favour the 
synthesis of smaller products where possible. 
6.3 Production and identification of TTRJERCC1 transgenic mice 
The transgene construct 7TRIERCC1 #3 was restricted with Hindifi and gel purified, 
as described in the methods chapter, to liberate the .transgene fragment from the 
plasmid. backbone. Transgenic mice were produced by the microinjection of the 
purified transgene fragment into the pronuclei of fertilised mouse eggs. All resultant 
offspring were screened by PCR for the presence of the transgene. In addition to the 
surviving animals, genotyping was also carried out post-mortem on three pups that 
were found dead soon after birth. It was found that two of these pups were transgene 
positive. A single female founder animal (TG#17) was identified from 23 mice that 
survived to weaning. All subsequent 7TR/ERCC1 transgenic lines were established 
from this animal. 
6.4 Crossing of the TTRJERCC1 transgene onto an ERCC1 -deficient 
background 
The purpose of generating the 7TR/ERCC1 transgenic strain was to determine 
whether the targeted expression of ERCC1 in the liver would be sufficient to rescue 
the lethal liver phenotype seen in ERCCI-deficient mice. Having successfully 
identified a founder animal it was necessary to cross the transgene onto an ERCCJ- 
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deficient background. In the first instance the founder animal was crossed with a wild 
type MF1 male (MF1 mice typically have large litters ) simply to generate more 
transgene positive offspring, for expression analysis and subsequent breeding. 
Transgene positive animals from this cross were then crossed with ERCCJ 
heterozygotes from the ERCC1 breeding colony. Transgene positive heterozygotes 
identified from these matings were then crossed to generate transgene positive 
ERCCJ nulls. The animals on this background were given a TG# identification code. 
The TIR/ERCCJ transgene was later crossed onto the second of our ERCCJ-
deficient strains (KT#209) by mating the female founder animal with a male 
heterozygote from that strain. Once again, transgene positive heterozygotes from this 
mating were then crossed to generate transgene positive ERCCJ nulls. The animals 
on this background were given a KT/TG# identification code. 
6.5 The transgene is present as a single array 
The number of transgene arrays present in the founder animal was examined using 
Southern blot analysis. Genomic DNA isolated from a tail biopsy from TG#17 was 
cut with a range of restriction enzymes that were known not to cut within the 
transgene, including NotI, Sall, Clal, XbaI and Aatll. The DNA was separated by 
electrophoresis, transferred to a nylon membrane and the transgene array detected 
using an ERCC1 cDNA probe. As these restriction enzymes did not cut at sites 
within the transgene it meant that the enzymes would only cut at sites flanking the 
site of integration and each integration site would therefore produce a separate 
hybridising band on the Southern blot. The results of this analysis showed that only a 
single hybridising band was detected for each of the 5 restriction enzymes (data not 
shown). The interpretation of the Southern blots was not completely unambiguous; 
the use of rare cutting enzymes did not result in significant separation of the digested 
DNA by electrophoresis and as such it is possible that the single hybridising band, 
which was typically at the top of the DNA smear in each track, was actually present 
within uncut DNA. The use of pulse field gel electrophoresis (PFGE) would have 
enabled greater resolution of the high molecular weight DNA fragments. 
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However, further evidence that the transgene was present as a single array was gained 
from the genotyping of offspring from the first crosses between transgene positive 
ERCC1 heterozygotes, set up to produce transgene positive nulls. The ratio of 
transgene positive to transgene negative offspring from these mating  was 91:21 or 
4.3:1 which does not appear to be strikingly different from the predicted ratio of 3:1, 
where a single transgene array is present. The predicted ratio for the presence of two 
segregating arrays would have been 15:1, assuming both parents in these initial 
breeding pairs each had two arrays. However, as a consequence of the breeding 
scheme used to generate the transgene positive ERCC1 heterozygotes, it was possible 
that the parents in these crosses had either one or two arrays. Together, with the 
Southern blot observations, these results indicate that there is most likely only a 
single transgene integration site in the founder animal. 
6.6 Transgene copy number determination by Southern blot analysis 
It has been reported that the expression of the TTR transgene is detected in tissues 
other than the liver if present in more than six copies. Southern blot analysis was 
used to determine the number of copies of the transgene integrated into the genome 
of the founder animal and Fl offspring from each of the crosses onto knockout 
backgrounds, each hemizygous for the transgene array. 
The mouse genome size is estimated to be 3x10 9  bp and the transgene fragment was 
known to be 5.4kb. Using these figures it was possible to calculate the ratio of the 
two sizes, the transgene is roughly equivalent to 1/555,000 of the genome, and 
subsequently calculate the amount of transgene fragment equivalent to a single copy 
per genome for a 3jig amount of genomic DNA (1/555000 of 3ig is 5.4pg). In order 
to gauge the transgene copy number, 3pg mouse ES cell genomic DNA was spiked 
with various amounts of the transgene fragment, equivalent to 1, 2, 5, 10, 20 and 40 
copies per mouse genome. The concentration of the ES cell DNA could be 
determined accurately by its absorbence at 260nm, however the tail biopsy DNA is 
heavily contaminated with RNA and cannot be accurately quantified in this manner. 
Approximate loads of 3tg were obtained by adjusting the amount of DNA digested 
so that the transgenic sample digests matched the appearance of the ES cell lanes, by 
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Figure 6.3 Transgene copy number determination by Southern blot analysis 
Transgene copy number estimate by Southern blot analysis. Genomic DNA was 
prepared from tail biopsies of the founder animal (TG#17) and four Fl offspring 
(TG#26 and 9, KTTG#54 and 55). Genomic DNA isolated from mouse embryonic 
stem cells (HMI) was spiked with pre-determined amounts of transgene fragment 
DNA, equivalent to 1, 2, 5, 10, 20 and 40 copies of the transgene per genome. Upper 
panel, the DNA (3.tg) was digested with BamHI, electrophoresed through an agarose 
gel, transferred onto a nylon membrane and probed with an ERCCJ cDNA fragment. 
Lower panel, the blot was then stripped and reprobed using a mouse PrP probe to 
standardise for the amount of DNA in each track. The sizes of each of the hybridising 
bands are indicated (kb). 
The transgene fragment is represented below, schematically. The region of the 
fragment corresponding to the 4.8kb hybridising transgene band is indicated. Shown 
to scale, 1cm = 500bp. 
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eye. The copy number titration mixes and 3pg of each of the transgenic DNA 
samples were then digested using BamHI. Digestion of the transgene DNA with 
BamHI gave rise to two bands of 4.8 and 0.17kb, containing ERCC1 homology, both 
of which could be used to assess the copy number using Southern blot analysis 
(Figure 6.3). The digested DNA was separated by electrophoresis, transferred to a 
nylon membrane and ERCC1 sequences detected by hybridisation to an ERCC1 
cDNA probe. Due to the poor resolution of the internal 0.17kb band (data not 
shown), all copy number calculations were based on data obtained from the 5' end 
4.8kb fragment. Although the 4.8kb band was not an internal fragment, the normal 
head to tail transgene integration pattern and the presence of a BamHI site at the 3' 
end of the fragment, meant the band was detected from the chromosomal array. 
However, the 5' end copy of each transgene array would result in a 'junction 
fragment' and would not give rise to a band of the predicted size and as such any 
copy number calculations based on this fragment will have an in-built error of 1 
copy. The Southern blot analysis showed the presence of the endogenous 8.3 and 
weaker 4.3kb ERCC1 band in each track. The transgenic sample TG#9 was an 
ERCC1 heterozygote and consequently an additional band was evident at 6.7kb and a 
previously identified restriction fragment length polymorphism for the 8.3kb band 
was evident in TG#55 sample. Therefore, the endogenous ERCCJ bands were not 
considered as suitable for internal standards. The transgene specific band of 4.8kb 
was strongly evident in each of the transgenic sample lanes and at appropriately 
varying intensities in the copy number titration lanes. To provide a standard for the 
loading of DNA in each track the blot was then stripped and reprobed with a PrP 
probe. Phosphorimagery was used on both blots to quantify the level of the transgene 
signal relative to the 8.5kb PrP band (Figure 6.4). It was then possible to calculate 
the ratio for each of the transgene signals to the PrP signals and compare it directly 
with the ratio of spiked transgene fragments to the PrP signals from the copy number 
titration. For instance, the ERCCJ transgene/PrP ratio for 2 spiked copies was 0.76, 
the ratio for 5 spiked copies was 1.54, the ratio for the founder TG#17 was 0.65 
whilst the ratios for the Fl offspring ranged from 1.01 to 1.4. The data from the 
phosphorimager analysis was used to plot a standard curve for the quantification of 
156 
Figure 6.4 Phosphorimage analysis of transgene copy number determination 
Southern blots 
transgene copy number determination by phosphorimager analysis. The values 
from the phosphorimage were obtained using the ImageQuant software V3.3 image 
analysis package. The signal values represent the area, in arbitrary units, under the 
peak corresponding to the 4.8kb 17'R!ERCCJ bands and the 8.5kb PrP bands on the 
reprobed filter. The ratio represents the value of the transgene signal divided by the 
value of the PrP signal, i.e. the standardised transgene values. The copy number 
estimate was based on this standardised value relative to the values obtained for the 
spiked copy number titration. 
ratio of ERCCJ/PrP plotted against copy number for spiked copy titration. The 
ERCC1/PrP ratio for the spiked copy number samples was plotted against the 
number of spiked copies. Data points are represented by open circles, the best fit line 
is indicated. The relative positions of the equivalent ERCCJ/PrP ratios are shown 
and extended down onto the copy number axis to determine actual copy numbers for 
each of the samples. 
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Sample TG Signal PrP Signal TG / PrP 
Ratio  
Copy # 
HM1 - 168.7 - 
+1 63.73 180.5 0.35 1 
+2 111.5 146.1 0.76 2 
+5 215.2 139.7 1.54 5 
+10 531.8 167.5 3.17 10 
+20 1025 150.1 6.83 20 
+40 1798 169.5 10.6 40 
17 75.1 115.8 0.65 2 
26 146.6 117.8 1.24 4 
9 1 111.8 1110.8 1 	1.01 13 
54 1221.2 1 165.6 1 1.34 14 
55 1231.1 1 165.3 1 1.40 14 
No.Copies 
transgene copy number. The ERCC1/PrP ratio (i.e. the ratio of the spiked number of 
copies standardised for DNA load) plotted against copy number gave a linear result 
(Figure 6.4b). It was then possible to determine the copy number for each sample by 
using the previously determined ERCCJ/PrP ratio for each of the transgenic samples 
to derive a copy number estimate from the standard curve of the copy number 
titration. This analysis gave the estimated copy numbers as: 2 copies for TG#17, 3 
copies for TG#9 and about 4 copies for each of TG#26, KTTG#54 and KTTG#55. 
Each of the copy number estimates suggested that the Fl offspring had a higher copy 
number (-4) than the founder TG#17 (-2). This may indicate that the founder animal 
was a transgenic mosaic. If chromosomal integration of the transgene array occurred 
at the two cell stage of development, only half of the cells in the founder animal 
would actually contain the transgene sequences and consequently it would appear to 
have only half of the copies present in its offspring. 
6.7 Expression of TTRJERCC1 transgene mRNA is detected in the liver 
To determine whether the integrated copies of the 7TR/ERCC1 transgene were being 
expressed, riorthern blot analysis was carried out on a panel of tissues from a 
transgene positive ERCC1 wild type (Fl) mouse (Figure 6.5). The estimated size for 
the 7TR/ERCCJ transgene transcript was 1.5kb. Analysis was carried out on RNA 
isolated from brain, heart, lung, liver, spleen, kidney, testes and skin. Total RNA 
(30j.tg) was electrophoresed on a 1.4% agarose-formaldehyde gel, transferred onto a 
nylon membrane and ERCCJ transcripts detected by hybridisation to a mouse 
ERCC1 cDNA probe. 
The ethidium bromide staining of the gel is presented in the lower panel and suggests 
that the amount of RNA loaded in each of the tracks was equivalent. The detection of 
ERCCJ hybridising mRNAs is shown in the upper panel. The normal 1.1kb band was 
evident at low levels in each of the tissues examined and the additional 1.5kb skin 
specific transcript was also detected. The endogenous level of the 1.1kb ERCCJ 
mRNA is normally lowest in the liver. In this instance, there was an additional 
mRNA species of about 1.5kb, believed to be the transgene transcript, detected at 
extremely high levels in the liver. At this stage of analysis it appeared that the 
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Figure 6.5 Detection of TTRJERCC1 transgene mRNA expression in the liver 
using an ERCC1 cDNA probe 
Northern blot analysis of tissue RNA from a transgene positive ERCCJ wild type 
male. Upper panel, total RNA was isolated from a range of mouse tissues, 
electrophoresed on a 1.4% formaldehyde-agarose gel, transferred onto a nylon 
membrane and probed with an 800bp BamHI fragment of the mouse ERCCJ cDNA 
corresponding to exons 1 to 8. Positions of the 18S and 28S rRNAs and estimated 
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TI'R/ERCCJ transgene was being expressed at high levels specifically in the liver. 
However, the heterogeneous nature of the endogenous ERCC1 transcript in brain and 
heart along with the presence of the 1.5kb transcript in skin meant it was not possible 
to conclude that the transgene was not being expressed in these tissues. 
To investigate the tissue specificity of the transgene expression further, it was 
necessary to isolate a probe specific for the transgene. A 300bp StuLiBamHI fragment 
was isolated from the parental transgene plasmid TTR ExV3. The fragment spanned 
the second TTR exon and contained the SV40 derived 3' end sequences and it was 
predicted that the probe would hybridise with endogenous TTR transcripts as well as 
transgene transcripts. To test the specificity of the fragment for TTR transcripts, 
northern blot analysis was performed on a panel of wild type mouse tissues. Total 
RNA (30tg) from a range of tissues was separated by electrophoresis, transferred 
onto a nylon membrane and probed using the 300bp StuJIBamHI TTR ExV3 
fragment (Figure 6.6a). The northern blot showed that the probe hybridised to distinct 
transcripts of 0.7kb in the liver and brain. The hybridising mRNA species was much 
more abundant in liver than in brain. The sizes of the transcripts and pattern of 
expression both matched the expectations for the normal pattern of T[7'R expression. 
Thus it appeared that the fragment was suitable for use as a probe for the transgene 
transcripts which would also contain the 7TR exon two sequences. 
The StuIfBamHI fragment was then used for northern blot analysis of the ERCC1 
wild type transgene positive tissue RNAs. Total RNA (30ig) was separated by 
electrophoresis, transferred to a nylon membrane and transgene transcripts detected 
by hybridisation to the 300bp StuJJBamHI 7-TR1SV40 probe (Figure 6.6b). The 
endogenous TTR transcripts, of 0.7kb, were present in only liver and brain and in 
their normal abundance. An additional transcript, of approximately 1.5kb, was 
evident in the liver track. There was no evidence of hybridising mRNA species of 
this size in any of the other lanes. 
In summary, this analysis has shown that the TTRIERCCJ transgene is expressed 
specifically in the liver. The expression at the level of mRNA greatly exceeds the 
normal low level of ERCCJ in the liver but is less than the endogenous 7TR 
expression. 
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Figure 6.6 Identification of a probe specific for endogenous TTR and 
TTR/ERCCI transgene niRNA expression 
a, total RNA was isolated from a range of wild type mouse tissues, electrophoresed 
on a 1.4% formaldehyde-agarose gel, transferred onto a nylon membrane and probed 
with a 300bp StuIJBamHI 7TR/SV40 fragment from pTTR Ex V3. Positions of the 
endogenous 77R transcript, 18S and 28S rRNAs are shown. b, total RNA was 
isolated from a range of tissues from a transgene positive ERCCJ wild type male 
mouse, electrophoresed on a 1.4% formaldehyde-agarose gel, transferred onto a 
nylon membrane and probed with a 300bp StuJfBamHI 7TR/SV40 fragment from 
pTTR Ex V3. The positions of the endogenous 77'R transcript, transgene transcript 
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6.8 Analysis of TTRJERCCJ expression on an ERCC1-deficient background 
It was necessary to confirm the pattern of transgene expression on an ERCC1-
deficient background. This analysis was carried out on tissues from a transgene 
positive, ERCCJ -deficient mouse from each of the knockout backgrounds. 
Initially, RNA was isolated from a panel of tissues from a transgene positive male on 
the original ERCCI-deficient background. Total RNA (30.tg) from each of the tissues 
was separated by electrophoresis, transferred onto a nylon membrane and the 
transgene transcript detected by hybridisation to the 300bp StuJIBamHI TTR/SV40 
probe (Figure 6.7a). The endogenous TTR transcript was detected in the liver and 
brain at expected levels. The transgene transcript was once more evident at high 
levels in the liver. Two additional and much larger species were also evident in this 
lane. These two additional transcripts may correspond to pre-mRNA species for the 
transgene and endogenous ITR transcripts. In the skin lane there was evidence of 
very weakly hybridising bands at the same sizes as the endogenous TJTR and 
transgene transcripts It was felt that this may have arisen as a consequence of 
contamination of the skin sample with liver RNA, at the time of isolation. In addition 
to the presence of these transcripts in skin there was also evidence of transcripts in 
the testes lane, again at much lower levels. In this case there was no detection of a 
transcript matching the size of the endogenous 17'R mRNA and as such it is unlikely 
that the hybridising bands have arisen from contaminating liver RNA. 
This analysis was then repeated using samples from a transgene positive ERCCJ-
deficient mouse on the KT#209 knockout • background. A panel of tissues was 
analysed by northern blot analysis to investigate further the pattern of transgene 
expression (Figure 6.7b). Total RNA (30j.tg) from each of the tissues was separated 
by electrophoresis, transferred onto a nylon membrane and the transgene transcript 
detected by hybridisation to the 300bp StuJIBamHI 7TR/SV40 probe. Lower panel, 
the endogenous TTR transcript was detected in the liver and brain at expected levels. 
The transgene transcript was once more evident at high levels in the liver and at a 
higher level than that evident in the upper panel. As with the transgene positive 
sample from the original background, two additional and much larger species were 
also evident in this lane. At this stage there was no evidence of transgene expression 
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Figure 6.7 Expression of the TTRJERCCI transgene mRNA on two ERCC1-
deficient backgrounds 
a, total RNA from a range of tissues was isolated from a transgene positive ERCC1-
deficient male mouse on the original ERCCJ-deficient background, electrophoresed 
on a 1.4% formaldehyde-agarose gel, transferred onto a nylon membrane and probed 
with a 300bp StuIIBamHI 7 - TR/SV40 fragment from pTTR Ex V3. Positions of the 
endogenous TTR transcript, transgene transcript, 18S and 28S rRNAs are shown. b, 
total RNA was isolated from a range of tissues from a transgene positive ERCCJ-
deficient male mouse on the KT#209 ERCC1-deficient background, electrophoresed 
on a 1.4% formaldehyde-agarose gel, transferred onto a nylon membrane and probed 
with a 300bp StuJIBamHI TTR/SV40 fragment from pTTR Ex V3. The positions of 








in any tissues other than the liver. However, after prolonged exposure of the ITR 
probed filter, there was evidence of bands, of about 1.5kb, in the skin and brain lanes. 
The size of the band matched the size of the transgene transcript in liver. 
Phosphorimagery was used to determine the amount of the transcript in these tissues 
relative to the liver. The result of this analysis showed that the signal intensity of the 
transcript in skin and brain was 1.46 and 2.9%, respectively, of the transgene signal 
intensity in liver. 
In summary, it has been shown that expression of the TTRIERCCJ transgene was 
detected at high levels in the livers of ERCCJ-deficient mice from both knockout 
backgrounds, with some indication of variation in the levels of expression between 
the two lines. There was also evidence of very low levels of expression in other 
tissues including brain, testes and skin. It is possible that the non-specific expression 
of the transgene may reflect variation between individual animals. 
6.9 Transgene expression is stable with age and persists through four 
generations 
The aim of this work was to rescue the lethal liver phenotype associated with ERCCJ 
deficiency, by the targeted expression of an ERCCJ transgene. Simply crossing the 
transgene onto the original knockout background involved going through three 
generations of mice. It was important that the expression of the transgene was not 
silenced as it passed from generation to generation. The aim of targeting the 
expression of the transgene to the liver was primarily to extend the lifespan of the 
ERCCJ -deficient mice to enable studies of the consequences of ERCC1 deficiency in 
other tissues at later developmental stages. As such it was necessary to establish that 
the expression of the transgene was maintained in the liver throughout the life of an 
animal. 
Northern blot analysis was used to confirm the stable expression of the transgene in 
the livers of mice from each of the first three generations (Figure 6.8a). Total RNA 
(30.tg), from the livers of female mice from the first three generations after the 
founder, was separated by electrophoresis, transferred onto a nylon membrane and 
the transgene transcript detected by hybridisation to the 300bp StuIIBamHI 
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Figure 6.8 Expression of the TTRJERCCJ transgene mRNA is stable with age 
and through four generations 
a, northern blot analysis of RNA from the livers of transgene positive animals from 
three different generations. Total RNA was isolated from liver tissue of animals 
representing three different generations: Fl, F2 and F3. The RNA (30j.ig) was 
electrophoresed on a 1.4% formaldehyde-agarose gel, transferred onto a nylon 
membrane and probed with a 300bp StuLIBamHI 77'R/SV40 fragment from pTTR Ex 
V3. Positions of the endogenous 7TR transcript (Tl'R), transgene transcript (TG), 18S 
and 28S rRNAs are shown. b, northern blot analysis of RNA from the livers of 
transgene positive animals of various ages from four different generations. Total 
RNA was isolated from liver tissue of animals of various ages representing four 
different generations: Fl, F2, F3 and F4. Upper panel, the RNA (30pg) was 
electrophoresed on a 1.4% formaldehyde-agarose gel, transferred onto a nylon 
membrane and probed with a 300bp StuJIBamHI 17'R/SV40 fragment from pTTR. Ex 
V3. The animal identification code is indicated above each lane and the age of the 
animal, in weeks, is shown below each lane. Positions of the endogenous TFR 
transcript (TI'R), transgene transcript (TG), 18S and 28S rRNAs are shown. Lower 
panel, ethidium bromide staining to illustrate RNA loads. c, phosphorimager analysis 
of 7TR/ERCC1 transgene expression relative to endogenous 7- 1'R expression. The 
values from the phosphorimager were obtained using the ImageQuant software V3.3 
image analysis package. The signal values represent the area, in arbitrary units, under 
the peaks corresponding to the transgene and endogenous 77'R bands. The ratio 
represents the value of the transgene signal divided by the value of the endogenous 
TTR signal. The transgene mRNA expression is given as a percentage of the 
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7TR/SV40 probe. The endogenous 7TR transcript was evident in its normal 
abundance in each of the tracks. The 1.5kb transgene transcript was also detected in 
each of the tracks, confirming that the transgene was expressed through generations. 
Where the endogenous TTR was regarded as a suitable indication of equal loading of 
RNA in each track, by eye, it appeared that the level of transgene expression had 
actually increased with each generation. At this point it was noted that the RNA was 
isolated from animals of different ages at each generation. The F 1 sample was from a 
32-week old female, the F2 sample was from a 24-week old female and the F3 
sample was taken from a 16-week old female. It seemed possible that the level of 
transgene expression might have decreased as a function of age. 
To investigate further whether the level of transgene expression was related to the 
age of the animal, the northern blot analysis was repeated with additional samples 
spanning four generations and incorporating animals of different ages from each 
generation (Figure 6.8b). Total RNA was isolated from the livers of three 7-week old 
and one 12-week old Fl animal, one 24-week old and one 10-week old P2 animal, a 
single 16-week old F3 animal and four F4 animals between 4 and 8-weeks old. In the 
case of two of the F4 animals, a partial hepatectomy was performed to enable 
analysis of the level of transgene expression within a single animal over a period of 
time. RNA was first isolated from the biopsied tissue and then again when the animal 
was culled after two or four weeks. The RNA was separated by electrophoresis, 
transferred onto a nylon membrane and the 7TR/ERCCJ transgene transcript detected 
by hybridisation to the 300bp StuJIBamHI 7- TRíSV40 probe. The ethidium staining of 
the gel is presented in the lower panel to illustrate the relative loading of RNA in 
each lane. The blot showed that the endogenous 7TR transcript and the 1.5kb 
transgene transcript were evident in each of the lanes. By eye, the level of transgene 
expression generally appeared to be quite consistent across the samples. 
Phosphorimagery was used to quantify the level of transgene expression relative to 
the level of endogenous TTR expression for each sample (Figure 6.8c). Thus it was 
possible to express the level of transgene expression as a percentage of the 
endogenous 77'R expression in each case. 
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In the case of the Fl animals it was shown that the transgene expression was 44% of 
the endogenous 77'R level in the RNA samples from the twelve-week and two of the 
7-week old animals. The transgene level in the third 7-week old animal was seen to 
be 104% of the endogenous level. This sample was the only one taken from an 
animal on the KT#209 knockout background, it is possible that the elevated level of 
transgene expression seen in this sample reflects a difference in the genetic 
background. There was also some variation seen between the two F2 samples, the 
level of transgene expression in the 24-week old animal was 31% of the endogenous 
TTR compared to 105% of the endogenous level seen in the sample from the 10-week. 
old animal. The level of transgene transcript in the 16-week old F3 animal was 
measured at 63% of the endogenous TTR level. The level of transgene expression in 
the F4 samples varied between 29 and 42% of the endogenous transcript. In the case 
of the samples taken from the same animals at different time points there was little 
evidence of any major changes in the level of transgene expression. In the samples 
taken only two weeks apart (at 4 and 6 weeks) the level of transgene expression was 
measured as 29% of the endogenous TTR level in both samples. In the samples taken 
four weeks apart (at 4 and 8 weeks) the level of transgene expression was measured 
as 42 and 39% of the endogenous 77R level, respectively. Thus whilst it was clear 
that there was some degree of variation in the absolute level of transgene expression 
across the samples (105 to 29% of the endogenous transcript), this variation did not 
appear to correlate with either the age of the animal or the generation from which the 
sample was taken. It is possible that the observed variation was a consequence of the 
number of transgene arrays present within an individual animal, it was not 
determined whether these animals were hemi- or homozygous for the transgene array. 
6.10 Targeted in vivo expression of the TTR/ERCCJ transgene in the liver 
extends the lifespan of ERCC1 -deficient mice 
ERCCI-deficient mice die severely runted before weaning as the result of liver 
failure. The premature death of these animals has significantly restricted the extent of 
any analysis we have been able to perform, relating to the consequences of 
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6.9 Improved survival profile of TTRJERCC1 transgene positive ERCCJ-
deficient mice 
The percent of surviving mice is plotted as a function of time. Survival time was 
measured, in days, at the time when dying mice were sacrificed. Wild type, 
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ERCC1 deficiency in other organs or at later stages of development. The principle 
aim of this work was to sufficiently extend the lifespan of these animals, by 
correction of the lethal liver phenotype, so as to permit these studies. 
The improved survival profile of 77'R/ERCCl transgene positive ERCCJ-deficieñt 
mice relative to the transgene negative ERCCJ nulls is shown in Figure 6.9. As 
previously reported (McWhir et al., 1993), the ERCC1 nulls (n=5) died before 
weaning at about 21 days of age. The survival profile of the TI'R!ERCCJ transgene 
positive ERCC1 nulls (n=9) showed 100% survival up to 61 days of age, with all of 
the mice dying between day 61 and day 86. No wild type littermates (n=9) died 
within this period. The transgene positive nulls were seen to survive for three times 
as long their transgene negative null siblings, with some animals surviving as long as 
twelve weeks. 
6.11 Targeted in vivo expression of the TTRJERCC1 transgene in the liver 
alleviates the severe runting phenotype observed .in ERCC1 -deficient mice 
The severe runting associated with ERCCJ deficiency in mice has been reported 
separately by McWhir et a! (1993) and Weeda et a! (1997). In both cases it was 
reported that ERCC1 -deficient offspring were severely runted compared to their wild 
type siblings, with reported bodyweights ranging between 20 and 50% of the wild 
type weights. The ERCCJ-deficient mice from our original knockout background 
weighed only 20% of their siblings. The bodyweights of 77'R/ERCCJ transgene 
positive ERCCJ-deficient mice and their littermates, on this background, were 
measured at weaning (age 21-28 days). The average weight of a transgene positive 
ERCCJ-deficient mouse was found to be 7.75g (±0.56) compared to 13.25g (±0.3) 
for wild type littermates. The bodyweight in terms of percentage of wild type was 
measured as 58% for the transgene positive ERCCJ-deficient mice compared to the 
previously reported 20% for the knockout mice. Figure 6.10 shows the relative sizes 
of a 77'R/ERCC1 transgene positive ERCC1 null, a wild type sibling and a transgene 
negative ERCC1 null littermate. The clear size difference meant that transgene 
positive nulls were readily distinguished from transgene negative null littermates, by 
eye. 
169 
Figure 6.10 The severe runting phenotype associated with ERCC1 deficiency is 
alleviated in TTRIERCC1 transgene positive nulls 
A representative photograph of a 77'RIERCCl transgene positive ERCCJ -deficient 
mouse, a wild type littermate and a transgene negative ERCCJ null sibling at 20 days 
of age. The wild type mouse (black) is shown at the top of the photo, the transgene 
positive mouse(agouti) is shown at the bottom of the photo and the ERCCJ null 
(white) is in the middle of the group The transgene positive mouse is readily 
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6.12 Targeted in vivo expression of the TTRJERCC1 transgene in the liver 
corrects the nuclear abnormalities associated with ERCCJ deficiency 
We have previously reported that ERCC1-deficient mice die as a consequence of 
liver failure. Histologically, perhaps the most striking phenotype reported for the 
ERCCJ nulls was the nuclear abnormalities seen in the livers. Identical observations 
have been made for each of the known ERCC1 knockout mice (McWhir et al., 1993; 
Weeda et al., 1997 and Melton, unpublished data). At three weeks of age the liver 
nuclei in wild type mice are predominantly diploid and uniform in size. ERCC1 null 
mice at this age showed considerable variation in the sizes of hepatocyte nuclei, and 
flow cytometry analysis indicated the presence of aneuploid nuclei. We speculated 
that the incidence of abnormal nuclei in hepatocytes would be corrected by the 
targeted expression of the ITRIERCC1 transgene in the liver of an ERCCJ-deficient 
animal. 
In order to assess whether this phenotypic correction had indeed occurred, liver 
sections were taken from age matched transgene positive ERCCJ-deficient animals 
and wild type littermates for comparison with sections taken from ERCCJ-deficient 
animals on our original knockout background. The haematoxylin and eosin stained 
sections are presented in Figure 6.11. Similar results were seen for transgene positive 
nulls from both of our knockout backgrounds. The liver section representative of the 
ERCC1 null animals confirmed the previously reported incidence of variable nuclear 
sizes, including the presence of some extremely large nuclei. In comparison, the 
nuclear sizes seen in the liver section representative of a wild type mouse showed 
greater uniformity in the sizes of the hepatocyte nuclei. Similarly, the liver section 
representative of the ITR/ERCC1 transgene positive ERCCJ-deficient animals 
showed much greater uniformity in the sizes of the hepatocyte nuclei compared with 
the ERCC1 null sections. There was no evidence of the extremely large nuclei 
characteristically observed in the hepatocytes of ERCCJ-deficient mice. 
By way of confirming these histological observations, fluorescence activated cell 
scanning analysis (FACScan) was performed on liver biopsies from wild type, 
ERCC1 null and transgene positive ERCC1 null animals (Figure 6.11). The FACScan 
profiles represent the number of cells plotted against the DNA content of the nuclei 
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Figure 6.11 Targeted in vivo expression of the TTRJERCC1 transgene in the liver 
corrects the nuclear abnormalities associated with ERCC1 deficiency 
Comparison of the hepatocyte nuclear sizes and FACScan profiles between age 
matched wild type, ER CC] null and transgene positive ERCCJ null mice. 
Left panel, haematoxylin and eosin stained liver section from a 3-week old wild 
type mouse. Representative uniformly sized nuclei indicated by arrows. Right panel, 
FACScan profile showing frequency distribution of DNA content of hepatocyte 
nuclei from a 3-week old wild type animal. The % of total nuclei with elevated DNA 
content (the region indicated by the double-headed arrow) is also shown. 
Left panel, haematoxylin and eosin stained liver section from a 4-week old 
transgene positive ERCCJ null mouse. Representative uniformly sized nuclei 
indicated by arrows. Right panel, FACScan profile showing frequency distribution of 
DNA content of hepatocyte nuclei from a 4-week old wild type animal. The % of 
total nuclei with elevated DNA content (the region indicated by the double-headed 
arrow) is also shown. 
Left panel, haematoxylin and eosin stained liver section from 3-week old ERCCJ 
null mouse. Characteristic abnormally large nuclei indicated by arrows. Right panel, 
FACScan profile showing frequency distribution of DNA content of hepatocyte 
nuclei from a 3-week old ERCCJ null animal. The % of total nuclei with elevated 
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as measured by the fluorescence of the propidium iodide stained nucleic acid. The 
FACScan profile representative of the wild type animals showed a major peak 
corresponding to normal diploid cells (cells at Gi) a lesser peak representing cells 
that had undergone replication (cells at G2) was also evident, there was little 
evidence of any significant number of cells with DNA content incompatible with 
these cell cycle stages. This profile was all but duplicated by analysis carried out on 
liver tissue from the transgene positive ERCCJ-deficient animals. The representative 
profile from this genotype also showed a major peak representing the hepatocytes 
with normal diploid DNA content, a lesser G2 peak was again evident. Furthermore, 
there was little evidence of cells with increased DNA content. These profiles contrast 
sharply with the profile representative of the ERCCJ null animals. In addition to the 
major peak representing the normal diploid hepatocytes in GI, there were additional 
sizeable peaks corresponding to an increased number of tetraploid nuclei in GI or 
diploid cells in G2 as well as peaks suggestive of both higher ploidy and aneuploid 
nuclei. The percentage of the total cells counted, falling into this region of greatly 
increased DNA content (8N plus) was determined to enable direct comparison 
between the respective FACScan profiles representative of each genotype. It was 
found that only 0.3 and 1.0% of the nuclei counted from wild type and transgene 
positive null samples had this elevated level of DNA content compared with 9.3% of 
nuclei from the ERCC1 nulls. This result supports the histological observations of 
increased incidence of abnormally large nuclei in the hepatocytes of ERCC1 -deficient 
mice and the correction of this phenotype, to wild type appearance, in the livers of 
7TR/ERCC1 transgene positive ERCC1 nulls. 
In summary, the targeted expression of ERCC1 in the hepatocytes of ERCC1-
deficient mice results in the correction of the incidence of abnormally sized nuclei to 
apparent wild type levels. 
6.13 Targeted in vivo expression of the TTRJERCC1 transgene in the liver does 
not correct the associated abnormalities in the skin 
The aim of the work described in this chapter was to alleviate the phenotypic 
consequences associated with ERCCJ deficiency in mice by the targeted expression 
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of an ERCC1 transgene in the liver. We speculated that the restoration of expression 
of ERCC1 to the liver would extend the limited lifespan of the ERCC1 nulls 
sufficiently to permit further analysis of the consequences of ERCC] deficiency in 
tissues such as the skin. We have shown that the lifespan of the transgene positive 
ERCC1 nulls was significantly extended relative to the ERCC1-deficient animals 
and, as such, the phenotypically rescued animals could potentially permit further 
analysis of any consequences of ERCC1 deficiency in adult mouse skin. However, as 
described in chapter 6.7, we have detected evidence of very low levels of transgene 
mRNA expression in the skin of some transgene positive animals. If this expression 
was sufficient to bring about complete phenotypic correction in the skin it would 
preclude any further studies of the consequences of ER CC] deficiency in this tissue 
and systems relating to it. 
In order to determine whether such phenotypic correction had occurred in the 
transgene positive ERCC1 nulls, skin sections were taken from wild type mice and 
transgene positive nulls on both of our knockout backgrounds. The absence of 
subcutaneous fat from the dorsal skin of ERCCJ-deficient mice has previously been 
reported (Weeda et al., 1997 and Melton unpublished data). In this instance, for ease 
of dissection the skin biopsies were taken from the ears of the animals. The structure 
of the skin on the ears differs from body skin in that it lacks this subcutaneous layer 
of fat. The haematoxylin and eosin stained skin sections are presented in Figure 6.12. 
The wild type sections showed the normal thickness of the dermal layer and that the 
nuclei in the epidermal cells were of a uniform circular shape. The sections from the 
transgene positive ERCC1-deficient animals were both very similar. The nuclei 
within the epidermal layer appeared distorted as if they had been compressed in some 
way and the thickness of the dermal layer was reduced by approximately 50%. 
In summary, despite the northern blot evidence, presented earlier, which suggested 
that there maybe expression of the transgene in skin, we have shown that the skin of 
the transgene positive ERCC1-deficient animals is not normal. This suggests that 
even if there is expression of the transgene in skin it is at such a low level so as not to 
be able to bring about phenotypic correction in this tissue: As such we consider that 
the skin of the transgene positive nulls can be regarded as ERCCJ-deficient and 
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Figure 6.12 The phenotypic consequences of ERCCI deficiency in the skin are 
not corrected in TTRJERCC1 transgene positive ERCC1 null mice 
Comparison of skin sections between age matched wild type, ERCCI null and 
transgene positive ERCC1 null mice. 
haematoxylin and eosin stained skin section from a 7-week old wild type mouse. 
Large circular nuclei evident in the epidermal cells (E). Normal thickness of the 
dermal layer is indicated (D). The cartilaginous ear tissue is shown (C). 
haematoxylin and eosin stained skin section from a 3-week old ERCC1 null on the 
original knockout background. Large circular nuclei evident in the epidermal cells 
(E). Normal thickness of the dermal layer is indicated (D). The cartilaginous ear 
tissue is shown (C). 
haematoxylin and eosin stained skin section from a 3-week old ERCC1 null on the 
KT#209 knockout background. Large circular nuclei evident in the epidermal cells 
(E). Normal thickness of the dermal layer is indicated (D). The cartilaginous ear 
tissue is shown (C). 
haematoxylin and eosin stained skin section from a 6-week old transgene positive 
ERCC1 null on the original knockout background. Compressed nuclei evident in the 
epidermal cells (E). Thinning of the dermal layer is also evident (D). The 
cartilaginous ear tissue is shown (C). 
haematoxylin and eosin stained skin section from a 6-week old transgene positive 
ERCC1 null on the KT#209 knockout background. Compressed nuclei evident in the 
epidermal cells (E). Thinning of the dermal layer is evident (D). The cartilaginous ear 
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is thus suitable for further studies of the consequences of ERCC1 deficiency in this 
tissue and systems relating to it. 
6.14 TTRJERCC1 transgene positive ERCCJ-deficient mice exhibit kidney 
abnormalities 
We have reported that the transgene positive ERCCJ nulls live for up to 3 times as 
long as the transgene negative ERCCJ-deficient animals. This extended lifespan has 
enabled us to carry out further analysis of the consequences of ERCCJ deficiency in 
adult tissues. This study was carried out by sectioning the organs of transgene 
positive ERCCJ nulls for comparison with sections from wild type littermates. The 
initial characterisation of our original ERCC1 knockout line revealed detectable p53 
protein in brain and medullary collecting tubules of the kidneys in these ERCC1-
deficient animals (Mcwhir et al., 1993). At this stage, despite the detectable p53, 
there was no evidence of any physical abnormalities in these 3-week old animals. We 
have been able to re-examine these organs in our phenotypically rescued transgene 
positive animals. For the first time-we have been able to observe the consequences of 
DNA repair deficiency in the brains and kidneys of adult mice (aged 6 weeks and 
over). Comparison of the brain sections from our transgene positive nulls, from both 
knockout backgrounds, and age matched wild type littermates revealed no differences 
(data not shown). 
Comparison of the kidney sections from our transgene positive nulls, from both 
knockout backgrounds, and age - matched wild type littermates did reveal some 
changes in renal morphology (Figure 6.13). There was evidence of some abnormal 
enlarged nuclei, possibly polyploid, in cells of transgene positive mice on the original 
knockout background. Similar aberrant nuclei were identified in the animals on the 
KT#209 background to a lesser degree (not shown). Whilst there was some evidence 
of dilation of the renal tubules in the wild type sections, the tubule dilation appeared 
greater and more widespread in the transgene positive nulls from both knockout 
backgrounds. Furthermore there was evidence of tubules apparently blocked with 
protein casts, and a pyelonephritis like pattern. Pyelonephritis is a human condition in 
which the kidney becomes inflamed as the result of bacterial infection, treatment is 
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Figure 6.13 TTRJERCCJ transgene positive ERCCJ-deficient mice exhibit 
kidney abnormalities 
Comparison of kidney sections between age matched wild type, ERCCJ null and 
transgene positive ERCCJ null mice. 
haematoxylin and eosin stained kidney section from a 6-week old transgene 
positive ERCCJ null on the original background . A representative dilated renal 
tubule is indicated (T). Tubules apparently blocked with protein casts are shown (*). 
A representative glomerulus is indicated (G). Representative aberrant nuclei are 
indicated by arrows. 
haematoxylin and eosin stained kidney section from a 7-week old wild type 
animal. A representative tubule is indicated (T). A representative glomerulus is 
indicated (G) 	 - 
haematoxylin and eosin stained kidney section from a 6-week old transgene 
positive ERCC1 null on the KT#209 knockout background. A representative dilated 
renal tubule is indicated (T). A representative glomerulus with abnormal structure is 
indicated 	 (G) 
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generally by antibiotics. Rarely, when the infection is chronic, renal failure can 
follow. The appearance of the glomeruli in the transgene positive nulls was less 
ordered than in the sections from the wild type animals. 
In addition to these histological observations it was also noted that, towards the latter 
stages of their lives, the abdomens of the transgene positive animals appeared 
distended. Postmortem examination of these animals revealed ascites, an 
accumulation of fluid in the peritoneal cavity. In humans ascites is commonly 
associated with failure of the heart or kidneys, as fluid leaks away from the 
circulating blood. 
In summary, we have identified abnormalities in the kidneys of our adult transgene 
positive ERCC1 nulls. Presumably, these abnormalities were not detected in our 
original knockout mice as they reflect the consequences of prolonged ERCCJ 
deficiency through later stages of life not reached by the knockout mice. The post 
mortem observation of ascites in these animals may indicate renal failure, however, 
no assessment of renal function has been performed. 
6.15 Discussion 
Conventional transgenesis, by the pronuclear injection of cloned gene constructs, has 
enabled the study of the phenotypic effects of altered gene expression. Typically 
research has focussed on the effects of overexpression of genes (e.g. Wang et al., 
1998), the consequences of engineered changes within the control elements (e.g. Yan 
et al., 199 0) or the consequences of gene expression in an unusual cell type (e.g. 
Albers et al., 1995). We have exploited the ability to target the expression of a 
transgene to a particular cell type by targeting the expression of ERCC1 to 
hepatocytes. 
The lethal liver phenotype of our ERCC1 knockout mice has prevented us from 
studying the consequences of ERCCJ deficiency in other tissues. We speculated that 
the targeted in vivo expression of ER CC] in the liver of our ERCCJ knockout mice 
would extend the lifespan of these otherwise ERCC1-deficient animals. To bring 
about the targeted expression of ERCC1 within the liver of mice, we constructed an 
ERCC] transgene by cloning the mouse ERCC1 cDNA coding region into the second 
178 
exon of a transthyretin gene fragment, containing 3kb of transcriptional regulatory 
sequences within the promoter and the first two exons. This fragment was known to 
elicit high levels of hepatocyte specific transgene expression, with expression 
detectable in the choroid plexus of the brain only when 6 or more copies of the 
transgene were present (Yan et al., 1990). Pronuclear injections carried out using this 
transgene resulted in the production of a single surviving transgenic founder animal 
from which the transgene was crossed onto both of our ERCC1 knockout 
backgrounds. Two out of three pups that were found dead soon after birth were also 
genotyped as transgene-positive. The degraded condition of the DNA recovered from 
the cadavers prevented any analysis of transgene copy number in these animals. 
Whilst it was unlikely that the premature deaths of these animals was as a 
consequence of their transgene status, such a correlation could not be ruled out 
completely. It has been shown that overexpression of ER CC] in wild type Chinese 
hamster ovary cell lines resulted in an hypersensitivity to the DNA cross-linking 
agent melphalan, a nitrogen mustard derivative, without effecting sensitivity to UV 
irradiation (Bramson et al, 1993). It may be possible that these animals died as a 
consequence of overexpression of the transgene resulting in a dominant negative 
phenotype similar to that reported for the in vitro study. This would also suggest that 
the level of expression in the surviving transgenic founder was below the level for 
such an effect to be evident. An attempt to overexpress ERCCJ in human cultured 
cells showed only a four-fold increase in protein levels despite evidence suggesting 
more than a thousand-fold increase in gene copy number and a dramatic increase in 
the level of ERCCJ mRNA expression. Together these results may suggest that 
overexpression of the ERCC 1 protein is not beneficial to the survival of a cell. 
Further characterisation of the transgenic founder animal and Fl offspring indicated 
that, whilst the founder animal appeared to be mosaic with 1 to 2 copies of the 
transgene in a single array, between 3 and 4 copies of the transgene were detected in 
the offspring. Previous reports have indicated that the tissue specific expression of 
transgenes, where transcription is regulated by the transthyretin regulatory sequences, 
was most efficiently maintained where the copy numberS remains below 6 copies. 
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Animals with much higher copy numbers often had detectable levels of expression in 
other organs including kidney, salivary glands and intestines (Yan et al., 1990). 
Studies of LacZ reporter gene expression have shown that when transgenes are 
present in high copy number arrays gene expression can be silenced by mechanisms 
including hypermethylation of the transgene locus and formation of repressive 
chromatin confirmations (Garrick et al., 1998). Using the Cre/loxp system of site 
specific recombination to generate transgenic mouse lines in which varying copy 
numbers of the LacZ transgene were present at the same chromosomal location, 
thereby eliminating positional effects, it was possible to study the effect of copy 
number alone on transgene silencing. It was found that in lines where in excess of 
100 copies were present expression of the LacZ gene was very low. However when 
Cre-mediated reduction of the copy number was carried out, reducing the array to 
either 1 or 5 copies, expression was restored. Whilst it was unlikely that the array in 
our transgenic line would be subjected to repeat-induced silencing, it remained 
possible that other factors such as the chromosomal integration site may have had a 
repressive effect on transgene expression. We have shown, by northern blot analysis, 
that the 7TR/ERCC1 transgene was expressed at high levels, 20-100% of endogenous 
7TR levels, in the hepatocytes of all of the mice we analysed. Analysis of transgene 
expression on 'our ERCCJ knockout backgrounds indicated that in some of the 
animals there was evidence of expression in other tissues including testes, skin and 
brain. The level of transgene expression in these other tissues was at very low levels 
and at less than 3% of the level of expression detected in the liver. It has been 
reported that expression of a p21 transgene, using an identical TIR minigene vector 
backbone, was detected in the brain of a single transgenic line at the level of mRNA 
but p21 protein was not detected in the brain (Wu et at., 1996). Analysis of 
expression of other 17'R minigene based transgenes in skin has not been reported, 
presumably, as the analysis has not been performed. Expression of TTR minigene 
based transgenes in the testes has not previously been reported, where expression in 
this tissue has been analysed. The level and distribution of expression of the 7TR 
minigene in non-hepatic organs was reported as being sporadic even within lines 
(Yan et al., 1990). 
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Further, we have demonstrated that the expression of the TTR/ERCC1 transgene was 
apparently stable with the age of the animals, although the absolute level of 
expression was shown to vary from animal to animal, expression was evident in an 
animal at 24 weeks of age, and persisted through all generations analysed thus far. 
This was particularly significant, in that, if expression of the transgene were to bring 
about phenotypic correction it was important that expression was maintained in order 
that correction continued. The variation in the absolute level of transgene expression 
we have reported did not correlate with age. Age dependant silencing of 3-globin 
driven LacZ reporter genes has been described (Robertson et al., 1996). Expression 
of the LacZ reporter gene in red blood cells was assessed in animals of various ages 
within a number of independent transgenic lines. It was found that expression fell by 
as much as 40-fold in some lines between the ages of 1 and 8 weeks. The extent by 
which expression declined was greatest in the lines with the highest number of 
transgene copies and was thought to be the result of progressive 
heterochromatinisation. 
The ERCC1 knockout mice reported by Weeda et al., (1997) had a lifespan of 38 
days whilst mice carrying a subtle mutation, resulting in a premature stop codoñ at 
position 292, lived for approximately 2 to 6 months depending on their genetic 
background. The considerable difference reported for the lifespan of the knockout 
mice (38 days) and mice with the subtle mutation (up to 6 months) may suggest that 
the protein arising from ERCCJ allele carrying only the point mutation may retain 
some residual activity that contributes to this extended viability. The principle aim of 
the work reported here was simply to increase the lifespan of our ERCCJ-deficient 
mice so as to enable further analysis of the consequences of ERCC1 deficiency in 
other organs. We have reported that the 77R/ERCCJ transgene positive ERCC1 nulls 
survive for between 60 and 90 days compared to the transgene negative ERCCJ nulls 
which generally die before weaning at 21 days of age. As such we can conclude that 
the targeted expression of ERCCJ in the hepatocytes of our ERCCJ nulls has resulted 
in an increased lifespan. We are now able to study the progressive consequences of 
ER CC] deficiency in other organs in our ERCCJ knockout mice. 
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The observation of liver nuclear abnormalities has been confirmed for all of the 
ERCCJ knockout and mutant mice reported to date (McWhir et at., 1993; Weeda et 
al., 1997 and Hsia unpublished data). We have shown that the targeted expression of 
an ERCC1 transgene in the liver of our nulls results in the correction of this 
phenotype. The liver sections from our transgene positive nulls were seen to have a 
wild type appearance and this observation was further confirmed using FACScan 
analysis. The distribution of DNA content of hepatocyte nuclei from a four-week old 
transgene positive ERCC1 null matched the distribution seen in a three-week old 
wild type animal. We speculate that the observed correction of aberrant nuclear sizes 
reflected a correction of the loss of hepatic function and as such the ERCC1 null mice 
no longer died prematurely as a result of liver failure. 
As with the liver abnormalities, the severe runting phenotype is common to all 
ERCC1 targeted mice (McWhir et al., 1993; Weeda et al., 1997 and Hsia 
unpublished data). We have shown that this phenotype is partially corrected in our 
transgene positive nulls. We have reported that weight of the transgene positive 
ERCCJ nulls was 60% of their wild type littermates, compared to the transgene 
negative nulls which weighed only 20% of the weight of the wild type animals 
(Mcwhir et al., 1993). The severe runting associated with the nulls reflected the 
overall state of ERCC1 deficiency in the animal and was not solely a consequence of 
ERCC1 deficiency in the liver. As such it was not expected that the targeted 
expression of ERCC1 in the liver would bring about complete correction of this 
phenotype. The degree of phenotypic correction that was observed served to illustrate 
the significance of corrected liver function in the context of growth and development. 
Cutaneous abnormalities, including the lack of subcutaneous fat, in ERCCJ null mice 
have been reported (Weeda et al., 1997) and these abnormalities have been 
confirmed in our own knockout mice (unpublished data). Skin sections from the 
transgene positive ERCCJ-deficient mice showed that the skin structure was 
noticeably altered from that of wild type animals. The skin sections showed an 
apparent distortion of nuclei in the epidermal cells and a thinning of the dermal layer. 
Although transgene expression (mRNA) had been detected in the skin of some mice 
it appeared that this expression was not sufficient to bring about phenotypic 
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correction of the associated cutaneous abnormalities. As such we regard the skin of 
the transgene positive nulls as being ERCC1-deficient and it is thus an appropriate 
organ in which to study the progressive consequences of ERCC1 deficiency. There 
have been several reports concerning the predisposition of mice with defective NER 
to skin tumours (de Vries et al., 1995; Nakane et al., 1995 and Sands et al., 1995) The 
now extended lifespan of the transgene positive nulls would still preclude any long-
term carcinogenicity studies but may permit studies of acute carcinogenesis to be 
performed. This would establish whether our ERCC1 null mice were predisposed to 
developing skin cancer. 
In addition to the liver, our original knockout mice showed detectable levels of the 
tumour suppressor protein p53 in both brain and kidneys. However there was no sign 
of any pathological abnormalities in these organs immediately prior to death at 21 
days (Mcwhir et al., 1993). Detailed histological examination carried out on the brain 
and kidneys from transgene positive animals aged between 6 and 8 weeks, showed 
there was still no sign of any pathology in the brain. However, in the kidneys of these 
animals there was evidence of nuclear abnormalities and dilated tubules, which in 
some cases contained leaked proteinaceous material, indicative of renal dysfunction. 
Similar abnormalities, protein casts and aberrant nuclei, were observed in the kidneys 
of the ERCC1 targeted mice reported by Weeda et al., (1997). In addition to the 
histological observations, we have also reported that, prior to dying, the transgene 
positive ERCC1 nulls developed ascites, which can be an indication of renal failure. 
Although no assessment of renal function was carried out, it remains possible that the 
transgene positive ERCCJ nulls died as a result of renal dysfunction associated with 
the ERCCJ-deficient status of the kidneys in these animals; The abnormalities 
observed in the kidneys of these animals constitute the first additional consequence 
of ERCC1 deficiency identified as a result of the extended lifespan of the nulls, 
resulting from the targeted expression of the ERCC1 transgene in the liver. 
As a whole, the result of this work will enable us to carry out further in vivo studies 
of the consequences of ERCC1 deficiency that were previously constrained by the 
limited lifespan of our ERCC1 null mice. 
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Chapter 7 
Effects of UVB irradiation on epidermal Langerhans 
cells in ERCC1 -deficient mice 
IYMI 
The NER disorder xeroderma pigmentosum is principally characterised by 
hypersensitivity to UV light and the elevated incidence of skin cancers. The accepted 
theory of UV induced carcinogenesis suggests that skin neoplasias arise as a result of 
an accumulation of DNA damage in critical regions of the genome. When damage 
fails to be repaired before replication the damaged site is passed on as a cellular 
mutation. The accumulation of mutations in genes involved in the regulation of cell 
growth leads directly to carcinogenesis. This proposed, DNA repair focused model 
for carcinogenesis fails to consider the involvement of other cellular mechanisms in 
the observed predisposition to skin cancers. Pioneering work by Fischer and Kripke 
(1977) confirmed the carcinogenic capacity of UVB irradiation, long term exposure 
of mice to UV sources was shown to induce skin cancers. Further, they demonstrated 
that these tumours when transplanted into non-irradiated syngenic mice were 
destroyed by the host's immune response. When transplanted into UVB treated mice 
the tumours were seen to continue developing. These observations led to the proposal 
of a mechanism for tumour immunosurveillance which is impaired by UV irradiation. 
This immunosuppressive aspect of UV irradiation, combined with its mutagenic 
effects, may also contribute to the aetiology of the UV induced skin cancer associated 
with NER deficient XP patients. 
The transgene positive ERCC1 nulls do not survive long enough to perform any long-
term carcinogenicity studies, and as such we are unable to determine whether these 
animals are predisposed to skin cancers. However, as they do survive into adulthood 
we are now in a position to assess the consequences of ERCCJ deficiency on the 
immune functions implicated in preventing carcinogenesis. The majority of skin 
cancers initiate within the epidermis and as such cells with an immunological 
function in the epidermis are likely to be pivotal in establishing an anti-tumour 
response. The work presented in this chapter focuses on the effects of UVB exposure 
on the migratory properties and functional capacities of epidermal Langerhans cells 
in ERCCJ-deficient mice. First, a brief overview of Langerhans cells in the context 
of their role within the skin immune system is presented (reviewed by Lappin, 
Kimber and Norval, 1996 and Muller, Halliday and Woods, 1997). 
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Epidermal Langerhans cells (LC) are the principal antigen presenting cells of the skin 
and are regarded as the outermost sentries of the immune system. The cells play an 
important role in the afferent arm of the immune response, migrating from the 
epidermis to the draining lymph node to present antigen to the T cells. LC belong to 
the family of dendritic cells and constitute a small, yet important, cell population of 
the skin immune system. They are derived from haematopoeitic stem cells of the 
bone marrow but little is known of what happens to them between leaving the bone 
marrow and reaching the skin. It is assumed that precursor cells migrate to the skin 
via the blood circulatory system. The LC are dendritic-shaped cells that are identified 
in epidermal sheets by staining for ATPase activity, LC being the only epidermal 
cells with clear cell surface expression of this enzyme. In keeping with their antigen 
presenting function Langerhans cells also express high levels of the major 
histocompatibility complex (MHC) class II molecules on their cell surface. Antigen 
is first trapped by the LC dendrites and then taken up by the cell whereby proteolysis 
within intracellular vesicles leads to presentation of the antigenic peptide. The MHC 
class II molecules possess a characteristic groove that can be loaded with antigen 
derived peptides, forming the antigen! MHC complex which can interact with T. cell 
receptors to activate T cells. In order to complete their T cell activation the LC 
express additional surface molecules, co-stimulatory elements, which interact with 
their respective ligands on the T cell, stabilising the binding and enhancing 
activation. 
The potent antigen presentation capacity of the LC supports the idea that these cells 
may play a role in tumour immunosurveillance. The transformed tumour cells 
produce antigens which enable the immune system to distinguish between them and 
the normal cells of the body. Whilst LC are believed to be involved in the initiation 
of anti tumour immunity, the immunosuppressive effects of carcinogens such as 
UVB irradiation contribute to the failure of the tumour iminunosurveillance system 
and enable tumour development. Following exposure to UVB irradiation the LC are 
depleted from the epidermis as they embark on an inappropriate migration to the 
lymph nodes. It is not clear what mechanism leads to the UVB irradiation causing the 
LC migration to the lymph nodes in the absence of any antigen to present. Further, if 
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antigen is present at the time of irradiation, the presentation of antigen under these 
conditions elicits a tolerising effect as opposed to the more appropriate immune 
response. It is believed that production of the immune response is dependent on the 
presence of the co-stimulatory signals on the cell surface of the LC and that UV 
irradiation somehow abrogates their effect. The depletion of the LC from the 
epidermis following UV irradiation renders the skin immune system less able to 
respond to any antigen, whether it be in the form of a chemical substance or a 
transformed cell, that may be encountered during this immunosuppressed period. 
Chronic exposure to UV irradiation is capable of exerting mutagenic effects in 
addition to prolonging the period of LC depletion. 
The work presented in this chapter was carried out as part of a collaboration with Dr. 
Ali El-Ghorr and Dr. Mary Norval of the Department of Medical Microbiology, 
University of Edinburgh. Experimental procedures were performed by Dr. Ali El-
Ghorr. 
7.1 Langerhans cells are less abundant in the skin of ERCC1-deficient mice but 
show a normal pattern of depletion from the epidermis following UV irradiation 
The number of LC in the epidermis of ERCCJ-deficient mice, compared to wild type, 
was counted before and after UVB irradiation in order to determine whether the DNA 
repair deficient animals exhibited any enhancement of UV induced 
immunosuppression as measured indirectly by the depletion of LC from the 
epidermis. Previous attempts to study this in our original knockout mice were 
inconclusive. The lethal liver phenotype of these mice meant it was not possible to 
produce significant numbers of suitably aged null mice and the experimental 
procedures were not amenable to using young runted mice where the development of 
the ears was incomplete. Additionally it would not have been prudent to draw 
conclusions from analyses carried out using mice that were clearly not in good health 
prior to procedures. All the analyses presented in this chapter were performed using 
transgene positive ERCCJ nulls on the KT #209 knockout background, unless 
otherwise stated, and wild type littermates were used as controls. All the mice used 
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were adults, aged between six and eight weeks and showed absolutely no signs of ill 
health at the time of the experiment. There were five mice of each genotype in the 
UV irradiated groups and six mice of each genotype in the non-irradiated control 
groups. 
The mice were irradiated on their dorsal surfaces following shaving with electric 
clippers. To ensure equivalent doses were received, the mice were immobilised by 
administration of anaesthesia. A 1500 Jm 2 dose of broadband UVB was delivered 
using a bank of two TL20 W/12 lamps. This is equivalent to a minimal erythemal 
dose (MED) for wild type mice. Experimental analysis was performed 24 hours after 
the irradiation. 
At 24 hours after the irradiation the dorsal skin of the ERCC1 nulls was noticeably 
more erythemic than that of the irradiated wild type mice, indicating that the DNA 
repair deficient animals were more sensitive to UV irradiation. No detailed 
histological analysis was performed on the skin at this stage. 
Twenty-four hours after the irradiation, the mice were humanely killed and one ear 
from each mouse was removed, split and epidermal sheets were prepared from the 
dorsal surfaces only. LC were stained using adenosine-5'-diphosphate (ADP) and the 
number of ATPase cells were counted (Figure T 1). The staining is a result of the 
reduction of the ADP to AMP by the ATPase on the LC surface. In the non-irradiated 
groups the average number of LC per mm 2 was 498 ±37 for the wild type mice and 
366 ±24 for the ERCC1-deficient mice. Thus, there were significantly less LC 
present in the epidermis of the ERCCJ nulls compared to wild type mice. Following 
UV irradiation the number of LC present in the epidermis of the wild type animals 
fell to 166 ±17, which constituted a depletion of 67% of the normal number. In the 
ERCC1 nulls the number of LC present in the epidermis following UV irradiation 
was 137 ±20, which constituted a depletion of 63% of the normal number. It is 
therefore unlikely that DNA repair deficiency effects the UV induced depletion of 
these cells. 
Morphologically the dendritic LC in non-irradiated skin of the ERCC1 nulls were 
indistinguishable from those in wild type skin. Following UV irradiation a proportion 
of the LC that remained in the epidermis appeared to have lost their dendrites and 
Figure 7.1 Langerhans cells present at a lower density in the epidermis of 
ERCCJ nulls are depleted following UVB irradiation as normal 
Epidermal density of LC following a single 1500 Jm 2 dose of UVB irradiation. LC 
were stained and counted in non-irradiated controls and in the irradiated groups 
twenty-four hours after the irradiation. Results represent the mean (±SEM) of LC 
densities in epidermal sheets from five mice per non-irradiated group and six mice 
per irradiated group. Results were compared using Students t-test; WT vs Null 
p<0.005, WT vs WT+UV p<0.000, Null vs Null+UV p<0.000. 
UV induced morphological changes in epidermal Langerhans cells. i. A non-
irradiated wild type epidermis showing LC with clearly evident dendrites. ii. A non-
irradiated ERCC1 null epidermis showing LC present at a lower density but with 
evidence of dendrites. iii. Irradiated wild type epidermis showing depleted numbers 
of LC as well as morphological changes (less dendritic) in a proportion of the cells. 
iv. Irradiated ERCCJ null epidermis showing depleted numbers of LC and evidence 
of morphologically altered (less dendritic) LC. 
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looked rounded (Figure 7. lb). The extent of these differences was greater in the skin 
of the ERCC1 nulls (estimated at 90% of the cells) than in wild type skin (estimated 
at 20% of the cells). This observation suggested that the LC in the epidermis of the 
ERCC1 nulls were more sensitive to the UV irradiation. 
7.2 The Langerhans cells in ERCCJ-deficient mice are capable of antigen 
presentation as measured by the mixed skin lymphocyte reaction (MSLR) 
Having established that the Langerhans cells in the DNA repair deficient mice show 
the normal pattern of depletion from the epidermis following UV irradiation it was 
necessary to establish whether the LC in these animals were capable of presenting 
antigen. The antigen presenting capacity of the LC is determined by measuring the 
ability of the cells to stimulate proliferation of spleen cells in vitro. 
The remaining ear from the above mentioned mice was removed for preparation of 
epidermal cells (EC). Spleen cells from strain C3H female mice were used as the 
responder cells in the MSLR. For each of the experimental groups, 0.5 x 105 EC were 
incubated together with 10 spleen cells. After culturing for five days at 37°C 0.7tCi 
[H3]thymidine was added to each culture before harvesting the cells twenty-four 
hours later. The proliferative response of the spleen cells was determined by 
measuring the incorporation of the [H 3]thymidine. The net proliferative response was 
calculated as the mean of 5 experiments following the subtraction of the mean of 
control experiments, where EC were cultured alone (Figure 7.2). 
This analysis showed that specific proliferative response (measured in counts per 
minute (cpm)) resulting from incubation with non-irradiated wild type epidermal 
cells was 143 cpm, compared to 50 cpm when incubated with EC cells from 
irradiated wild type animals. This result indicates that the antigen presenting capacity 
of the EC from wild type animals is reduced following UV irradiation. The reduction 
in the antigen presenting capacity is a direct reflection of the reduced number of LC 
in the epidermis following irradiation. The specific proliferative response resulting 
from incubation with non-irradiated ERCCJ null EC was 176 cpm, compared to 40 
cpm when incubated with EC cells from UV irradiated ERCCJ null animals. This 
result indicates that, as with the wild type animals, the antigen presenting capacity of 
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Figure 7. 2 The epidermal cells of ERCC1 nulls exhibit a normal antigen 
presenting capacity in vitro 
A mixed skin lymphocyte reaction (MLSR) comparison of the antigen presenting 
capacity of epidermal cells from ERCCJ null and wild type mice before and after 
irradiation. The results represent the mean (±SEM) specific proliferation of cells 
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the EC from ERCC1 nulls is reduced following UV irradiation. Thus the antigen 
presenting capacity of the EC from ERCC1 nulls did not differ from those from wild 
type animals. Further, the observed morphological changes after UV irradiation did 
not appear to effect the antigen presenting function in this experiment. 
7.3 Langerhans cells of the ERCC1 nulls do not accumulate in the draining 
lymph nodes following UV irradiation 
Having demonstrated that the LC were depleted from the epidermis of the ERCC1 
null mice it was necessary to investigate whether the cells had migrated to the 
draining lymph nodes to fulfil their antigen presentation function. 
The accumulation of dendritic cells in the draining lymph nodes was measured. 
Twenty four hours after irradiation the mice were humanly killed and their auricular 
and axillary lymph nodes were removed and pooled. A single cell suspension was 
made from the pooled lymph nodes and the lymph node cells were counted 
microscopically, to establish the total number of cells per lymph node. The dendritic 
cells were then isolated by a process of centrifugation on a 14.5% metrizamide 
cushion. The dendritic cell enriched population at the cushion interface was counted 
microscopically to determine the number of dendritic cells per lymph node (Figure 
7.3a). This analysis showed that, for the wild type animals, the number of dendritic 
cells per lymph node prior to UV irradiation was 2262 compared to 5533 following 
irradiation. This result illustrates the normal migratory response of epidermal LC 
following UV irradiation. The number of dendritic cells in the lymph nodes of the 
ERCCJ nulls prior to irradiation was counted as 1412 compared with 1560 twenty-
four hours after UV irradiation. There was no evidence to suggest that the LC from 
the ERCCJ nulls accumulated in the draining lymph nodes following UV irradiation. 
This result was confirmed when the experiment was repeated (Figure 7.3b). The 
animals used in the second experiment included a mixture of transgene positive nulls 
from both of the ERCCI knockout backgrounds In the second experiment the number 
of dendritic cells per lymph node, in the wild type animals, was 1779 compared to 
3083 following UV irradiation. The number of dendritic cells per lymph node, in the 
ERCC1 null mice, was 1699 prior to irradiation and 1594 following irradiation. 
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Figure 7. 3 Following UVB irradiation LC from the epidermis of ERCCJ null 
mice fail to accumulate in the draining lymph nodes 
The number of dendritic cells per draining lymph node following a single 1500 
Jm 2 dose of UVB irradiation. Results represent the mean number of dendritic cells 
per lymph node from 12 lymph nodes per non-irradiated group and 10 lymph nodes 
per irradiated group. 
Repeated analysis of the number of dendritic cells per lymph node following UI/B 
irradiation (1500 Jm 2). Results represent the mean number of dendritic cells per 
lymph node from 24 lymph nodes per wild type group and 18 lymph nodes per 
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These results confirm that following UV irradiation LC cells do not accumulate in 
the draining lymph nodes of ERCC1-deficient mice. 
7.4 Discussion 
Patients with the DNA repair disorder xeroderma pigmentosum are hypersensitive to 
sunlight and predisposed to developing UV induced skin cancer. Whilst the nature of 
the DNA repair defect is well documented, little is understood about the mechanisms 
by which the defective NER results in the clinical symptoms such as hypersensitivity 
to sunlight. The carcinogenic properties of UVB irradiation have long been 
recognised and it is also recognised that UVB irradiation has an immunosuppressive 
effect (Fischer and Kripke, 1977). It has been suggested that, in patients with 
defective DNA repair, it is the combined immunosuppressive and mutagenic effects 
of UVB irradiation that lead to the observed increased incidence of skin cancer. The 
work presented in this chapter is a preliminary investigation into the consequences of 
ER CC] deficiency on the afferent limb of the skin immune system, namely the 
antigen presenting epidermal Langerhans cells. 
We have shown that the density of LC in the epidermis of ERCCJ -deficient mice was 
significantly lower than that seen in wild type littermates. It is not clear why the 
density of LC was lower in the ERCCJ nulls prior to irradiation. The animals had 
been maintained in an animal facility with no windows and covered fluorescent 
lighting and as such it is unlikely that the lower density of LC was a consequence of 
an enhanced response to incidental exposure to UV irradiation prior to the 
experimental procedure. We have already reported that the structure of the ERCC 1-
deficient skin differs from that of the wild type skin (Chapter 6.13). It may be that the 
epidermis in our repair deficient animals is unable to provide the necessary 
physiological environment required to support the LC at the normal density. We have 
also observed that the ERCCJ-deficient mice exhibited visible erythema following 
the UVB irradiation, unlike the wild type littermates. This suggested that the actual 
MED for the DNA repair deficient animals was less than the MED for wild type 
mice. In a previously reported study comparing the MED of XP patients with normal 
subjects it was shown that the MED of XPA, XPD and XPV patients was typically 
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lower than that of normal subjects. The XPA patient had the lowest MED at 0.1 of 
normal, the XPD patient had an MED of 0.33 of normal, whilst the XPV patients had 
an MED of about 0.5 of normal (Jimbo etal., 1992). 
Following UVB irradiation the LC depletion from the epidermis of the ERCCJ-
deficient animals was equivalent to that seen in the wild type littermates. In this 
respect the repair deficient animals exhibited a normal response to UVB irradiation. 
Of the cells that remained in the epidermis many were rounded and lacked dendrites 
and the morphological changes were more extensive in the ERCCJ nulls (90%) 
compared to the wild type animals (20%). This observation suggested that the LC in 
the ER CC] nulls may have been more sensitive to the effects of the UVB irradiation. 
Alternatively, this may have been a reflection of the abnormal structure of the 
epidermis in these animals; the previously described compression of the epidermal 
layer may have afforded the LC less protection from the UV irradiation. The results 
we have reported here differ from results previously reported for similar studies 
carried out on XPA-deficient mice (Miyauchi-Hashimoto et al., 1996). The structure 
of the skin in general and number of LC in the skin of the XPA-deficient animals did 
not differ from that of the wild type controls and following UV irradiation the 
depletion of LC from the XPA-deficient skin (59% depletion) was greater than that of 
the wild type controls (33% depletion). The depletion of LC from the epidermis is 
thought to be dose dependent and as such the differences observed between our mice 
and the XPA-deficient mice may reflect the different UV doses that the animals 
received. Whilst the XPA-deficient mice received a UVB dose of only 250 Jm 2 our 
animals received a dose of 1500 Jm 2. It is possible that the 6-fold higher UV dose 
received by the mice in our study had the effect of masking differences in LC 
depletion that may have been evident at lower doses of UV. Although, when exposed 
to a single UVB dose of 1000 Jm 2 the LC depletion in XPA-deficient mice was 
reported to be almost 100%, compared to 62% in wild type animals. In a study 
carried out on XP patients, it was demonstrated that following exposure to a single 
MED dose of UV the depletion of LC from the skin of XP patients was greater than 
in normal subjects. However, when the same individuals were exposed to UV doses 
equivalent to three times the MED, the depletion of LC from the epidermis normal 
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subjects was similar to that seen in the XP patients (Jimbo et al., 1992). The study 
carried out on the XPA-deficient mice also reported that the cells remaining in the 
epidermis had undergone morphological changes similar to those that we have 
reported. However, unlike our study, no changes were seen in wild type animals. 
Once again this is likely to be as a consequence of the lower UV dose administered in 
the XPA study. 
We also reported that the LC in the epidermis of the ERCCJ-deficient animals were 
capable of antigen presentation as shown by the MSLR. Although the capacity for 
antigen presentation was greatly reduced following UV irradiation, this reduction was 
mirrored in the wild type animals and as such does not reflect the consequences of 
DNA repair deficiency, rather it was a direct reflection of the reduced numbers of LC 
present in the skin following the normal migratory response after UV irradiation. 
Having already reported that the LC remaining in the epidermis of UV irradiated 
ERCC1 - deficient animals exhibited considerable morphological changes the 
retention of their capacity to present antigen to any extent was quite surprising. It 
would not be unreasonable to assume that the loss of dendrites from these cells 
would have impaired their antigen presenting capacity to some extent. A study by 
Vink et al.(1996) demonstrated that the proportion of LC, containing DNA damage, 
in the draining lymph nodes peaked at - 10% twenty-four hours after irradiation. They 
went on to demonstrate that these migrated cells exhibited normal in vivo antigen 
presenting activity at this time. However, cells that were collected from lymph nodes 
following sensitising with an antigenic substance three days after the UV dose were 
less able to present antigen in vivo. This suggests that although DNA damage is 
present immediately after irradiation, the impairment of antigen presentation 
develops with time. It remains possible that we may have observed impaired antigen 
presentation in our ERCC1 nulls relative to wild type if we had performed the MSLR 
four days after the initial irradiation. 
Finally, we have reported that following UVB irradiation the LC of the ERCCJ-
deficient mice do not appear to accumulate in the draining lymph nodes, contrary to 
the situation observed in wild type mice. Whilst, this does not mean to say that the 
LC do not migrate to the lymph nodes it simply states that they do not accumulate in 
196 
the nodes. It could be that the LC of the repair deficient mice are more inclined to 
pass through the lymph node. It would not be unreasonable to suggest that DNA 
repair deficient LC might be more sensitive to UV, which could result in altered 
expression of the cell surface proteins required for the normal interactions with the T 
cells in the lymph nodes. The failure of such an interaction may mean that the LC do 
not accumulate. Further, we can not rule out the possibility that the LC in these 
animals are incapable of successful migration to the draining lymph node. It remains 
possible that the altered structure of the skin in these animals in some way perturbs 
the normal migratory pathway. if this were indeed to be the case, it would be 
reasonable to assume that the ERCCJ-deficient animals would suffer from enhanced 
skin immunosuppression on the basis that the LC were incapable of antigen 
presentation in vivo. We do not have any evidence to suggest that these DNA repair 
deficient animals are immunocompromised relative to wild type animals. 
In summary, we have shown that the density of LC in the skin of the ERCC1-
deficient mice is lower than in wild type mice and following exposure to UVB 
irradiation these LC fail to accumulate in the draining lymph nodes. Although the 
antigen presenting capacity of the cells appears to be normal in vitro, the previous 




Summary and concluding remarks 
Transgenic animal technology and in particular the use of germline manipulation by 
gene targeting offers an ideal strategy for the in vivo analysis of the mechanisms of 
DNA repair. Knockout mice provide an opportunity to study the function of disrupted 
genes and to determine the consequences of the loss of function following exposure 
to genotoxic agents. Additionally, they have the potential to assist the development of 
gene therapies. The work presented in this thesis relates such analysis performed on 
our previously reported ERCCJ knockout mice, an animal model for NER deficiency. 
ERCCJ was previously reported as being expressed at low levels in all tissues and 
stages of development. Given that ERCC 1 plays such an important role in the repair 
of UV induced DNA damage, we felt that it would not be unreasonable to expect that 
the expression of a DNA repair gene may be altered in a tissue where the gene 
product would be of greater biological relevance, namely the skin. Northern blot 
analysis of ERCC1 expression in mouse tissues revealed that differential expression 
of the gene was indeed evident in the skin as well as cultured mouse keratinocytes 
and embryonic fibroblasts. In addition to the normal 1.1kb mRNA a novel ERCC1 
transcript was identified in these cell types and mouse skin. Characterisation of this 
transcript by 5' and 3' RACE analysis revealed that the 1.5kb skin specific transcript 
was produced by differential initiation of transcription, presumably from an upstream 
promoter. Preliminary mapping of the transcriptional initiation site, at 389 nt 
upstream of the transcriptional start site of the normal transcript, was based on the 
sequence analysis performed on the 5' RACE clone. It is intended that this initial 
mapping be confirmed using either primer extension or RNase protection analysis. 
This work constitutes the first report of a skin specific transcription pattern 
associated with an NER gene. It would be of interest to establish whether any of the 
other NER genes exhibit similar tissue specific expression patterns. 
Subsequent analysis failed to provide evidence relating to the UV induction of this 
transcript. Although this ERCC1 mRNA was expressed at higher levels in the skin, 
relative to the normal 1.1kb transcript in other tissues, the biological significance of 
the novel transcript remains to be elucidated. Western blot analysis is currently being 
performed in our laboratory to determine whether the difference in expression seen at 
the level of mRNA results in any differences at the level of the protein. Preliminary 
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findings have not provided any evidence indicating significant differences at this 
level (Kan-Tai Hsia, unpublished data). We have also reported an elevated level of 
ERCCJ expression evident in the testes, which may be indicative of some biological 
significance. Consequently, we are currently involved in studying the phenotypic 
consequences of ERCCJ deficiency in this tissue. 
Following on from the identification of the skin specific transcript we began work 
ultimately aimed at characterising the elements within the upstream promoter region 
responsible for this skin specific pattern of expression. The first step towards this 
analysis required the construction of a functional ERCCJ minigene that could then be 
used, by means of conventional deletional analysis, to identify the control elements. 
A prototype minigene was constructed and shown to be functional by virtue of its 
ability to rescue the UV sensitivity of a variety of different ERCCJ-deficient cell 
lines including mouse embryonic fibroblasts, keratinocytes and Chinese hamster 
ovary cells. Using northern blot analysis, we observed that the expression pattern of 
the minigene did not match the endogenous skin specific expression pattern, where 
the 1.5kb transcript is the more abundant species relative to the 1.1kb transcript, in 
any of the keratinocyte or embryonic fibroblast cells transfected with this construct. 
The failure to include any significant 3' flanking sequences in the minigene construct 
also meant that the minigene appeared to be subject to aberrant polyadenylation. It 
would not have been prudent to proceed with the proposed deletional analysis of the 
promoter region whilst the expression pattern of this ERCC1 minigene was so far 
removed from the skin specific pattern. It is intended that the minigene should be 
redesigned to include more 3' flanking sequences in an attempt to overcome the 
problem of aberrant polyadenylation. Further, it may be beneficial to consider 
reducing the overall size of the minigene by replacing genomic fragments with cDNA 
sequences where appropriate. 
The premature death of the ERCC1 knockout mice, from liver failure, has prevented 
any significant studies of the consequences of ERCC1 deficiency in adult tissues. The 
work presented in the second half of this thesis was aimed at rectifying this problem 
by extending the lifespan of these DNA repair deficient mice. This was first 
approached by attempting to develop an efficient retroviral gene therapy. We have 
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described the production of ER CC] retrovirus and its subsequent in vitro use in 
correcting the UV sensitivity of ERCC]-deficient mouse embryonic fibroblasts. 
Although we were able to demonstrate that a proportion of cells within a pool of 
infected fibroblasts were corrected to wild type levels, it was apparent that the viral 
titre from the viral producing pool was not sufficiently high enough to infect most 
target cells. Attempts to increase the viral titre using clones from the viral producing 
pool were unsuccessful. The limited degree of success achieved when using this 
system to correct the consequences of ERCCJ deficiency in vitro meant that it was 
not plausible to consider attempting to rescue the lethal liver phenotype of the 
ERCC1 knockout mice using this gene therapy strategy. It was concluded that the 
phenotypic rescue of the ERCC1 null mice should be attempted using a non-retroviral 
strategy. 
We speculated that, by restoring ER CC] function in the liver, the lifespan of the 
ERCC1 nulls would be extended significantly to enable the further studies already 
mentioned. We have described how, using conventional transgenesis, we have 
generated mice expressing ERCC1 specifically in hepatocytes and that crossing this 
line with our knockout line has increased the lifespan of our ERCC1 null mice. A 
single transgenic line with hepatocyte specific expression was produced using an 
ER CC] transgerie under the control of transthyretin regulatory sequences. Southern 
blot analysis indicated that the founder animal had 1 or 2 copies of the transgene 
present as a single array. Northern blot analysis of the expression pattern of this 
transgene revealed that it was expressed at high levels and essentially restricted to the 
liver. Expression was detected at very low levels in other tissues including skin and 
brain in some animals. The transgene expression was stable with age and through the 
four generations of mice generated thus far. 
When crossed onto the ERCC1 knockout backgrounds the transgene expression was 
shown to increase the lifespan of the ERCC] null mice by four-fold from the 
previous 21 days to up to 86 days. The severe runting associated with the ERCC] 
nulls was also alleviated; the transgene positive nulls weighed 58% of wild type 
compared to the 20% of wild type reported for the straight nulls. We have also shown 
that the expression of the ERCCI transgene corrects the liver nuclear abnormalities 
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previously associated with the ERCCJ-deficient mice. Histological and FACScan 
analysis was used to demonstrate that the livers of the transgene positive nulls were 
indistinguishable from wild type livers. 
We reported that histological analysis showed that the transgene positive nulls 
exhibited renal abnormalities, which had not previously been identified in our 
knockout mice. In addition to the presence of abnormal nuclei we also found dilation 
of the renal tubules to be a common feature in the kidneys of the adult transgene 
positive nulls. Frequently, these tubules appeared to be blocked with protein casts 
indicating that renal function may have been impaired. Postmortem examination of 
the transgene positive nulls revealed ascites and, bearing in mind the histological 
evidence, we suggested that the cause of death in these animals was likely to be renal 
failure. 
Despite the reported observation of low levels of ERCCJ expression evident in the 
skin of some of the transgenic animals we did not see any phenotypic consequences 
of this leaky expression. In all of the animals examined it was evident that the 
structure of the ERCC1-deficient skin was not the same as wild type. The nuclei of 
the epidermal cells appeared to be compressed and the dermal layer was consistently 
thinner than in wild type animals. We concluded that the skin of the transgene 
positive animals remained DNA repair deficient and as such served as a suitable 
tissue in which to study the consequences of NER deficiency in what were otherwise 
healthy animals. Essentially the aim of this work presented in this part of the thesis 
was achieved, the lifespan of the ERCCJ nulls was extended to such an extent as to 
permit analysis of the consequences of ERCC1 deficiency in other tissues. 
Indeed, it was the success of the phenotypic rescue of the nulls by conventional 
transgenesis that made it possible to carry out the work presented in the final chapter 
of this thesis. We were able to investigate the consequences of ERCCJ deficiency on 
the antigen presenting Langerhans cells of the skin immune system. In this respect, it 
was shown that the LC were present in the epidermis at a significantly lower density 
in the transgene positive nulls compared to wild type. Further, it was demonstrated 
that the ERCC1 null LC were depleted from the epidermis by UVB irradiation as 
normal, but that they failed to accumulate in the draining lymph nodes as was 
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observed in wild type animals. We have speculated whether these differences stem 
from the basic histological differences between ERCC1 null and wild type skin. 
Following the UVB irradiation we observed that the LC in the epidermis of the null 
mice exhibited more widespread morphological changes (dendritic loss) than seen in 
the wild type epidermis. It was believed that the apparent differences in the extent of 
dendritic loss would have been reflected in a reduced ability to present antigen. 
However, it was also demonstrated, using a mixed skin lymphocyte reaction, that 
whilst the antigen presenting ability of the ERCC1 null LC was diminished following 
irradiation, the wild type LC exhibited an equivalent impairment. Although the 
antigen presenting capacity of the ERCCJ null LC was apparently normal in vitro; we 
speculated that the initial observations, of lower LC density and failure to accumulate 
in the draining lymph nodes, may indicate that the skin immune system in these 
animals may well be effected as a consequence of the associated DNA repair 
deficiency. More extensive studies in this area have been restricted by the limited 
availability of transgene positive ERCCJ -deficient mice. 
The increased lifespan of the transgene positive ERCC1 nulls enabled us to extend 
our previously reported studies of the in vivo consequences of ERCC1 deficiency. In 
our laboratory, we have recently, produce a mouse with a foxed ERCCJ allele, which 
will enable us to further extend the studies presented here, by studying the 
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